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1 | Summary  
The adult mouse mammary epithelium contains self-sustained cell lineages that form the inner 
luminal and outer basal cell layers, with stem and progenitor cells contributing to its 
proliferative and regenerative potential. A key issue in breast cancer biology is the effect of 
genomic lesions in specific mammary cell lineages on tumor heterogeneity and progression. 
The impact of transforming events on fate conversion in cancer cells-of-origins and thus their 
contribution to tumor heterogeneity remains largely elusive.  
The phosphoinositide 3-kinase (PI3K) signaling pathway is crucial for cell growth, 
proliferation, metabolism and survival and is frequently deregulated in human cancer, 
including ~70% of breast tumors. The gene encoding for the alpha catalytic subunit of PI3K 
(PIK3CA) is mutated and/or amplified in over 30% of breast cancers. Mutations in either the 
kinase domain (H1047R) or the helical domain (E545K) are most common and result in a 
constitutively active enzyme with oncogenic capacity. PIK3CA
H1047R
 was previously shown to 
induce heterogeneous mammary tumors in transgenic mouse models. Whether overexpression 
of the PIK3CA
E545K
 mutant is sufficient to induce mammary tumors in transgenic mice has not 
been defined. Moreover, the origin of PIK3CA
H1047R
-evoked tumor heterogeneity and the 
influence of the cell-of-origin on aggressiveness of breast cancer have remained elusive. 
In my PhD studies, we demonstrate that expression of PIK3CA
E545K
 in the mouse 
mammary gland induces heterogeneous mammary carcinomas but with a longer latency than 
PIK3CA
H1047R
 suggesting that the helical domain mutant PIK3CA
E545K
 is a less potent inducer 
of mammary tumors. Furthermore, by using in situ genetic lineage tracing, gene expression 
analyses and limiting dilution transplantation, we have unraveled the potential of 
PIK3CA
H1047R
 to induce multipotency during tumorigenesis in the mammary gland. We show 
that expression of PIK3CA
H1047R
 in lineage-committed basal Lgr5-positive and luminal 
keratin 8-positive cells of the adult mouse mammary gland evokes cell dedifferentiation into a  
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multipotent stem-like state, suggesting this to be a mechanism involved in the formation of 
heterogeneous, multi-lineage mammary tumors. Moreover, we show that the tumor cell-of-
origin influences the frequency of malignant mammary tumors. Our results define a key effect 
of PIK3CA
H1047R
 on mammary cell fate in the pre-neoplastic mammary gland and show that 
the cell-of-origin of PIK3CA
H1047R
 tumors dictates their malignancy, thus revealing a 
mechanism underlying tumor heterogeneity and aggressiveness. 
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3 | Introduction 
3.1 The mouse mammary gland 
3.1.1 The mouse mammary gland development and physiology 
The mammary gland undergoes dynamic changes during development and throughout life. 
Derived from ectodermal cells, it forms a rudimentary ductal tree, the mammary primordium, 
before birth. Postnatal development is regulated by hormones, with puberty inducing the 
outgrowth of the ductal tree into the mammary fat pad under the influence of growth 
hormone, insulin-like growth factor 1 and estrogen. During pregnancy progesterone and 
prolactin stimulate further remodeling of the gland, generating the alveoli that secrete milk 
during lactation. Following lactation, the mammary gland ductal tree regresses to a pre-
pregnancy-like stage, a process called involution (Macias and Hinck, 2012; Petersen and 
Polyak, 2010; Sternlicht, 2006).  
The branched ductal-alveolar tree making up the postnatal mouse mammary gland is 
surrounded by a basement membrane and stromal cells and is composed of hierarchically 
organized cell types that contribute to tissue homeostasis. Two major cell lineages organized 
in a bi-layered tubular structure constitute the mammary epithelium (Fig. 3-1). The luminal 
layer lining the ducts and the alveoli is composed of cells expressing keratin 8/18 (K8/18) 
and/or estrogen and/or progesterone receptor (ER/PR). The contractile myoepithelial layer 
with a basal location is composed of cells expressing keratin 5/14 (K5/14) and/or smooth 
muscle actin (SMA) and/or p63 (Bissell et al., 2003; Hennighausen and Robinson, 2001).  
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Figure 3-1 │Mouse mammary gland physiology 
Scheme of an adult mouse mammary gland and duct. The branched mammary gland epithelium of 
adult nulliparous mice is surrounded by the mammary fat pad which comprises stromal cells, vascular 
cells and adipocytes (left). The mammary duct is organized in a bi-layered structure surrounded by a 
basement membrane (magnification, right). The luminal layer lining the ducts is composed of cells 
expressing keratin 8/18 and/or estrogen receptor/progesterone receptor. The basal layer is composed of 
cells expressing keratin 5/14 and/or smooth muscle actin and/or p63.      
 
3.1.2 The mouse mammary gland hierarchy 
The mouse mammary gland epithelium is hierarchically organized (Visvader and Stingl, 
2014) (Fig. 3-2). Multipotent cells that generate both the luminal and basal lineages are found 
in the mouse embryonic mammary gland (Spike et al., 2012; Van Keymeulen et al., 2011) but 
their existence in the adult gland is still under debate. Studies using serial transplantation into 
cleared mammary fat pad of mammary fragments, retroviral-infected mammary cells (Deome 
et al., 1959; Faulkin and Deome, 1960; Kordon and Smith, 1998), or cells isolated by 
fluorescence-activated cell sorting (FACS) using cell surface markers (e.g. CD24, Sca1, 
EpCAM, CD49f, CD29, CD61) (Prater et al., 2014; Shackleton et al., 2006; Sleeman et al., 
2006; Sleeman et al., 2007; Stingl et al., 2006) (Fig. 3-3) supposed the existence in the adult 
mouse mammary gland of multipotent stem cells with myoepithelial features. Arguably, these 
assays reflected the regenerative potential of the transplanted cells rather than their properties 
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Figure 3-2 │Model of mammary cell hierarchy 
During embryonic development, multipotent mammary stem cells (MaSCs) contribute to the luminal 
and basal lineages. Currently, the existence of adult multipotent MaSCs is under debate. Self-sustained 
unipotent luminal and basal stem cells as well as multipotent stem cells may maintain the homeostasis 
of the adult virgin mammary gland. The organization of their hierarchy is still unknown. 
 
in situ (de Visser et al., 2012; van Amerongen et al., 2012; Van Keymeulen et al., 2011). 
Lineage-tracing studies, which permit targeted expression of a fluorescent reporter in a given 
cell and its progeny, showed that tissue homeostasis is maintained by unipotent luminal 
K8/18-positive and basal K5/14/Lgr5-positive stem cells after birth. Lineage-tracing of  
K8/18-, K5/14- and Lgr5-progeny found no evidence for the presence of multipotent stem 
cells in the adult mammary gland (Van Keymeulen et al., 2011) but did not exclude the 
possibility that rare cells not targeted by these reporters, or only at a very low frequency, have 
multipotent potential. Whilst tracing of the progeny of axin2-positive cells showed the 
presence of multipotent stem cells during puberty and pregnancy, this and other studies, 
revealed that the basal and luminal lineages are self-sustained in the adult virgin gland (de 
Visser et al., 2012; Tao et al., 2014; van Amerongen et al., 2012). In contrast, recent three-
dimensional whole-mount imaging (Rios et al., 2014) and the identification of the Procr-
positive subset (Wang et al., 2015) argue for the presence of multipotent stem cells in the 
adult virgin mouse mammary gland, thus reopening the debate. Delineating normal mammary 
cell hierarchy in mouse and humans is fundamental to the understanding of breast tumor 
heterogeneity. 
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Figure 3-3│ Separation of mammary epithelial cell subpopulations by FACS 
a, Representative FACS-plot for separation of basal and luminal mammary subpopulations using anti-
CD24 and anti-Sca1 cell surface markers. b, Representative immunofluorescence staining of isolated 
mammary epithelial cells for basal (K14, red) and luminal (K8/18, green) markers.  
The red box indicates CD24
low
Sca1
negative
 basal population. The orange and yellow boxes indicate 
CD24
high
Sca1
negative
 and CD24
high
Sca1
positive
 luminal populations, respectively.  
 
3.2 Breast cancer 
3.2.1 Breast cancer prevalence and classification 
Breast cancer is the most frequently diagnosed cancer and the leading cause of death in 
female cancer patients with yearly over 1.5 million cases and 500,000 deaths worldwide 
(Torre et al., 2015). Breast cancer progresses from a premalignant disease (e.g., hyperplasia, 
ductal carcinoma in situ) to invasive carcinoma and metastasis. Differing histopathological 
parameters such as receptor status (estrogen-receptor, progesterone-receptor and/or 
ERBB2/HER2 overexpression) and proliferation status (Ki67-expression) (Viale, 2012), and 
molecular profiling subdivides breast cancer into at least six subtypes (normal-like, luminal 
A, luminal B, HER2-enriched, claudin-low, and basal-like). These expression profiles mostly 
reflect different clinical prognoses (Perou et al., 2000; Prat et al., 2010; Sorlie et al., 2001; 
Sorlie et al., 2003) and to some extent responses to therapy (Troester et al., 2004). Integrated 
genomic and transcriptomic analysis of breast tumors has revealed further subgroups with 
distinct clinical outcomes (Curtis et al., 2012). 
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3.2.2  Heterogeneity in breast cancer 
Breast cancer displays molecular, phenotypic, and functional diversity within a patient’s 
tumor (intratumor heterogeneity) and among tumors from different patients (intertumor 
heterogeneity). This tumor heterogeneity challenges accurate prognosis and a single biopsy 
can misjudge the complexity of the disease. Pathologists biopsy multiple regions of a tumor 
and reach a diagnosis based on the most malignant region, yet further aggressive areas may be 
missed due to their scarcity and/or topological heterogeneity (Komaki et al., 2006). Generally, 
only a few histopathological parameters are assessed and this may overlook meaningful 
information. Furthermore, gene expression profiling of breast cancer is usually performed on 
the total biopsy, which may dilute information on aggressiveness. Breast cancer mortality 
essentially results from metastases in bone, lung, brain and liver, but a systematic and 
comprehensive assessment of the molecular makeup of metastases is still not available. 
Indeed, metastases may display varying genetic and non-genetic alterations, also when 
compared to the bulk of the primary tumor (Ding et al., 2010; Shah et al., 2009). This is a 
possible cause of a significant number of therapy failures. Therefore, imprecise sampling, 
particularly of metastases, and lack of in-depth molecular analysis are serious problems that 
need to be tackled if research discoveries are to be translated into long-lasting therapies. 
The origins of intra- and intertumor heterogeneity are as yet not fully understood. Cell-
autonomous (e.g., genetic and epigenetic) and non-cell-autonomous (e.g., tumor 
microenvironment) factors, as well as stochastic events (reviewed in (Marusyk et al., 2012)) 
are possible sources of cancer cell diversity and their delineation is important for a better 
understanding of tumor progression and could ultimately help design better therapies. 
 
Introduction 
10 
 
3.2.3 Tumor heterogeneity in preclinical cancer models  
The use of preclinical models havs led to significant progress in understanding breast cancer. 
Mouse models of mammary tumors induced by the mouse mammary tumor virus (MMTV) 
provided a means to study tumor heterogeneity (Cohen et al., 1979). Numerous mouse models 
have been genetically engineered to investigate tumor initiation and progression and to test 
anti-cancer drugs. These were generated by genomic deletion of tumor suppressor genes 
and/or by expression of oncogenes under a mammary-specific promoter. Early studies 
expressing ErbB2/Neu, Myc, H-ras or PyMT (Guy et al., 1992; Muller et al., 1988; Sinn et al., 
1987; Stewart et al., 1984), the generation of conditional mouse models using tamoxifen-
inducible Cre/loxP (Jonkers et al., 2001) or doxycycline-inducible tet-on (Gunther et al., 
2002), as well as advances in tissue- and cell type-specificity have demonstrated the 
importance of mouse models for studying inter- and intratumor heterogeneity of breast 
cancers (Cleary et al., 2014; Koren and Bentires-Alj, 2013; Liu et al., 2007; Melchor et al., 
2014; Meyer et al., 2011; Meyer et al., 2013; Molyneux et al., 2010; Tao et al., 2015). 
But the question remains how accurately murine models reflect human breast cancer 
heterogeneity. Histological phenotypes of several mouse mammary tumors do not resemble 
human breast cancers and the frequency of hormone-dependent mammary cancers is much 
lower in mouse models than in humans (Cardiff, 2001; Cardiff et al., 2000). Nonetheless these 
models recapitulate some aspects of molecular human breast tumor heterogeneity. Some 
mouse models resemble human breast cancer molecular subtypes and show conserved 
tumorigenic pathways (Herschkowitz et al., 2007; Hollern and Andrechek, 2014; Pfefferle et 
al., 2013). As expected, none of the current genetically engineered mouse models can 
recapitulate all characteristics of human breast cancer, yet such model systems are valuable 
for interrogating specific aspects of human disease and for testing hypotheses related to in situ 
tumor progression at the organismic level and in the presence of an intact immune system. 
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Human breast cancer cell lines are the most widely used preclinical model. Established 
human cell lines are derived from human breast cancer samples and pleural effusions and are 
propagated and manipulated in vitro or as xenograft transplants in vivo. They display many 
but not all of the recurrent genomic alterations found in human samples (Neve et al., 2006). 
Nevertheless, cell lines have proved useful as preclinical models in oncology (Neve et al., 
2006; Voskoglou-Nomikos et al., 2003). 
Primary human tumors can be transferred directly from patients into immunodeficient 
mice. These “patient-derived xenografts (PDXs)” generally show inter- and intra-tumor 
heterogeneity (Cassidy et al., 2015; DeRose et al., 2011; Zhang et al., 2013). PDXs display 
clonal dynamics (Eirew et al., 2015) and can be used to investigate patient-specific response 
to therapy (Hidalgo et al., 2014; Whittle et al., 2015). Breast PDXs mostly maintain the 
genomic and histopathological profiles and estrogen receptor-dependencies of the 
corresponding patient tumors during multiple passages in vivo (DeRose et al., 2011; Reyal et 
al., 2012). Yet because of cross-species incompatibilities and their transplantation into 
immunodeficient mice, human cell line xenografts and PDX models both lack the contribution 
of some non-cell autonomous drivers and the immune system to tumor heterogeneity. Even 
so, such model systems are promising tools to further investigate the heterogeneity of breast 
cancer and to develop precision therapy. 
 
3.2.4 Sources of breast tumor heterogeneity 
Different concepts relating to the origin of tumor diversity have been proposed, including the 
differentiation state of the initially transformed cell (cell-of-origin of cancer), cancer cell 
plasticity, genetic evolution and tumor microenvironment. Genetic and non-genetic alterations 
underlie these not mutually exclusive sources of heterogeneity.  
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3.2.4.1 Differentiation state of the cell-of-origin  
Theoretically, each cell type within the mammary gland hierarchy can be the subject of 
genomic alterations (Fig. 3-4) but whether all cell subtypes are prone to cancer is unclear. 
Moreover, the contribution of the cell-of-origin to tumorigenesis has proved largely elusive. 
Human mammary epithelial cells (HMECs) with distinct differentiation states caused by 
different culture media were transformed with the same set of oncogenes and tested in 
xenograft transplantations (Ince et al., 2007). The resulting tumors exhibited differences in 
histopathology, tumorigenicity, and metastatic behavior. Moreover, analysis of FACS-sorted 
transformed HMEC subsets suggested that the differentiation state of the cell-of-origin is a 
determinant of the tumor phenotype (Chaffer et al., 2011). Similarly, transformation of human 
epithelial cell adhesion molecule (EpCAM
+
)-positive cells led to the formation of ER-positive 
and -negative tumors, while transformation of CD10
+
 cells resulted in metaplastic tumors 
reminiscent of claudin-low breast cancer (Keller et al., 2012). While it is difficult to analyze 
the tumor cell-of-origin in human breast cancer retrospectively, mouse models have proven 
 
 
Figure 3-4 │ Cells-of-origin and tumor-initiating genomic alterations dictate the tumor  
phenotype 
Schematic illustration of possible sources of tumor heterogeneity. The combination of the 
differentiation state of the cell-of-origin and the tumor-initiating genomic alteration (A or B) 
determines the tumor phenotype.  
Introduction 
13 
 
informative. By targeting different cell types, conditional inactivation of p53 in cells 
expressing the Cre recombinase under the control of the mouse mammary tumor virus long 
terminal repeat (MMTV-Cre) evoked ER-negative tumors with a longer latency than its 
inactivation in Whey acidic protein (WAP-Cre) expressing models that developed ER-
positive and ER-negative tumors (Lin et al., 2004). Rb deletion in MMTV-Cre but not in 
WAP-Cre mice resulted in mammary tumors (Jiang et al., 2010), emphasizing the importance 
of the cell-of-origin in tumor susceptibility. 
It was long believed that basal-like breast cancers that express high levels of basal cell 
markers originate from transformed basal progenitor/stem cells and that luminal-type breast 
cancers with high levels of luminal cell markers originate from luminal progenitors. However, 
it has been shown that basal-like mammary cancer can arise from luminal progenitors 
(Molyneux et al., 2010). Similarly, analysis of pre-neoplastic human tissue from BRCA1 
mutation carriers revealed an expanded population of aberrant luminal progenitor cells whose 
expression profile associated with basal cancers, suggesting the luminal progenitor population 
as a target population in BRCA1-associated basal-like breast tumors (Lim et al., 2009). The 
use of the term “basal-like” is debatable as discussed in a review by B. Gusterson (Gusterson, 
2009).  
Just how different cell types yield different tumor types is yet little understood at the 
molecular level. Each cell type in the mammary gland hierarchy has its own signaling, 
transcriptional and epigenetic profile that determines cell identity (Kendrick et al., 2008; Lim 
et al., 2010; Pal et al., 2013). Further in-depth analysis is warranted to understand better the 
critical differences between cells-of-origin and heterogeneous tumors. 
It is probable that mammary tumor phenotypes depend on interactions between cells-
of-origin and initiating genetic alterations (Melchor et al., 2014). Multiple phenotypes can 
arise depending on the initiating depletion of a tumor suppressor gene (Brca1/2, p53 and/or 
Pten) in basal (K14-Cre model) or luminal ER-negative cells (beta-lactoglobulin (Blg)-Cre 
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model). Luminal ER-negative cells can give rise to various phenotypes, including ER-
negative and -positive mammary tumors. In contrast, tumors arising from basal cells show 
similar phenotypes irrespective of the depleted gene. For example, while Brca2/p53 depletion 
in Blg-Cre cells evokes invasive ductal carcinomas of no special type and metaplastic spindle 
cell carcinomas, its depletion in K14-Cre cells evokes malignant adenomyoepitheliomas. The 
initiating mutation seems to be the prime determinant of the molecular profile of tumors of 
breast cancer, as Brca1/2 and Pten depletion in any of the tested cells-of-origin generates 
basal-like or normal-like cancers, respectively (Melchor et al., 2014). A further recent study 
suggested that one cell-of-origin can give rise to different breast cancer subtypes depending 
on the oncogene expressed. While expression of Neu or PyMT gives rise to tumors with 
purely luminal differentiation originating from luminal WAP-Cre cells, expression of Etv6-
NTRK3 oncoprotein under the same promoter leads to tumors with basal differentiation (Tao 
et al., 2015), indicating that distinct oncogenes might have distinct effects on the tumor 
phenotype. Arguably, WAP can drive expression in ER-positive and ER-negative cells and 
conceivably Etv6-NTRK3 preferentially transforms the ER-negative population while Neu or 
PyMT preferentially transform ER-positive cells.    
Premalignant ductal or lobular carcinoma in situ already display heterogeneity (Clark 
et al., 2011) conceivably originating from several cell-of-origins. Important selection pressure 
during the transition from in situ to invasive carcinoma and to metastasis may further 
contribute to intra-tumor heterogeneity, highlighting the complexity of this disease. 
These studies show that the combination of initiating transforming events and tumor 
cells-of-origin has a bearing on breast cancer diversity and that phenotypes do not reflect the 
cell-of-origin of a cancer. The recognition of these two contributors to tumor heterogeneity 
may have great implications for the diagnosis, prognosis and treatment of cancer. 
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3.2.4.2 Cell plasticity and tumor cell hierarchy  
Sorting of cancer cell subpopulations has revealed that some tumor cells are tumorigenic but 
others are not. Notably, tumorigenic subpopulations can give rise to tumorigenic and non-
tumorigenic progenies. The term “cancer stem cells” (CSCs) was coined to describe 
tumorigenic cells that can self-renew (i.e., form tumors when serially passaged at limiting 
dilutions) and give rise to tumors that display the phenotypic heterogeneity of the parental 
tumor. This concept implies a hierarchical organization of tumors reminiscent of normal 
tissue in which stem cells are at the apex of the hierarchy, giving rise both to further stem 
cells and to differentiated cells (Kreso and Dick, 2014). Even though the organization of 
tumor cell hierarchy is not yet clear, recent studies have proposed dynamic bidirectional cell 
conversion. Using transformed HMECs in vitro, Chaffer et al. showed not only that CSCs 
give rise to differentiated cells but that differentiated tumor cells are also able to 
dedifferentiate (Chaffer et al., 2011). Cancer cell interconversions appear to maintain the 
equilibrium of cell states within a tumor (Gupta et al., 2011) (Fig. 3-5). Exome sequencing of 
CSCs from 12 breast cancer patients using paired primary tumor samples showed that the 
majority of mutations are shared between CSCs and the bulk primary tumor, which suggests a 
 
 
Figure 3-5 │ Cell plasticity contributes to the phenotypic diversity of breast cancer  
Schematic illustration of cancer cell plasticity as a possible source of tumor heterogeneity. Dynamic 
bidirectional cell conversions occur between cancer stem cells and non-cancer stem cells within a 
tumor.   
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dynamic switch between CSCs and differentiated cell states (Klevebring et al., 2014). A 
further in vitro study reported culture medium-dependent phenotypic plasticity in DKAT cells 
derived from an aggressive, treatment-resistant triple-negative heterogeneous human breast 
cancer. Whereas DKAT cells cultured in serum-containing medium displayed epithelial 
morphology, growth in serum-free media evoked mesenchymal characteristics (D'Amato et 
al., 2012). In vivo studies in prostate (Choi et al., 2012; Wang et al., 2013) and intestine 
(Schwitalla et al., 2013) have demonstrated deregulation of epithelial differentiation during 
tumorigenesis.  
The mechanism underlying this oncogene-triggered plasticity is not yet understood. 
The dedifferentiation processes might involve epithelial-to-mesenchymal transitions (EMT), 
given that overexpression of several EMT-markers (including SNAI1, SNAI2, TWIST1) has 
been found in basal-like cancers (Skibinski and Kuperwasser, 2015). For example, Slug and 
Sox9 were shown to induce interconversions between luminal progenitor and stem cell states 
and these factors are required for the maintenance of tumor-initiating capacity in human 
MDA-MB231 cells (Guo et al., 2012). Additionally, ablation of Slug in MMTV-Myc mice 
resulted in resistance to tumorigenesis, suggesting that plasticity is crucial to tumor 
development. Slug also interacts with chromatin-modifier lysine-specific demethylase 1 
(LSD1) and, thus, epigenetic remodeling may be involved in these processes (Phillips et al., 
2014). A further study showed that cell plasticity is triggered by epigenetic remodeling driven 
by the EMT-transcription factor ZEB1 (Chaffer et al., 2013). Hence, plastic tumor cells may 
maintain bivalent chromatin configurations and activate/repress transcriptional programs in 
response to cell-cell and microenvironmental cues, conceivably resulting in different cell fates 
and degrees of tumor aggressiveness. At present, it is still not known whether all tumor cells 
can undergo bidirectional cell conversion, and the exact molecular mechanisms underlying 
cancer cell plasticity need further investigation. 
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3.2.4.3 Genetic evolution  
Substantial genetic diversity is found in human breast cancers (Banerji et al., 2012; Cancer 
Genome Atlas, 2012; Curtis et al., 2012; Ellis et al., 2012; Shah et al., 2012; Stephens et al., 
2012). The concept of genetic evolution as a source of tumor heterogeneity has existed for 
several decades. Tumorigenesis is an evolutionary process driven by mutations and Darwinian 
selection (Nowell, 1976). Heritable beneficial mutations in a tumor cell may pass to the 
progeny, which gain survival and proliferation advantages. Such tumor cells with increased 
robustness may form clones that become dominant through the occurrence of further 
favorable mutations in a multi-step manner. Hence, clones within a tumor form independent 
phylogenetic lineages and this genetic heterogeneity translates into phenotypic tumor 
diversity (Kreso and Dick, 2014; Marusyk and Polyak, 2010; Nowell, 1976) (Fig. 3-6). 
Molecular profiling of 21 human breast cancers by whole-genome sequencing was performed 
to gain insight into their genomic architecture. By bioinformatic analysis, Nik-Zainal et al. 
 
Figure 3-6 │ Genetic evolution contributes to tumor heterogeneity 
Schematic illustration of genetic evolution as a possible source of tumor heterogeneity. Tumorigenesis 
is a multi-step branched evolutionary process. Phylogenetic lineages of clones form by genomic 
alteration and Darwinian selection. This genomic heterogeneity translates into phenotypic tumor 
heterogeneity.  
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reconstructed a phylogenetic tree for one tumor, highlighting the evolution of breast cancer 
through the occurrence of driver mutations and clonal expansion (Nik-Zainal et al., 2012a; 
Nik-Zainal et al., 2012b). Single-cell sequencing of different sectors of a breast tumor 
revealed distinct clonal subpopulations suggesting sequential clonal expansions with few 
persistent intermediates. Moreover, analysis of single cells from a monogenomic primary 
tumor and its liver metastases indicated that a single clonal expansion formed the primary 
tumor and seeded the metastases (Navin et al., 2011). Similarly, multi-region genetic analysis 
(exome sequencing, chromosome aberration analysis, and ploidy profiling) of renal carcinoma 
and matched metastases has revealed branched evolutionary tumor progression (Gerlinger et 
al., 2012). The results of a further recent study investigating the genetic landscape of 
multifocal lesions in breast cancer concur with the notion of genetic evolution. Oncogenic 
variants were found to be shared frequently between lesions, especially proximal rather than 
distal lesions, indicating the common origin and evolutionary process of tumor progression 
(Desmedt et al., 2015). Sequencing of multifocal cancers from another study revealed that 
distinct foci were clonally related suggesting that tumor subclones are capable of transiting 
distances through normal tissue and during progression (Yates et al., 2015). 
The concept of genetic evolution by itself is insufficient to explain tumor 
heterogeneity as it only considers homogeneous genetic pools within clones and not the 
functional diversity of cell states (e.g., CSCs) of clone constituents. The genetic evolution and 
CSC models are not necessarily mutually exclusive and a unifying model has been proposed 
in which CSCs may evolve and change in frequency under the influence of clonal genetic 
evolution during tumor progression (Kreso and Dick, 2014). 
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3.2.4.4 Tumor stroma and clonal cooperation  
In healthy tissue, cell identity and homeostasis are tightly controlled not only by cell 
autonomous mechanisms but also by reciprocal interactions with the environment. Failure to 
preserve tissue stability may result in neoplastic transformation (Goubran et al., 2014). Cell 
plasticity and tumor heterogeneity are also influenced by extrinsic factors. Interactions 
between tumor cells and their microenvironment, which includes stromal cells, blood vessels 
and the immune system via paracrine factors, contribute to tumor progression (Allinen et al., 
2004; Bissell and Hines, 2011) (Fig. 3-7). In cancer, physiological interactions between cells 
and the microenvironment are disrupted as tumor cells are not sensitive to growth restrictive 
cues from their surroundings (Joyce and Pollard, 2009; Quail and Joyce, 2013). Cancer-
associated fibroblasts (CAFs) differ from normal fibroblasts and are among the most abundant 
cell types in the tumor stroma. While normal fibroblasts from reduction mammoplasties retain 
the epithelial morphology of HMECs, co-culture with CAFs evokes a mesenchymal 
morphology (Dumont et al., 2013), highlighting the influence of the tumor stroma on cell 
 
 
Figure 3-7 │ Cross-talk of tumor cells and their microenvironment influences tumor  
heterogeneity 
Schematic illustration of the interaction and cross-talk between tumor cells and their 
microenvironment including stromal cells, blood vessels and immune cells. Interclonal and heterotypic 
cell interactions contribute to tumor heterogeneity.  
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identity and breast cancer heterogeneity. Similarly, the tumor microvasculature influences 
disseminated tumor cells, as demonstrated by the promotion of tumor growth by sprouting of 
neovasculature; in contrast, a stable microvasculature induces tumor cell quiescence and is, 
thus, tumor suppressive (Ghajar et al., 2013). 
The interaction of tumor clones also may affect the tumor landscape (Marusyk et al., 
2014; Tabassum and Polyak, 2015). Clonal interaction has been reported between 
hierarchically different clonal populations in MMTV-Wnt1 mammary tumors, in which basal 
and luminal subclones were both required for tumorigenesis. This process was highly 
dependent on Wnt1 production by the luminal cells, which affected basal clones (Cleary et al., 
2014; Tabassum and Polyak, 2015). These examples show that not only cell-intrinsic 
determinants such as genomic alterations, cell plasticity, and cell-of-origin have a crucial 
impact on the development of heterogeneous breast cancer, but also interclonal, interlineage 
and heterotypic interactions. 
 
3.2.5 Consequences of breast tumor heterogeneity 
Heterogeneity enhances the robustness of tumors (Marusyk and Polyak, 2010). It can confuse 
diagnosis and prognosis and challenge cancer therapies. Indeed, while targeted therapy (e.g., 
Trastuzumab and Lapatinib, Everolimus combined with endocrine therapy) and cytotoxic 
drugs are efficient strategies to treat some subtypes of breast cancer (Zardavas et al., 2013), 
high variability in therapeutic response and modest clinical benefit in terms of overall survival 
occur. As the progression of heterogeneous breast tumors rarely depends on a single pathway, 
this can be the basis of resistance to targeted therapies (De Palma and Hanahan, 2012; Ramos 
and Bentires-Alj, 2015). Mutations resulting in resistance may already be present at a very 
low frequency in the primary tumor or may occur during treatment (Bhang et al., 2015; 
Ramos and Bentires-Alj, 2015). Despite the elimination of responsive clones, the presence of 
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resistant clones may reduce treatment success and lead to tumor relapse and therapy failure 
(Marusyk and Polyak, 2010).  
 
3.2.6 Conclusion and counter-measures of breast tumor heterogeneity 
Our knowledge of tumor heterogeneity is presumably only the peak of the iceberg. The 
complexity and diversity of breast cancers needs to be characterized at the level of individual 
patients if efficient prognostic and predictive decisions are to achieve long-lasting therapeutic 
responses. This in-depth understanding is critical to the efficacy of personalized medicine (De 
Palma and Hanahan, 2012). Predictive preclinical trials may prove useful in which several 
PDXs from the same patient are established and characterized at the genomic and proteomic 
levels. The PDXs would be subjected to an ex vivo educated screen of drugs or drug 
combinations based on the results of genomic/proteomic analysis. The most efficient 
treatments revealed by such a screen would be compared to the current standard of care ex 
vivo and in vivo. Based on these data, treatment could be adjusted using approved drugs or 
patients may be directed to relevant clinical trials. Generating PDXs from different sites 
within primary tumors and metastases would permit assessment of tumor heterogeneity at 
different stages of tumor progression and facilitate identification of biomarkers in individual 
patients. Moreover, personalized PDX models might reveal therapy resistance before this 
emerges in the patient (Hidalgo et al., 2014; Nardella et al., 2011). Arguably, PDXs 
established in immunodeficient mice are not subject to the effects of the immune system or 
species-specific heterotypic signaling interactions between neoplastic cells and recruited 
stromal cells. The development of humanized mouse models may overcome this potential 
limitation. In-depth longitudinal studies in which tumor and liquid biopsies at different time 
points of tumor progression (particularly for metastases) should also help define tumor 
evolution and allow adjustment of the therapy as needed. These predictive preclinical trials 
Introduction 
22 
 
and longitudinal studies should be applied as a priority to patients who fail first-line therapies. 
Such a personalized approach has been performed (Bousquet et al., 2014), but it remains 
costly and is time- and resource demanding. To overcome the cost issue and avoid a two-
tiered society, health authorities, the pharmaceutical industry, and health insurance companies 
should work together to identify a new paradigm for personalized medicine.  
Distinct cellular and molecular mechanisms account for the development of tumor 
heterogeneity. Here, several processes are highlighted that contribute to diversity in breast 
cancer. It is clear that none of these mechanisms alone explain all facets of breast cancer 
heterogeneity and, thus, a combination of several factors is most likely involved. These 
include tumor-initiating alterations in distinct cells-of-origin, cancer cell plasticity, genomic 
evolution during tumor progression and treatment, as well as reciprocal interaction with the 
tumor environment. Systems-medicine investigations are warranted in the future to clarify and 
model all aspects of these multipronged processes during tumor progression and, as a 
consequence, to develop long-lasting, beneficial therapies. 
 
3.3 Phosphoinositol 3-Kinase (PI3K) signaling 
3.3.1 PI3K classification 
Phosphoinositide 3-kinases (PI3Ks) belong to a family of lipid kinases involved in 
metabolism, growth, proliferation and survival signaling. PI3Ks are heterodimers of 
regulatory (p85α, p85β, p50α, p55α, p55γ) and catalytic (p110α, p110β, p110γ or p110δ) 
subunits (Yuan and Cantley, 2008; Zhao and Vogt, 2008a). PI3Ks are classified in three 
classes (I-III) according to their substrate preference and sequence homology. Each class has 
different roles in cellular signaling (Engelman et al., 2006). Class I PI3Ks preferentially 
phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-
trisphosphate (PIP3) and are divided into two subgroups depending on the receptors which 
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activate the signaling cascade. Class IA PI3Ks are activated by growth factor receptor 
tyrosine kinases (RTKs) while class IB is activated by G-protein-coupled receptors (GPCRs). 
Class II PI3Ks preferentially phosphorylate phosphatidylinositol and to a lesser extent 
phosphatidylinositol-4-phosphate (PI-4-P). This class can be activated by RTKs, cytokine 
receptors and integrins. Class III was initially identified in yeast. The enzyme Vsp34 and its 
mammalian homologue hVsp34 are predominantly involved in membrane trafficking, 
endosomal protein sorting, endosome-lysosome maturation, autophagy and cytokinesis 
(Engelman et al., 2006; Jean and Kiger, 2014). 
3.3.2 Class IA PI3K–signaling axis 
Class IA PI3Ks are heterodimers of a p85 regulatory subunit and a p110 (α, β or δ) catalytic 
subunit. In an inactive state, the regulatory p85 subunit interferes with the kinase activity of 
the catalytic subunit p110. Class IA PI3Ks are activated by growth factor receptor tyrosine 
kinases (RTKs) including insulin receptor, members of the epidermal growth factor receptor 
family and platelet-derived growth factor receptor. Ligand binding to the respective receptors 
leads to receptor dimerization and autophosphorylation, which recruits adapter molecules 
(e.g., insulin receptor substrate (IRS) 1 or 2) and the regulatory subunit p85. By binding to the 
phospho-tyrosine residues of the RTKs or adapter molecules, p85 releases the catalytic 
subunit p110 which then translocates to the plasma membrane and phosphorylates the 3-
hydroxyl group of phosphatidylinositol-4,5-bisphosphate (PIP2), resulting in the production of 
the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3). This recruits and 
activates several signaling proteins, including the phosphoinositide-dependent kinase 1 
(PDK1) and protein serine-threonine kinase AKT, leading to the activation of their 
downstream effectors. PI3K action is reversed by the PTEN phosphatase (Cantley, 2002; 
Engelman, 2009; Yuan and Cantley, 2008) (Fig. 3-8).  
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Figure 3-8 │ PI3K-signaling axis 
Scheme of the class IA phosphoinositol-3 kinase (PI3K) signaling axis. Upon ligand binding, 
dimerization and autophosphorylation of receptor tyrosine kinases (RTKs), adapter molecules 
including insulin receptor substrate (IRS) and the regulatory p85 subunit of the PI3K are recruited. 
Binding of the p85 subunit to the phospho-tyrosine residues of the RTKs releases the catalytic subunit 
p110 which then translocates to the plasma membrane and phosphorylates phosphatidylinositol-4,5-
bisphosphate (PIP2) resulting in the production of the second messenger phosphatidylinositol-3,4,5-
trisphosphate (PIP3). This results in recruitment and activation of signaling proteins such as 
phosphoinositide-dependent kinase 1 (PDK1) and protein serine-threonine kinase AKT leading to the 
activation of downstream effectors involved in several cellular programs as cell cycle, apoptosis, 
growth and metabolism. PI3K action is reversed by the phosphatase PTEN.  
 
3.4 PIK3CA mutations in breast cancer 
Genomic alterations of components of the PI3K pathway are found in over 70% of breast 
cancers (Cancer Genome Atlas, 2012; Miller et al., 2011). The gene PIK3CA encodes the 
catalytic subunit p110α and its amplification and/or mutation is associated with several kinds 
of human solid tumors (Bachman et al., 2004; Kadota et al., 2009; Levine et al., 2005; 
Samuels et al., 2004; Wu et al., 2005). Activating somatic mutations in PIK3CA are present in 
approximately 30% of human breast cancers at all stages (Bachman et al., 2004; Barbareschi 
et al., 2007; Miller, 2012; Saal et al., 2005; Samuels et al., 2004). In 47% of these cases, 
mutations occur in the kinase domain, the most frequent one is H1047R in exon 20. In 33% of 
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these cases, mutations occur in the helical domain, the most frequent ones are E545K and 
E542K in exon 9 (Bader et al., 2005; Samuels et al., 2004). These mutations lead to a 
constitutively active enzyme with oncogenic capacity in vitro and enhance tumorigenicity in 
xenograft models (Bader et al., 2006; Isakoff et al., 2005; Zhao et al., 2005). It was suggested 
that kinase and helical domain mutations may trigger gain of function through different 
mechanisms. While E545K-mutations are independent of binding to the adaptor molecule p85 
but require interaction with Ras-GTP, the H1047R-mutants are highly dependent on p85 for 
its oncogenic capacity but are independent of Ras-GTP (Zhao and Vogt, 2008b). Moreover, it 
was shown that in contrast to kinase mutants, the helical domain mutants directly associate 
with IRS1 without growth factor stimulation and without the interaction with p85 (Hao et al., 
2013). Additionally, studies showed that alterations in distinct exons of PIK3CA have varying 
impacts on tumor development and progression. One study demonstrated PIK3CA
H1047R
 to be 
more potent in inducing tumors in transplantation assays in vivo (Bader et al., 2006) while 
another study found no trend (Zhao et al., 2005). The exact impact of these mutations on 
breast cancer has remained controversial. 
Alterations in PIK3CA are found at similar frequencies in pure ductal carcinoma in situ 
(DCIS), DCIS adjacent to invasive ductal carcinoma (IDC), and in IDC, indicating that 
PIK3CA mutations occur early in carcinoma development (Miron et al., 2010). In addition, 
mutant p110α has been found in distinct human breast cancer subtypes such as ERα-positive, 
PR-positive, HER2/Neu positive and triple-negative breast cancers (Boyault et al., 2012; Saal 
et al., 2005), but the correlation between PIK3CA mutations and pathological parameters 
remains controversial (Bachman et al., 2004; Campbell et al., 2004; Dunlap et al., 2010; 
Dupont Jensen et al., 2011; Kalinsky et al., 2009; Li et al., 2010; Li et al., 2006; Perez-
Tenorio et al., 2007; Saal et al., 2005). Also assessment of the clinical outcome associated 
with these hotspot mutations showed contradictory results: some studies reported poor 
prognosis in breast cancer patients harboring PIK3CA exon 20 (Lai et al., 2008; Mangone et 
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al., 2012) or exon 9 mutations (Barbareschi et al., 2007) whereas others reported favorable 
prognosis with improved overall survival in patients with exon 20 mutations (Barbareschi et 
al., 2007; Kalinsky et al., 2009). Notably, PIK3CA mutations were shown to reduce the 
efficacy of HER2- and ER-targeted therapies (Eichhorn et al., 2008; Kataoka et al., 2010; 
Miller et al., 2009).  
 
3.5  Mouse models of PIK3CA mutations 
3.5.1 Tumor formation in PIK3CAH1047R mutant mice  
Adding to the list of mammary tumor mouse models (Borowsky, 2011), several groups have 
generated transgenic mice expressing PIK3CA
H1047R
 in the mammary gland (Adams et al., 
2011; Liu et al., 2011; Meyer et al., 2011; Tikoo et al., 2012; Yuan et al., 2013) (Fig. 3-9, 
Table 3-1). In contrast to mouse models such as Neu, Myc or polyoma middle T-antigen that 
evoke tumors with a very specific phenotype, expression of PIK3CA
H1047R
 in mice induces 
heterogeneous tumors. In previous studies two different promoters for conditional mammary-
specific expression of human PIK3CA
H1047R
 or murine Pik3ca
H1047R
 were used to drive Cre 
recombinase expression. First, Cre driven by the MMTV-Cre promoter results in mosaic 
expression of mutant PIK3CA/Pik3ca in differentiated mammary luminal cells and progenitor 
cells, and in further organs, depending on the MMTV-Cre line (Andrechek et al., 2005; 
Soriano, 1999; Srinivas et al., 2001; Tikoo et al., 2012; Wagner et al., 2001; Wagner et al., 
1997). Second, Cre driven by the WAPi-Cre (Wintermantel et al., 2002) results in expression 
of mutant PIK3CA
H1047R
 in alveolar progenitor cells and differentiated secretory luminal cells 
(Meyer et al., 2011) (Fig. 3-9a). Tetracycline-inducible promoter systems (combined with 
MMTV-rtTA (Gunther et al., 2002)) were also used to drive overexpression of H1047R 
leading to a 7-8 fold change in expression of mutant PIK3CA compared to endogenous Pik3ca 
(Liu et al., 2011) (Fig. 3-9b). Other groups have used a knock-in system to express 
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Figure 3-9│Schematic overview of constructs that were used to generate mutant PIK3CA/Pik3ca 
models 
a, WAPi-Cre PIK3CA
H1047R
 and MMTV-Cre PIK3CA
H1047R
 models (Meyer et al., 2011). b,  MMTV-
rtTA TetO-PIK3CA
H1047R
 model (Liu et al., 2011). c, MMTV-Cre Pik3ca
H1047R
 model (Yuan et al., 
2013). d, MMTV-Cre Pik3ca
H1047R
 model (Tikoo et al., 2012). e, MMTV-Cre
NLST
 Pik3ca
H1047R
 model 
(Adams et al., 2011). f, MMTV-MYR-p110a model (Renner et al., 2008).  
EGFP, enhanced green fluorescent protein; HA, hemagglutinin; IRES, internal ribosome entry site; 
PGK, phosphoglycerate kinase; SA, splice acceptor sequence. Triangles represent loxp sites. 
 
endogenous levels of Pik3ca
H1047R
 under the control of the native promoter (combined with 
MMTV-Cre (Wagner et al., 2001; Wagner et al., 1997)) (Tikoo et al., 2012; Yuan et al., 2013) 
(Fig. 3-9c,d).  
Meyer et al. showed mammary-tumor independent high lethality (~75%) in MMTV-
Cre PIK3CA
H1047R
 mice. Whilst the cause of death could not be identified, promoter leakiness 
leading to expression of PIK3CA
H1047R
 mutant in other tissues was suggested (Meyer et al., 
2011). Using two different MMTV-Cre lines (Soriano, 1999; Srinivas et al., 2001; Wagner et 
al., 1997) to induce expression of the PIK3CA
H1047R
 mutation (Fig. 3-9e), Adams et al. found 
that some of MMTV-Cre
lineA
 Pik3ca
H1047R
 and MMTV-Cre
NLST 
Pik3ca
H1047R 
mice reached 
endpoint (e.g., lethargy, impaired breathing, tumors) independently of mammary tumors  
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Mouse model 
Mean age at 
tumor onset 
Pathology Ref. 
MMTV- myr- 
PIK3CA and 
MMTV-myr- 
PIK3CA ; p53
+/-
 
Not reported Nulliparous: adenosquamous carcinoma;  
 
Parous: 66% adenosquamous carcinoma, 34% 
carcinoma; (all ER+, cathepsin D+)  
(Renner et al., 2008) 
MMTV-myr-
PIK3CA 
CDK4(R24C) 
Not reported Nulliparous: adenosquamous carcinoma, papillary 
adenocarcinoma, carcinoma, sarcoma;  
Parous: adenosquamous carcinoma, complex 
adenocarcinoma, carcinoma, sarcoma (all ER+ except 
sarcoma) 
(Renner et al., 2008) 
MMTV-Cre
NLST
 
PIK3CA
H1047R
 
5 months 
 
Adenosquamous carcinoma (51%; ER+, K8+, K14+, 
K8/14+, K8/14-, N-Cadherin+, Vimentin+, Atf3+, 
K10+, β-Catenin+), adenomyoepithelioma (45%; 
ER+, K8+, K14+, N-Cadherin+, Atf3+, Desmin+, β-
Catenin+), spindle cell tumors (1%), poorly 
differentiated adenocarcinoma (3%) 
(Adams et al., 2011) 
MMTV- 
Cre
NLST
 
PIK3CA
H1047R
  
p53
fl/+
 
< 5 months Spindle cell/EMT tumors (33%, ER+, K8+, K14+, N-
Cadherin+, Desmin+), adenosquamous carcinoma 
(52%, ER+, K8+, K14+, K8/14+, K8/14-, N-
Cadherin+, Desmin-, K10+), radial scar type lesions 
(10%) and poorly differentiated adenocarcinoma 
(5%, ER+, K8+, K14+, K8/14+, K8/14-) 
(Adams et al., 2011) 
MMTV-rtTA 
TetO-
PIK3CA
H1047R
 
7 months  Adenocarcinoma and adenosquamous carcinoma (Liu et al., 2011) 
WAPi-Cre 
PIK3CA
H1047R
 
Parous: 140.3 
(±6.9) days 
(=36.8±4.9 days 
after delivery); 
nulliparous: 219 
(± 12) days 
Adenosquamous carcinoma (54.6%), 
adenomyoepithelioma (22.7%, PR+), 
adenocarcinoma with squamous metaplasia (13.6%), 
adenocarcinoma (9.1%) (all ER+, K14+, K18+, 
K14/18+)  
(Meyer et al., 2011) 
MMTV-Cre 
PIK3CA
H1047R
 
214 (±22.6) 
days 
Adenomyoepithelioma (100%) (ER+, PR+, K14+, 
K18+ and α-SMA) 
(Meyer et al., 2011) 
MMTV-Cre 
PIK3CA
H1047R
  
Parous: 465 
days; 
nulliparous: 492 
days 
Fibroadenoma (76.9%), adenocarcinoma (15.4%) 
(both K5+, K18+, ER+ and PR+); spindle cell 
neoplasia (7.7%, ER-,PR- ,K5-, K18+ ,Vimentin+) 
(Yuan et al., 2013) 
MMTV-Cre 
PIK3CA
H1047R
  
Parous: 393 
days; 
nulliparous: 484 
days  
Benign fibroadenoma (45%), carcinosarcoma (both 
ER+, K5/6+, K8/18+, K5/K8+, K8/E-Cadherin+) or 
sarcoma (42.5%); adenosquamous carcinoma (10%) 
(K5/6+, K8-, E-Cadherin-); osteosarcoma (2.5%) 
(Tikoo et al., 2012) 
Table 3-1│ Summary of mouse models of PIK3CA alterations  
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(Adams et al., 2011). These observations raise the concern whether MMTV-Cre is the optimal 
promoter system to study PIK3CA-induced mammary cancer in mice. Each of these systems 
leads to the development of heterogeneous mammary tumors. The most prominent 
phenotypes, adenosquamous carcinoma and adenomyoepithelioma express ERα, as well as 
basal (e.g., keratin 5 and 14) and luminal markers (e.g., keratin 8 and 18). The Pik3ca
H1047R
 
knock-in models of Yuan et al. and Tikoo et al. led mostly to hormone receptor-positive 
fibroadenomas (76.9% and 45%, respectively) or sarcomas (42.5%). Other histopathological 
features such as adenocarcinoma, carcinosarcoma and osteosarcoma were also observed 
(Tikoo et al., 2012; Yuan et al., 2013) (Table 3-1). Heterogeneity, a feature of human breast 
cancer, was also reported in mouse models of Pten inactivation (Li et al., 2002; Stambolic et 
al., 2000). In another study, however, loss of PTEN resulted only in adenomyoepithelioma 
(Dourdin et al., 2008) (for a Review of PTEN mouse models, please see (Hollander et al., 
2011)).  
Tumor heterogeneity and the observation that PIK3CA
H1047R
 mutants develop keratin 
5/14- and keratin 8/18-positive mammary carcinomas (Adams et al., 2011; Meyer et al., 2011; 
Tikoo et al., 2012; Yuan et al., 2013) suggest either a luminal and basal tumor cell-of-origin, 
transdifferentiation or the dedifferentiation of cell lineage committed tumor cells to 
multipotent progenitors that then give rise to keratin 5/14- and keratin 8/18-positive cells. 
Tikoo et al. found that expression of Pik3ca
H1047R
 results in an expansion of the luminal 
progenitor population. Furthermore, the putative mammary stem cell-enriched basal 
population and the luminal progenitors of mutants display enhanced colony-forming ability 
and a larger colony size (Tikoo et al., 2012), but the molecular mechanisms underlying these 
effects have not yet been defined. The current mouse models do not definitely address the 
question what causes heterogeneity in PIK3CA
H1047R
-evoked tumors and which cell type gives 
rise to which subtype of mammary cancer. Lineage-tracing experiments should provide 
further information about the cell-of-origin and cellular hierarchy in tumors. 
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Nulliparous animals developed tumors at an average of 219 days in WAPi-Cre 
PIK3CA
H1047R
 animals (S.K. and M.B.A., unpublished data) and 484 and 492 days in MMTV-
Cre Pik3ca knock-in H1047R animals (Tikoo et al., 2012; Yuan et al., 2013). Notably, tumor 
latencies in parous animals ranged from an average of 140 days in WAPi-Cre PIK3CA
H1047R
 
animals (Meyer et al., 2011) to 392 and 465 days in MMTV-Cre Pik3ca knock-in H1047R 
animals (Tikoo et al., 2012; Yuan et al., 2013), showing that pregnancy accelerates 
tumorigenesis in these models. An increase in the number of H1047R-expressing cells after 
pregnancy and a delay in involution, due to a reduced number of apoptotic cells, was observed 
in WAPi-Cre PIK3CA
H1047R
 mice (Meyer et al., 2011). 
Tumor formation was also investigated using MMTV-driven expression of non-
mutated p110α fused to a Src myristolyation sequence (Fig. 3-9f), which results in the 
recruitment of p110α to the membrane and constitutive activation of PI3K signaling (MMTV-
MYR-p110α). Transgenic mice developed heterogeneous ER-positive mammary tumors but 
at a frequency lower than mice expressing mutant PIK3CA (Renner et al., 2008). 
 
3.5.2 Synergism between PIK3CAH1047R and P53 alterations 
Whole-exome capture and sequencing of mammary tumors from MMTV-Cre knock-in 
Pik3ca
H1047R
 mice of various histotypes has revealed an increase in somatic mutations in 
spindle cell tumors (~44-88) and adenocarcinoma (~4-61) more than in fibroadenoma (~2-13) 
(Yuan et al., 2013). Moreover, comparative genomic hybridization (CGH)-array profiling 
showed a greater accumulation of chromosomal copy number alterations in spindle cell 
tumors than in adenocarcinoma and fibroadenoma, compared with normal mammary glands 
(Yuan et al., 2013). Functional validation and examination of the clinical relevance of these 
secondary genomic alterations are warranted.  
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The most common alterations in breast cancer are found in the PI3K- and p53-
signaling pathways (Cancer Genome Atlas, 2012). Some human breast tumors harbor 
alterations in PIK3CA in combination with mutant P53 (Boyault et al., 2012; Buttitta et al., 
2006; Maruyama et al., 2007). P53 mutations (R245H, A135V, I192N) were among the 
secondary mutations identified by Yuan et al. (Yuan et al., 2013) in adenocarcinoma and 
spindle cell neoplasia. It is likely that these mutations prevented the well-established p53-
dependent tumor suppression. Notably, Pik3ca mutant mouse models were used to investigate 
the interaction of Pik3ca
H1047R
 and p53 (Adams et al., 2011; Yuan et al., 2013). 
Heterozygosity in p53 was shown to accelerate tumor onset in MMTV-Cre Pik3ca
H1047R
 
mutant mice (Adams et al., 2011). The tumor histotype in double mutants consisted mostly of 
ER-, K14- and K8-positive spindle cell tumors that express EMT markers, or adenosquamous 
carcinoma (Adams et al., 2011) (Table 3-1). 
p53 is found inactivated in MMTV-MYR-p110α-evoked tumors suggesting that p53 
loss is important for tumorigenesis in this model. No difference was found in tumor latency or 
tumor phenotype between MMTV-MYR-p110α mice in a heterozygous p53 background and 
MMTV-MYR-p110α mice (Renner et al., 2008). Notably, MMTV-MYR-p110α mice in an 
inactive pRB background (CDK4 R24C knock-in line (Quereda et al., 2007; Sotillo et al., 
2001)) showed enhanced mammary tumorigenesis. These data suggest that tumor suppression 
mechanisms can be circumvented by inactivation of either p53 or pRB in PIK3CA
H1047R
 
mutant tumors (Renner et al., 2008).  
 
3.5.3 PIK3CAH1047R mutations and metastasis 
Mouse models of altered PI3K pathway can increase our understanding of breast cancer 
progression and metastatic spread. Metastases were reported in Pten heterozygous mice: One 
study found a metastatic tumor in the regional lymph node of one mouse, while three other 
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animals had lung metastases. Their morphological appearance was similar to the primary 
tumor (Stambolic et al., 2000). In contrast, metastases are rarely found in 
PIK3CA/Pik3ca
H1047R
 mouse models. There is only one report of isolated lung metastasis in 
MMTV-Cre
NLST
 Pik3ca
H1047R
 mice (Adams et al., 2011). However, PIK3CA mutations occur 
at high frequencies in metastatic human breast cancer. The comparison of primary tumors 
with matched metastases revealed 42% and 20% of exon 20 (H1047R/H1047L) or exon 9 
(E545K/E542K) mutations in the corresponding metastatic tumors, respectively. Cases were 
reported in which matched metastases from PIK3CA wildtype primary tumors gained PIK3CA 
mutations or in which metastases from PIK3CA mutant primary tumors lost its mutation. 
Moreover, mutations in both exons occur (Dupont Jensen et al., 2011). Surprisingly, 
oncogenic PIK3CA-driven breast tumors have a longer time to recurrence after surgery 
(Dupont Jensen et al., 2011) and some clinical studies reported a good prognosis (Barbareschi 
et al., 2007; Kalinsky et al., 2009). These observations may mean that mutant PIK3CA results 
in a selective advantage for breast cancer cells at the primary site but not during metastatic 
progression and colonization of distant sites. Further analysis of PIK3CA status in a large 
number of metastatic lesions, circulating tumor cells and matched primary tumors should 
clarify this “PIK3CA paradox” (Meyer and Bentires-Alj, 2010). An alternative explanation is 
that patients with mutations in PIK3CA respond well to current standard of care resulting in 
this apparent paradox.  
Constitutively active PI3K signaling, in association with further genomic alterations, 
induces mammary cancer in mice, which suggests a causative role for PIK3CA mutations in 
breast tumorigenesis. Additional gain- or loss-of-function genomic alterations may also 
contribute to metastasis in breast tumor progression. The identification of these synergistic 
oncogenic pathways is of paramount importance for the elucidation of the “wiring diagram” 
of tumors cells with PIK3CA mutations. 
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3.5.4 Therapeutic strategies and resistance in mutant PIK3CA mouse models 
Several PI3K pathway-targeting compounds are currently being evaluated in cancer-related 
clinical trials (Leroy et al., 2014). PIK3CA mouse models also serve as a valuable tool for 
testing anti-cancer drugs (Courtney et al., 2010; Engelman et al., 2008). A test of the efficacy 
of the PI3K inhibitor GDC-0941 by Yuan et al. showed a decline in tumor growth in spindle 
cell tumors with Pik3ca
H1047R
 and P53 mutations (Yuan et al., 2013). 
These mouse models have already proved useful for investigating resistance 
mechanisms. For example, PIK3CA
H1047R
-driven tumors were shown to recur after 
PIK3CA
H1047R
 inactivation in a PI3K-dependent or -independent manner (Liu et al., 2011). 
Tumor survival in c-MET elevated tumors was shown to depend on an active endogenous 
PI3K pathway, whereas c-MYC elevation contributed to oncogene independence and GDC-
0941 resistance (Liu et al., 2011). The PI3K-independent recurrence of PIK3CA
H1047R
-
initiated mammary tumors shows how important it is to investigate associated pathways 
involved in tumor formation that may result in escape from treatment. Their delineation 
should pave the way for the development of mechanism-based combination therapies. 
 
Parts of this introduction were published in  
 
FEBS J. 2013 Jun;280(12):2758-65. doi: 10.1111/febs.12175. Epub 2013 Mar 1. 
Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors. 
Shany Koren and Mohamed Bentires-Alj. 
The full published review can be found in appendix 10.4.  
 
and are in press in  
 
Molecular Cell. 2015  
Breast tumor heterogeneity: Source of fitness, hurdle for therapy. 
Shany Koren and Mohamed Bentires-Alj. 
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4 | Rationale of the work 
Tumor heterogeneity impinges on prognosis, response to therapy, and metastasis. As such, 
heterogeneity is one of the most important and clinically relevant areas of cancer research. In-
depth characterization and understanding of the origin of this phenotypic and molecular 
diversity is paramount to improving diagnosis, the definition of prognostic and predictive 
biomarkers, and the design of therapeutic strategies.  
Breast cancer displays frequent intra- and intertumor heterogeneity as the result of 
genetic and non-genetic alterations that often enhance the vigor of cancer cells. Heterogeneity 
is found in histopathological subtypes, molecular profiles, clinical outcomes and responses to 
therapy. This heterogeneity suggests that distinct breast cancer subtypes derive from distinct 
epithelial cell subtypes in the mammary gland (Ince et al., 2007) and/or that cells acquire 
plasticity upon transformation (Brooks et al., 2015; Skibinski and Kuperwasser, 2015). As 
histology of tumors does not necessarily reflect the nature of the cell-of-origin (Lim et al., 
2009; Molyneux et al., 2010), the key to understand pathogenesis of cancer is the 
identification of the target cells of transformation. Moreover, delineating mammary cell 
hierarchy and the consequences of transforming events on lineage organization is important, 
not only for understanding the cell-of-origin but also the heterogeneity and the aggressiveness 
of breast cancer. 
As PIK3CA is the most frequent gain of function mutation in human breast cancer 
(Cancer Genome Atlas, 2012) and it can give rise to heterogeneous mammary tumors in 
animal models, it is of paramount importance to investigate the effect of oncogenic PIK3CA 
on tumor heterogeneity and aggressiveness. Several PIK3CA
H1047R
-expressing mouse models 
were developed (Adams et al., 2011; Liu et al., 2011; Meyer et al., 2011; Tikoo et al., 2012; 
Yuan et al., 2013). However, whether expression of PIK3CA
E545K
 mutants also evokes 
mammary tumors in vivo and how they differ from PIK3CA
H1047R
-expressing tumors 
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remained elusive. Moreover, the target cell of transformation in mutant PIK3CA-evoked 
tumors has remained unknown. Expression of mutant PIK3CA in specific subpopulations of 
the mammary gland can reveal associations between targeted cell and tumor incidence, 
progression and phenotype. Additionally, the impact of mutant PIK3CA
H1047R
 on fate 
switching and cell plasticity during mammary tumor development has remained largely 
unclear. Its identification is essential for understanding tumor heterogeneity.  
 
Specifically I wanted to elucidate the effect of: 
i. PIK3CAE545K expression on mammary tumorigenesis and tumor heterogeneity in vivo. 
ii. PIK3CAH1047R expression on the mammary cell hierarchy in vivo.  
iii. PIK3CAH1047R expression in basal Lgr5-positive and luminal keratin 8-positive 
mammary cells on tumor onset, heterogeneity and phenotype.  
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5 | Results Part I 
Effects of PIK3CA
E545K
 expression on mammary tumorigenesis 
 
Research article published in Oncogenesis. 2013 Sep 30;2:e74. doi: 10.1038/oncsis.2013.38 
(shared first authorship) 
 
 
 
 
The full published article can be found in appendix 10.4.   
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5.1 Summary   
The PI3K signaling cascade is a key mediator of cellular growth, survival and metabolism and 
is frequently subverted in human cancer. The gene encoding for the alpha catalytic subunit of 
PI3K (PIK3CA) is mutated and/or amplified in ∼30% of breast cancers. Mutations in either 
the kinase domain (H1047R) or the helical domain (E545K) are most common and result in a 
constitutively active enzyme with oncogenic capacity. PIK3CA
H1047R
 was previously 
demonstrated to induce tumors in transgenic mouse models; however, it was not known 
whether overexpression of PIK3CA
E545K
 is sufficient to induce mammary tumors and whether 
tumor initiation by these two types of mutants differs. Here, we demonstrate that expression 
of PIK3CA
E545K
 in the mouse mammary gland induces heterogeneous mammary carcinomas 
but with a longer latency than PIK3CA
H1047R
-expressing mice. Our results suggest that the 
helical domain mutant PIK3CA
E545K
 is a less potent inducer of mammary tumors due to less 
efficient activation of downstream Akt signaling. 
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5.2 Results 
5.2.1 Expression of PIK3CAE545K but not wild-type PIK3CA induces mammary tumors 
Previously it was shown that PIK3CA
H1047R
 induces mouse mammary carcinomas (Adams et 
al., 2011; Liu et al., 2011; Meyer et al., 2011; Tikoo et al., 2012). To test whether expression 
of wild-type human PIK3CA (PIK3CA
wt
) or PIK3CA
E545K
 also induces mammary tumors, we 
generated novel transgenic mice that conditionally express PIK3CA
wt
 or PIK3CA
E545K
 (Fig. 5-
1a). To achieve equivalent transgene expression, we integrated PIK3CA
wt
 or PIK3CA
E545K
 
into the ROSA26 locus using RMCE-mediated recombination (Tchorz et al., 2009). Correct 
integration of the target cassettes was confirmed in the resulting PIK3CA
wt
 and PIK3CA
E545K
 
lines (Fig. 5-1b, left). PIK3CA
wt
 and PIK3CA
E545K
 animals were then crossed to WAPiCre 
mice in which expression of recombinase Cre is controlled by the whey acidic protein (WAP) 
promoter, which is mainly active in secretory mammary epithelial cells (Booth et al., 2007; 
Boulanger et al., 2005; Bruno and Smith, 2011; Wintermantel et al., 2002), and expression of 
the transgenes confirmed (Fig. 5-1b, right). This enabled us to directly compare the kinetics 
of tumor onset in PIK3CA
wt
 and PIK3CA
E545K
 mice, and the previously reported WAPiCre 
PIK3CA
H1047R
 mice (Meyer et al., 2011). 
The resulting bi-transgenic WAPiCre PIK3CA
wt
 and WAPiCre PIK3CA
E545K
 female 
mice were impregnated to achieve maximal Cre-mediated recombination and the pups 
removed 1 day after delivery. All WAPiCre PIK3CA
E545K
 mice developed mammary tumors 
on average 80 (±10) days after delivery, while parous WAPiCre PIK3CA
wt 
mice did not form 
tumors within 520 days (Fig. 5-1c). This indicates that overexpression of wild-type PIK3CA 
itself is insufficient to induce mammary tumors. Of note, the latency to tumor onset in 
WAPiCre PIK3CA
E545K
 animals was significantly longer than that observed previously for 
WAPiCre PIK3CA
H1047R
 mice (36 (± 4.9) days) (Meyer et al., 2011). We also crossed 
PIK3CA
E545K
 and PIK3CA
H1047R
 lines to CAGs-CreERT2 mice that express a tamoxifen-
inducible Cre/estrogen receptor (ER) fusion protein under the control of a modified β-actin  
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Figure 5-1│Expression of PIK3CA mutant PIK3CAE545K but not PIK3CAwt induces mammary 
tumors 
a, Schematic of the constructs used for generating transgenic mice conditionally expressing human 
wild-type and mutant 5’-terminally HA-tagged PIK3CA. Vectors were constructed in which the 
PIK3CA cDNA is flanked by a floxed STOP cassette upstream and an IRES2-EGFP reporter element 
downstream. The transgene is driven by a modified chicken β-actin (CAGs) promoter. The vector was 
introduced into a modified Rosa26 locus of Balb/c mouse embryonic stem cells by recombination-
mediated cassette exchange. b, Southern blot of genomic DNA from PIK3CA
E545K
 and PIK3CA
wt
 
transgenic mice (left) and immunoblots of lysates from mammary glands isolated 12 h after onset of 
involution from WAPiCre control, WAPiCre PIK3CA
wt
 and WAPiCre PIK3CA
E545K
 mice (each n=3) 
probed for HA. Erk2 levels were used as control for equal loading (right). c, Kaplan-Meier plot 
showing tumor onset in parous WAPiCre PIK3CA
wt
 (n=8) and WAPiCre E545K (n=16) mice. The 
mice were impregnated and the pups weaned 1 day after delivery. WAPiCre PIK3CA
wt
 mice did not 
develop palpable tumors within 520 days while mice expressing PIK3CA
E545K
 developed tumors on 
average 80 (±10) days after delivery. d, Seven-week-old CAGs-CreERT2 PIK3CA
E545K
 and 
PIK3CA
H1047R
 donor mice were treated with Tamoxifen on three consecutive days for transgene 
induction and fragments of glands were transplanted into cleared fat-pads of 3-week-old Balb/c 
recipient mice. Kaplan-Meier curves show tumor onset in recipient Balb/c mice transplanted with 
CAGs-CreERT2 PIK3CA
E545K
- (n=10) or CAGS-CreERT2 PIK3CA
H1047R
-derived mammary glands 
(n=10). Balb/c mice developed palpable tumors on average 336 (±20) days (PIK3CA
E545K
) or 229 
(±17) days (PIK3CA
H1047R
) after transplantation; P= 0.0033. 
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promoter; this results in the expression of Cre-ER in virtually all cells. Unexpectedly, bi-
transgenic CAGs-Cre PIK3CA
E545K
 and PIK3CA
H1047R
 mice died by the age of 4 months even 
when no Tamoxifen was administered. Although we were unable to identify the exact cause 
of death, we concluded that leakiness of the CAGs-CreERT2 system caused premature and 
deleterious PIK3CA
E545K
 or PIK3CA
H1047R
 expression in various tissues of these mice (D.S.M. 
and M.B-A., unpublished observations).  
To compare the tumor-initiating potential of the two different PIK3CA mutants, we 
then transplanted pieces of mammary gland tissue from CAGs-CreERT2 PIK3CA
E545K
 or 
PIK3CA
H1047R
 donor mice previously treated with Tamoxifen into cleared fat pads of Balb/c 
mice. The mammary glands reconstituted by either CAGs-CreERT2 PIK3CA
E545K
 or 
PIK3CA
H1047R
-derived epithelium were hyperplastic (data not shown) and eventually formed 
tumors after 229 (±17, PIK3CA
H1047R
) and 336 days (±20, PIK3CA
E545K
), respectively (Fig. 5-
1d). As observed in the WAPiCre mouse cohorts, PIK3CA
E545K
 was significantly less potent 
than PIK3CA
H1047R
 in the induction of mammary carcinomas, which is a possible explanation 
for the lower frequency of E542K/E545K mutations in human breast cancer (Cancer Genome 
Atlas, 2012; Saal et al., 2005).  
 
5.2.2 WAPiCre PIK3CAE545K-evoked mammary tumors are heterogeneous 
Examination of 30 WAPiCre PIK3CA
E545K
-derived tumors identified six distinct histotypes. 
By far the most prevalent tumor phenotype was adenosquamous carcinoma (60%) (Fig. 5-
2a,b), which was also the most common histotype formed by WAPiCre PIK3CA
H1047R
 mice 
(54.6%) (Meyer et al., 2011). Adenocarcinomas (23.3%) and carcinomas (6.7%) were also 
observed albeit at lower frequencies (Fig. 5-2a,b). An adenocarcinoma with squamous 
metaplasia (3.3%), an adenomyoepithelioma (3.3%) and spindle cell tumor (3.3%) were 
observed in one tumor only (Fig. 5-2a,b). The low frequency of adenomyoepithelioma in 
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WAPiCre PIK3CA
E545K
 mice is in stark contrast to the WAPiCre PIK3CA
H1047R
 animals, in 
which adenomyoepitheliomas accounted for ~23% of the tumors (Meyer et al., 2011). A 
further discrepancy between mice expressing PIK3CA
E545K
 or PIK3CA
H1047R
 was the complete 
absence of diffuse and invasive adenocarcinomatosis in WAPiCre PIK3CA
E545K
-derived 
glands, a histological feature that was displayed by all tumor-surrounding tissue in WAPiCre 
PIK3CA
H1047R
 mice (Meyer et al., 2011). 
The PIK3CA
E545K
-induced tumors were stained for luminal keratin 8/18 (K8/18), 
basal/myoepithelial keratin 14 (K14), and myoepithelial α-smooth muscle actin (α-SMA) 
markers. The most frequent histotypes, adenosquamous carcinoma and adenocarcinoma, were 
positive for both luminal K8/18 and basal K14 (Fig. 5-2c). In tumors of the adenosquamous 
carcinoma type, the relative tumor areas positive for K8/18 and K14 were ~35% and ~39%, 
respectively and largely negative for α-SMA (<1%) (Fig. 5-2d). WAPiCre PIK3CAE545K-
evoked adenosquamous carcinomas also stained positive for ER (~8% of the tumor cells) and 
displayed a high proportion of Ki-67-positive cells (~35%) (Fig. 5-2c,d). The relative tumor 
areas and cells positive for K14, K8/18, α-SMA, ER and Ki-67 were very similar to those 
observed in PIK3CA
H1047R
-driven adenosquamous carcinomas (Meyer et al., 2011).   
However, the number of apoptotic cells staining positively for cleaved caspase-3 was 
higher in PIK3CA
E545K
-evoked adenosquamous carcinomas (~7%) (Fig. 5-2c,d) than those 
derived from WAPiCre PIK3CA
H1047R
 mice (~1%) (Meyer et al., 2011), indicating that 
PIK3CA
H1047R 
is a more potent suppressor of apoptosis than PIK3CA
E545K
 in mammary 
tumors. 
In summary, both PIK3CA
E545K
 and PIK3CA
H1047R
 produced K14/K8/18-positive 
tumors of various histotypes, with the adenosquamous carcinoma type being the most 
common in both transgenic models. However, differences between the mouse models 
included low abundance of adenomyoepitheliomas and the absence of adenocarcinomatosis in 
WAPiCre PIK3CA
E545K
 mice. 
Results Part I 
42 
 
 
 
Figure 5-2│WAPiCre PIK3CAE545K-evoked tumors are heterogeneous and express basal and 
luminal keratins 
a, Diagram showing relative abundance of adenosquamous carcinoma (60%, red), adenocarcinoma 
(23.3%, green), carcinoma (6.7%, purple), adenocarcinoma with squamous metaplasia (3.3%, dark 
blue), adenomyoepithelioma (3.3%, light blue) and spindle cell tumor (3.3%, orange) among tumors 
(n =30) from parous WAPiCre PIK3CA
E545K
 mice. b, H&E-stained tumor sections of the indicated 
histotypes from parous WAPiCre PIK3CA
E545K
 mice. The top-left image shows a representative 
adenosquamous carcinoma with glands and squamous features. The top-right image shows an 
adenocarcinoma; the arrows indicate the gland lumen. The glands are lined by malignant epithelium. 
The center-left image shows an adenocarcinoma with squamous metaplasia; the asterisk shows an area 
with glands and the arrow indicates areas of metaplasia. The center-right image shows a spindle cell 
tumor with possible osseous metaplasia, intense pink stroma and large cells in the interstices. The 
bottom image shows an adenomyoepithelioma. Scale bar = 100 µm. c, Immunostaining for K14, 
K8/18, α-SMA, ER, Ki67 and cleaved caspase-3. Scale bars = 50 µm. d, Quantification of 
immunostaining for K8/18, K14, α-SMA, ER, Ki67 and cleaved caspase-3 isolated from parous 
WAPiCre PIK3CA
E545K
-evoked adenosquamous carcinomas (n=8). The data are presented as 
percentages of positive tumor area and tumor cells. Histological features of WAPiCre PIK3CA
E545K
-
evoked adenosquamous carcinomas are compared to those of WAPiCre PIK3CA
H1047R
-evoked 
adenosquamous carcinomas previously reported (Meyer et al., 2011) (indicated by an asterisk). 
 
Results Part I 
43 
 
5.2.3 Pregnancy accelerates PIK3CA-evoked tumorigenesis and PIK3CA mutants delay 
mammary gland involution 
The variations in tumor histotypes and the discrepancy in tumor latency in WAPiCre 
PIK3CA
E545K
 and PIK3CA
H1047R
 mice suggest that different mechanisms underlie tumor 
initiation by these mutants. To gain a mechanistic insight that might explain these differences, 
we investigated whether pregnancy accelerates tumor onset in WAPiCre PIK3CA
E545K
 as it 
does in WAPiCre PIK3CA
H1047R
 mice (Meyer et al., 2011). Pregnancy accelerated tumor 
onset in WAPiCre PIK3CA
E545K
 mice, reducing latency from 228 ±15 days in nulliparous to 
165 ±10 days in parous mice (Fig. 5-3a). Interestingly, pregnancy appeared to accentuate the 
difference in tumor latency between WAPiCre PIK3CA
E545K
 and PIK3CA
H1047R
 mice, shown 
by 32 days difference in nulliparous versus 48 days difference in parous mice (Fig. 5-3a) 
(Meyer et al., 2011). We showed previously that a pregnancy-induced delay in mammary 
gland involution accounts, at least in part, for accelerated tumor kinetics in parous versus 
nulliparous PIK3CA
H1047R
 mice (Meyer et al., 2011). Thus, we hypothesized here that the 
longer tumor latency of parous WAPiCre PIK3CA
E545K
 compared with parous WAPiCre 
PIK3CA
H1047R
 animals is the result of a less-pronounced involution delay. Comparison of 
WAPiCre PIK3CA
E545K
 and WAPiCre PIK3CA
H1047R
 glands 15 days after weaning revealed a 
dramatic delay in involution compared with control animals (Fig. 5-3b). The relative gland 
area occupied by epithelial cells was the same in WAPiCre PIK3CA
E545K
 and PIK3CA
H1047R
 
mice and significantly larger than in WAPiCre control glands (Fig. 5-3c). Similarly, there was 
no difference in the number of apoptotic or proliferating cells in glands expressing either of 
the PIK3CA mutations (Fig. 5-3d). Interestingly, glands from WAPiCre PIK3CA
wt
 mice, 
which did not form tumors, displayed normal involution and numbers of apoptotic and 
proliferating cells similar to the controls (Fig. 5-3), indicating that delay in involution is 
caused by mutant PIK3CA rather than by overexpression of the transgene. In summary, 
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Figure 5-3│Pregnancy accelerates PIK3CA-evoked tumorigenesis and PIK3CA mutants delay 
mammary gland involution.  
a, Kaplan-Meier curves showing tumor onset in parous WAPiCre PIK3CA
E545K
 (n=16) and nulliparous 
WAPiCre PIK3CA
E545K
 (n=6) animals. Parous WAPiCre PIK3CA
E545K
 mice developed palpable 
tumors on average after 165 (±10) days while nulliparous mice developed tumors on average after 228 
(±15) days (PIK3CA
E545K
); P=0.0023. b, Representative images of whole mount (top panel), 
magnification of whole mount (center panel) and H&E (lower panel) staining of involuting glands 
from WAPiCre control, WAPiCre PIK3CA
wt
, WAPiCre PIK3CA
E545K
, and WAPiCre PIK3CA
H1047R
 
mice as indicated. The glands were isolated 15 days after removal of the pups. Scale bar = 1cm (whole 
mounts). Scale bar = 100 µm (H&E sections). c, Bar graph showing relative epithelium to total gland 
area of involution at day 15 in whole mounts prepared from WAPiCre control (n=3), WAPiCre 
PIK3CA
wt 
(n=4), WAPiCre PIK3CA
E545K
 (n=4) and WAPiCre PIK3CA
H1047R
 (n=2). Shown are means 
± s.d.; P=0.001 (WAPiCre vs. WAPiCre PIK3CA
E545K
); P=0.01
 
(WAPiCre vs. WAPiCre 
PIK3CA
H1047R
); P=0.46 (WAPiCre PIK3CA
E545K
 vs. WAPiCre PIK3CA
H1047R
). d, Immunostaining for 
Ki67 and cleaved caspase-3 of day-15 involuting glands from WAPiCre control, WAPiCre 
PIK3CA
E545K
 and WAPiCre
H1047R
 mice (upper panel). Scale bar = 50 µm. Quantification of Ki67- and 
cleaved caspase-3-positive cells (lower panel). Shown are means ± s.e.m. *For Ki67-positive cells: 
P=2.18x10
-5
 (WAPiCre vs. WAPiCre PIK3CA
E545K
), P=2.90x10
-7
 (WAPiCre vs. WAPiCre 
PIK3CA
H1047R
). For cleaved caspase-3-positive cells: P=6.55x10
-3
 (WAPiCre vs. WAPiCre 
PIK3CA
E545K
). NS=not significant. 
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PIK3CA
E545K
 and PIK3CA
H1047R
 transgene expression caused a dramatic but comparable delay 
in involution and, therefore, involution does not explain the different tumor kinetics observed 
in parous versus nulliparous mice expressing these mutations.  
 
5.2.4 WAPiCre PIK3CAE545K involuting glands show reduced pAkt and increased 
pStat3  
Comparison of lysates from WAPiCre PIK3CA
E545K
- and WAPiCre PIK3CA
H1047R
-derived 
mammary glands and tumors showed equal expression of p110α in tumors from both 
transgenic models (Fig. 5-4a). Despite the enhanced oncogenic potential of the PIK3CA
H1047R
 
mutant, no differences in activation of the PI3K/Akt or the Erk pathways were observed in the 
tumors (Fig. 5-4a). Similarly, a more detailed analysis of Akt1 and Akt2 isoform-specific 
phosphorylation revealed no difference between PIK3CA
E545K
- and WAPiCre PIK3CA
H1047R
-
induced signaling (Fig. 5-4b). Conceivably, by the time mammary tumors were established, 
numerous secondary mutations had resulted in a tumor heterogeneity that compromises the 
detection of potentially subtle differences in oncogenic signaling induced by either PIK3CA 
mutant. To circumvent this, we investigated molecular signaling events in mutant PIK3CA-
expressing epithelial cells at an early pre-neoplastic stage. Protein lysates from mammary 
glands isolated 12 hours after the onset of involution revealed increased phosphorylation of 
Akt and decreased phosphorylation of the signal transducer and activator of transcription 3 
(Stat3)  in mutant relative to control glands. These observations were both more pronounced 
in PIK3CA
H1047R
 than in PIK3CA
E545K
 glands (for pAkt P=2.5x10
-4
; for pSTAT3 P=0.047) 
(Fig. 5-4c). 
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Figure 5-4│WAPiCre PIK3CAE545K involuting glands show reduced pAkt and increased pSTAT3 
compared with WAPiCre PIK3CA
H1047R
 at 12 h of involution. 
a, Immunoblots of lysates from WAPiCre PIK3CA
E545K
 and WAPiCre PIK3CA
H1047R
 mammary tumors 
probed for the indicated proteins. b, Lysates of mammary tumors from WAPiCre PIK3CA
E545K
 and 
WAPiCre PIK3CA
H1047R
 mice were first immunoprecipitated with antibodies against either Akt1 or 
Akt2 and then probed for total Akt or S473 pAkt (upper panel). Bar graph showing relative levels of 
S473 pAkt normalized to total Akt in Akt1 or Akt2 immunoprecipitates (lower panel). c, Lysates of 
mammary glands isolated 12 h after onset of involution from WAPiCre control, WAPiCre 
PIK3CA
H1047R
 and WAPiCre PIK3CA
E545K
 mice (each n=3) probed for p110α, pAkt, Akt, pStat3, Stat3 
and Erk2 as loading control (upper panel). Bar graphs showing relative amounts of pAkt (normalized 
to total Akt), pStat3 (normalized to total Stat3) and p110α (normalized to Erk2) in lysates of WAPiCre 
control, WAPiCre PIK3CA
H1047R
 and WAPiCre PIK3CA
E545K 
mammary glands (lower panel). 
*WAPiCre vs. WAPiCre PIK3CA
H1047R
: For pAkt P=3.8x10
-5
; for pStat3 P=0.002; for p110α 
P=0.007. WAPiCre vs. WAPiCre PIK3CA
E545K
: For pAkt P=1.8x10
-4
; for pStat3 P=0.02; for p110α 
P=8.8x10
-5
.WAPiCre PIK3CA
H1047R
 vs. WAPiCre PIK3CA
E545K
: For pAkt P=2.5x10
-4
; for pStat3 
P=0.047; for p110α P=0.7. NS= not significant.  
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5.3 Discussion 
In summary, we found that expression of PIK3CA
E545K
 in a transgenic mouse model potently 
induces heterogeneous mammary tumors while expression of wild-type PIK3CA does not. 
Notably, although PIK3CA
E545K
 evokes tumors with 100% penetrance it is a weaker inducer 
of mammary tumors than PIK3CA
H1047R
 in two independent mouse models in which mutant 
PIK3CA is either driven by the WAP or CAGs promoter. This may explain the lower 
frequency of helical versus kinase domain mutations in human breast cancer (Bader et al., 
2005; Koren and Bentires-Alj, 2013).   
It was proposed that PIK3CA
E545K
 and PIK3CA
H1047R
 mutants increase PI3K activity 
by distinct mechanisms. Biochemical assays suggest that PIK3CA
E545K
 mutants mimic the 
activated wildtype p110α. PIK3CAE545K shows high basal activity and lipid binding and 
cannot be further activated by RTK phosphopeptides. In contrast, mutations in the catalytic 
domain (e.g., PIK3CA
H1047R
) increase basal kinase activities and lipid binding, which can be 
further enhanced by RTK phosphopeptides (Hon et al., 2012). Moreover, mutations in the 
helical domain (e.g., PIK3CA
E545K
) were shown to disrupt an inhibitory charge-charge 
interaction with the p85 N-terminal SH2 domain (Miled et al., 2007), while mutations in the 
catalytic domain were shown to increase the affinity for substrate-containing membranes 
(Mandelker et al., 2009). Another study showed that PIK3CA
E545K
 mutants are independent of 
binding to the adaptor molecule p85 but require interaction with Ras-GTP. PIK3CA
H1047R 
mutants are highly dependent on p85 for its oncogenic capacity but are independent of Ras-
GTP (Zhao and Vogt, 2008b). Moreover, it was shown that in contrast to kinase mutants, the 
helical domain mutants directly associate with IRS1 without growth factor stimulation and 
without the interaction with p85 (Hao et al., 2013).  
 Here, we found differences in Akt and Stat3 activation in pre-neoplastic mammary 
glands from PIK3CA
E545K
 and PIK3CA
H1047R
 transgenic mice. This observation might explain 
the longer tumor latency observed in WAPiCre PIK3CA
E545K
 compared with WAPiCre 
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PIK3CA
H1047R
 mice. Further investigation to understand the exact consequences of these 
mutations on downstream signaling and tumorigenesis is of profound interest.  
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5.4 Materials and methods 
Transgenic Mice. We constructed a vector with a transcriptional STOP sequence flanked by 
loxP sites upstream of the 5’-terminally HA-tagged human PIK3CA cDNA (Addgene) and an 
IRES2-EGFP reporter element (pIRES2-EGFP vector, Clontech). The resulting construct was 
introduced into the modified Rosa26 locus of Balb/c mouse embryonic stem (ES) cells by 
RMCE as described earlier (Meyer et al., 2011).  Chimeric mice were backcrossed to Balb/c 
mice and transgenic mice identified by genotyping (Meyer et al., 2011).  
 
Immunoblotting. Protein lysates were extracted from inguinal mammary glands or tumors 
using LB buffer (50mM Tris-HCl pH8, 150mM NaCl, 1% NP-40) supplemented with 0.5mM 
sodium orthovanadate. Anti-p110α, anti-pAkt (Ser473), anti-Akt, anti-pErk1/2 
(Thr202/Tyr204), anti-Erk1/2, anti-pS6 (Ser235/236), anti-S6, anti-Akt1, anti-Akt2, anti-
pStat3 (Tyr705) and anti-Stat3 antibodies were purchased from Cell Signaling Technology. 
 
Immunohistochemistry. The following antibodies were used: K14 (Thermo Scientific, RB-
9020, 1:100), K8/18 (Fitzgerald, #GP11, 1:200), ER (Santa Cruz, SC-542, 1:1000), α-SMA 
(Thermo Scientific, RB-9010, 1:500), cleaved caspase-3 (Cell Signaling, #9661, 1:100) Ki-67 
(Thermo Scientific, RB-9106, 1:50). 
 
Southern Blotting. Genomic DNA from mouse tails was digested with 8 U of AvrII enzyme 
(New England BioLabs (NEB)) and separated on a 1% agarose gel. A DIG-labeled DNA 
probe targeting the neomycin resistance cassette was amplified using the PCR DIG Probe 
Synthesis Kit (Roche) and the primers 5’-ATGGGATCGGCCATTGAACAAGAT-3’ and 5’-
CGGCCATTTTCCACCATGATAT-3’.  
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6 | Results Part II 
Effects of PIK3CA
H1047R
 expression on mammary cell fate and cancer 
 
Research article published in Nature. 2015 Sep 3;525(7567):114-8. doi: 10.1038/nature14669. 
Epub 2015 Aug 12. 
 
 
The full published article can be found in appendix 10.4.   
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6.1 Summary  
The adult mouse mammary epithelium contains self-sustained cell lineages that form the inner 
luminal and outer basal cell layers, with stem and progenitor cells contributing to its 
proliferative and regenerative potential (de Visser et al., 2012; Tao et al., 2014; van 
Amerongen et al., 2012; Van Keymeulen et al., 2011). A key issue in breast cancer biology is 
the effect of genomic lesions in specific mammary cell lineages on tumor heterogeneity and 
progression. The impact of transforming events on fate conversion in cancer cells-of-origins 
and thus their contribution to tumor heterogeneity remains largely elusive. Using in situ 
genetic lineage tracing and limiting dilution transplantation, we have unraveled the potential 
of PIK3CA
H1047R
, one of the most frequent mutations occurring in human breast cancer 
(Cancer Genome Atlas, 2012), to induce multipotency during tumorigenesis in the mammary 
gland. We show that expression of PIK3CA
H1047R
 in lineage-committed basal Lgr5-positive 
and luminal keratin 8-positive cells of the adult mouse mammary gland evokes cell 
dedifferentiation into a multipotent stem-like state, suggesting this to be a mechanism 
involved in the formation of heterogeneous, multi-lineage mammary tumors. Moreover, we 
show that the tumor cell-of-origin influences the frequency of malignant mammary tumors. 
Our results define a key effect of PIK3CA
H1047R
 on mammary cell fate in the pre-neoplastic 
mammary gland and show that the cell-of-origin of PIK3CA
H1047R
 tumors dictates their 
malignancy, thus revealing a mechanism underlying tumor heterogeneity and aggressiveness. 
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6.2 Results  
6.2.1 Mutant PIK3CA induces mammary cell plasticity 
To address the effects of mutant PIK3CA
H1047R
 on basal or luminal lineage-restricted cells, we 
performed lineage tracing in adult Lgr5-creERT2/Tomato-reporter and K8-creERT2/Tomato-
reporter mice with or without PIK3CA
H1047R 
(Meyer et al., 2011) (Extended Data Fig. 6-1a). 
Moreover, we used Lgr5- and K8-creERT2/PIK3CA
H1047R 
or PIK3CA
WT
 animals (Meyer et 
al., 2011; Meyer et al., 2013) for tracing of the GFP-reporter, and Lgr5-creERT2 and K8-
creERT2 as controls (Extended Data Fig. 6-1b). As previously reported (Plaks et al., 2013; 
Van Keymeulen et al., 2011), we found Lgr5-activity only in a subset of basal cells in the 
nipple area of the mammary gland (Extended Data Fig. 6-2a-e). We further assessed the 
effects of PIK3CA
H1047R
 expression on the distribution of mammary subpopulations by 
fluorescence activated cell sorting (FACS) on isolated mammary epithelial cells labeled with 
CD24 and Sca1, which were shown to enrich for luminal (CD24
high
Sca1
negative
, 
CD24
high
Sca1
positive
) and basal (CD24
low
Sca1
negative
) cells (Sleeman et al., 2006; Sleeman et al., 
2007) (Extended Data Fig. 6-3). Four days lineage-tracing confirmed Tomato-labeling of 
basal cells in Lgr5-creERT2/Tomato and Lgr5-creERT2/PIK3CA
H1047R
/Tomato and of 
luminal cells in K8-creERT2/Tomato and K8-creERT2/PIK3CA
H1047R
/Tomato animals 
(Extended Data Fig. 6-2b,f and 6-4a,b). We further performed 4-, 8- and 13-week lineage-
tracing. The distribution of Tomato-labeled subsets in Lgr5-creERT2/Tomato glands did not 
change with time where the progeny of Lgr5-positive cells was mostly of basal origin (Fig. 6-
1a,b and Extended Data Fig. 6-2g,h). In K8-creERT2/Tomato animals, labeling was 
restricted to the luminal subset, marking mostly mature CD24
high
Sca1
positive
 in 4 weeks and 
mostly CD24
high
Sca1
negative
 luminal progenitors in 13 weeks tracing, indicating the targeting of 
a long-term unipotent luminal subset (Fig. 6-1a,c and Extended Data Fig. 6-4c,d). Further  
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Figure 6-1│Mutant PIK3CA induces mammary cell plasticity 
a, Timeline for lineage-tracing studies. b,c, Representative images of 4-, 8- and 13-week tracing and 
FACS quantification of Tomato-positive epithelial basal (CD24
low
Sca1
negative
) and luminal 
(CD24
high
Sca1
negative/positive
) subsets from Lgr5-creERT2/Tomato (b, immunofluorescence: left n=3, 
middle n=11, right n=6 mice; FACS: left n=4 technical replicates (each 1-3 pooled mice), middle n=3 
technical replicates (each 1-2 pooled mice), right n=3 technical replicates (each 1 mouse)), Lgr5-
creERT2/PIK3CA
H1047R
/Tomato (b, immunofluorescence left n=3, middle n=10, right n=4 mice; 
FACS: left n=3 technical replicates (each 1-2 pooled mice), middle n=6 technical replicates (each 1 
mouse), right n=5 technical replicates (each 1-2 pooled mice)), K8-creERT2/Tomato (c, 
immunofluorescence left n=4, middle n=8, right n=5 mice; FACS: left n=4 technical replicates (each 
1-3 pooled mice), middle n=4 technical replicates (each 1-2 pooled mice), right n=5 technical 
replicates (each 1 mouse)) and K8-creERT2/PIK3CA
H1047R
/Tomato animals (c, immunofluorescence 
left n=4, middle n=4, right n=3 mice; FACS: left n=4 technical replicates (each 1-2 pooled mice), 
middle n=4, right n=3 technical replicates (each 1 mouse)). White arrowheads indicate luminal and 
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yellow arrowheads basal Tomato-labeled cells. Scale bar 100 μm; magnification 20 μm. Bar graphs 
means ±s.e.m.; two-sided unpaired student`s t-test; *P<0.05; NS= not significant. 
 
 
tracing of 20-28 weeks confirmed lineage-restriction in both models (Unpublished Data Fig. 
6-1). In contrast, expression of PIK3CA
H1047R
 in Lgr5-creERT2/PIK3CA
H1047R
/Tomato and 
K8-creERT2/PIK3CA
H1047R
/Tomato mice resulted in labeling of both the luminal and the 
basal compartments (Fig. 6-1b,c Extended Data Fig. 6-2g,h and 6-4c,d). PIK3CA
H1047R
-
evoked multi-lineage labeling was not observed at 4-7 days post-induction (Extended Data 
Fig. 6-2f,i and 6-4b). Since PIK3CA
H1047R/WT
 constructs contain an IRES-GFP, we also used 
GFP as a readout of transgene expression. At 4 days post-Tamoxifen induction, K8-
creERT2/PIK3CA
WT
 and K8-creERT2/PIK3CA
H1047R
 glands expressed similar levels of GFP 
indicating similar Cre recombination efficiency. In both models, 4- and 8-11-week lineage-
tracing revealed an increase in GFP-labeled basal and luminal subsets in PIK3CA
H1047R
 
compared to PIK3CA
WT
 animals that showed lineage-restricted GFP-labeling, consistent with 
higher PI3K-pathway activation (Extended Data Fig. 6-5 and 6-6). These results suggest that 
expression of PIK3CA
H1047R
 in basal- or luminal-restricted mammary cells triggers lineage 
plasticity and cell expansion.  
 
6.2.2 Activation of PIK3CAH1047R leads to expression of basal and luminal lineage-genes 
Next, we assessed the effects of PIK3CA
H1047R
 on global gene expression in the pre-neoplastic 
gland. Microarray and QRT-PCR analyses were performed on mammary epithelial cell 
subpopulations from Lgr5-creERT2 control versus Lgr5-creERT2/PIK3CA
H1047R
 and K8-
creERT2 control versus K8-creERT2/PIK3CA
H1047R
 animals. Genes expressed differentially 
between subpopulations of control and mutant mice were compared to subpopulation 
signatures from Meier-Abt et al. (Meier-Abt et al., 2013) and Lim et al. (Lim et al., 2010). 
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We found enrichment of luminal progenitor signature-genes in the basal Lgr5-
creERT2/PIK3CA
H1047R
 subset and in the newly formed basal K8-creERT2/PIK3CA
H1047R
 
subset. Enrichment of myoepithelial signature-genes was found in the newly formed luminal 
Lgr5-creERT2/PIK3CA
H1047R
 and in the K8-creERT2/PIK3CA
H1047R
 luminal subsets (Fig. 6-
2a,b and Extended Data Fig. 6-7). Mammary cells co-expressing basal and luminal markers 
in neoplastic areas in vivo (Fig. 6-2c) and in freshly sorted mammary cells (Unpublished 
Data Fig. 6-2) confirmed that PIK3CA
H1047R
 induces cell plasticity. 
 
 
Figure 6-2│Activation of PIK3CAH1047R leads to expression of basal and luminal lineage-genes 
Plots indicating enrichment of gene expression from FACS-sorted (a) Lgr5-creERT2/PIK3CA
H1047R
 
versus Lgr5-creERT2 control and (b) K8-creERT2/PIK3CA
H1047R
 versus K8-creERT2 control subsets 
in signatures of mammary subpopulations from Lim et al.(Lim et al., 2010) and Meier-Abt et 
al.(Meier-Abt et al., 2013). Microarray was performed 4 weeks post Tamoxifen on basal 
CD24
low
Sca1
negative
 and luminal
 
CD24
high
Sca1
negative/positive
 subsets of pooled mammary glands of 2-3 
estrus-synchronized animals from three independent sortings. c, Representative images of 
immunostaining for basal (K14 red, K5 white) and luminal (K8/18 green) markers on mammary 
glands 4 weeks post Tamoxifen (n=3 mice). White arrowheads indicate double-positive cells. Scale 
bar 100 μm; magnification 20 μm. 
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6.2.3 Expression of PIK3CAH1047R evokes multipotent stem-like cells 
We addressed how lineage plasticity is evoked by PIK3CA
H1047R
 in functional assays. 
Limiting dilution transplantation revealed an increase in mammary-repopulating capacity of 
basal cells from Lgr5-creERT2/PIK3CA
H1047R
 and K8-creERT2/PIK3CA
H1047R
 compared with 
the respective controls (Fig. 6-3). The GFP-negative basal CD24
low
Sca1
negative
 population 
from K8-creERT2 mice comprises the bulk of basal cells (myoepithelial and mammary-
repopulating cells) (Sleeman et al., 2006; Sleeman et al., 2007), explaining the lack of 
outgrowths at the number of cells transplanted. As previously reported (Sleeman et al., 2006), 
repopulating capacity can be found when 1,000 and more K8-creERT2 control basal cells are 
transplanted (Unpublished Data Fig. 6-3). PIK3CA
H1047R
-expressing luminal cells also had 
repopulating capacity (Extended Data Fig. 6-8a-c). All outgrowths expressed luminal and 
basal markers. In colony formation assays, PIK3CA
H1047R
 increased the percentage of double-
positive (K14/K8/18) colonies derived from the newly formed luminal (Lgr5-
creERT2/PIK3CA
H1047R
) and basal cells (K8-creERT2/PIK3CA
H1047R
). PIK3CA
H1047R
-
expressing subsets overcame lineage-restriction, giving rise to both lineages albeit at low 
frequencies. Moreover, basal cells from Lgr5- and K8-creERT2/PIK3CA
H1047R
 animals 
showed increased colony formation capacity (Extended Data Fig. 6-8d-f). In mammosphere 
cultures, PIK3CA
H1047R
 increased sphere-forming capacity of luminal cells. While control 
cells formed spheres with a hollow lumen after passaging, PIK3CA
H1047R
-expressing cells 
formed filled spheres, indicating the accumulation of less differentiated cells (Extended Data 
Fig. 6-8g,h). Altogether, the data suggest that PIK3CA
H1047R
 evokes cell dedifferentiation to a 
multipotent stem-like state, from which cells further differentiate into both cell lineages. 
 
 
 
 
Results Part II 
57 
 
 
Figure 6-3│ Expression of PIK3CAH1047R evokes multipotent stem-like cells 
a, Number of outgrowths in cleared-fat pad transplantation of GFP-positive (Lgr5-positive) control 
and PIK3CA
H1047R
-expressing basal subsets (upper panel). Outgrowths of GFP-negative control and 
GFP-positive PIK3CA
H1047R
-expressing basal subsets (lower panel). The GFP-negative control basal 
subset comprises mammary repopulating cells and mostly myoepithelial cells. b, Representative 
immuno-stained sections (n=3 mice) and carmine-stained whole mounts of outgrowths from cleared-
fat pad transplantation (100 cells condition). Scale bar 50 μm and 500 μm. Pooled data from 3 
independent experiments (a-b). 
 
6.2.4 The frequency of malignant tumor lesions is dictated by the cell-of-origin 
Expression of PIK3CA
H1047R
 in Lgr5- and K8-positive cells induced mammary tumors on 
average after 108 and 78 days, respectively. Control and PIK3CA
WT
 animals developed no 
tumors (Fig. 6-4a). FACS analysis of GFP-positive tumor cells revealed a similar distribution 
of cancer subpopulations, with an accumulation of the CD24
high
Sca1
negative
 subset. 
PIK3CA
H1047R
-evoked mammary tumors expressed basal and luminal markers (Extended 
Data Fig. 6-9a-d). Additionally, cells double positive for basal and luminal markers were 
found (Fig. 6-4b). These results suggest that PIK3CA
H1047R
-evoked cell plasticity results in 
multi-lineage tumors and that expression of basal and luminal markers is not an indicator of 
the origin of mammary cancers. It was proposed that basal-like mammary tumors may 
originate from luminal cells (Lim et al., 2009; Molyneux et al., 2010). Therefore, any 
inference of the cell-of-origin from the differentiation state of the tumor can be misleading. 
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Histological analysis showed heterogeneous phenotypes and differences in malignancy 
between both models. Lgr5-creERT2/PIK3CA
H1047R
 formed unique benign multi-nodular 
rosette-type adenomyoepitheliomas, aggressive adenosquamous carcinomas with 
pilosebaceous differentiation and carcinosarcomas. K8-creERT2/PIK3CA
H1047R
 led mainly to 
aggressive adenosquamous carcinoma, carcinosarcomas that infiltrated the surrounding tissue, 
adenocarcinomas and benign adenomyoepitheliomas. These results show that PIK3CA
H1047R
 
mainly evokes benign tumors (74%) with high intra-tumor heterogeneity when expressed in 
Lgr5-positive cells, in contrast to mostly aggressive mammary tumors (62%) with a 
distinctive infiltrative densely fibrotic phenotype when the cell-of-origin is K8-positive (Fig. 
6-4c and Extended Data Fig. 6-9e-f). 
Microarray analysis, principle component analysis and hierarchical-clustering of 
tumors revealed a single cluster of Lgr5-creERT2/PIK3CA
H1047R
 and 3 clusters of K8-
creERT2/PIK3CA
H1047R
 tumors. We found no correlation between tumor phenotype and 
clustering likely due to intra-tumor heterogeneity. We compared tumor expression profiles to 
different human breast cancer subtypes (Cancer Genome Atlas, 2012). The majority (7/10) of 
the K8-creERT2/PIK3CA
H1047R
 tumors correlated best with the malignant Basal-like, HER2-
enriched and Luminal-B profiles, whereas 3/10 clustered with benign Luminal-A and Normal-
like breast cancers. Lgr5-creERT2/PIK3CA
H1047R 
tumors resembled benign (2/10) but also 
malignant subtypes (3/10). However, 5/10 showed no similarity to a single subtype but were 
equidistant from all, representing the high intra-tumor heterogeneity in this model (Fig. 6-4d 
and Extended Data Fig. 6-10). The fact that K8-creERT2/PIK3CA
H1047R
 tumors but not 
Lgr5-creERT2/PIK3CA
H1047R
 tumors clustered mostly with malignant breast cancers that have 
a poor prognosis is consistent with the histopathological results and suggests that, in the 
presence of the same initiating oncogenic mutation, the cell-of-origin dictates the frequency of 
aggressive tumors. 
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Figure 6-4│The frequency of malignant tumor lesions is dictated by the cell-of-origin 
a, Kaplan-Meier plots depicting tumor onset in Lgr5-creERT2/PIK3CA
H1047R
 (average 108 days; 
n=15) and K8-creERT2/PIK3CA
H1047R
 (average 78 days; n=15) mice compared with PIK3CA
WT 
and 
control animals after Tamoxifen injection (upper panel, n=14; lower panel, n=9 and n=12, 
respectively). *P<0.0001 Log-rank test. b, Representative images of immunostaining and 
quantification of double-positive epithelial area in Lgr5-creERT2/PIK3CA
H1047R
 and K8-
creERT2/PIK3CA
H1047R
 tumors (n=10). Yellow arrowheads indicate double-positive cells. Scale bar 
100 µm and magnification 20 µm. Means ±s.d. two-sided unpaired student`s t-test; *P=0.0002; 
NS=not significant.  c, Pie chart showing phenotypes of tumors evoked in Lgr5-
creERT2/PIK3CA
H1047R
 (n=50) and K8-creERT2
/
PIK3CA
H1047R
 (n=29) animals. d, Clustered heat map 
showing correlation coefficients between human breast cancer profiles and 10 K8- and Lgr5-
creERT2/PIK3CA
H1047R
 mouse mammary tumors. 
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6.3 Extended Data Figures and Unpublished Data Figures 
 
 
 
Extended Data Figure 6-1│Scheme depicting mouse lines generated for lineage tracing studies 
a, Lgr5-creERT2 (Kinzel et al., 2014) or K8-creERT2 (Van Keymeulen et al., 2011) animals were 
crossed to transgenic lox-STOP-lox PIK3CA
H1047R (Meyer et al., 2011)
 and/or Tomato-reporter mice, 
generating Lgr5-creERT2/Tomato, K8-creERT2/Tomato, Lgr5-creERT2/PIK3CA
H1047R
/Tomato and 
K8-creERT2/PIK3CA
H1047R
/Tomato animals for lineage-tracing studies. Lgr5-creERT2/Tomato and 
K8-creERT2/Tomato
 
animals were used as controls. b, Lgr5-creERT2 (Kinzel et al., 2014) and K8-
creERT2 (Van Keymeulen et al., 2011) animals were crossed to lox-STOP-lox PIK3CA
H1047R
 (Meyer 
et al., 2011) or PIK3CA
WT 
(Meyer et al., 2013) animals. Lgr5-creERT2 and K8-creERT2
 
animals were 
used as controls. Tamoxifen injection induces PIK3CA
H1047R
, PIK3CA
WT
, and/or Tomato expression. 
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Extended Data Figure 6-2│Lgr5-creERT2/Tomato and PIK3CAH1047R/Tomato labeling in the 
mammary nipple area 
a, Lgr5-expression in the nipple and distal area of Lgr5-creERT2 glands (n=3 mice). b, Tracing 
scheme. c,d, Representative images of mammary glands after 4 weeks tracing (n=3 mice for each 
genotype). Scale bar 2 mm; magnification 100 μm. e, Representative H&E-staining of a Lgr5-
creERT2/PIK3CA
H1047R
 mammary gland with a tumor. Scale bar 500 μm. LN: lymph node. f, 
Representative images, FACS plots and quantification of 4 days tracing (24 h after the last Tamoxifen 
injection) (upper panel: immunofluorescence n=3 mice, FACS: n=5 technical replicates (each 1-2 
pooled mice); lower panel: immunofluorescence n=3 mice, FACS: n=3 technical replicates (each 1 
mouse)). Scale bar 100 μm; magnification 20 μm. g, Representative FACS plots of 4-week tracing. h, 
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Percentage of total Tomato-positive cells in the tracing experiments (Lgr5-creERT2/Tomato: 4 days 
n=5, 4 weeks n=4, 8 and 13 weeks n=3 technical replicates (each 1-2 pooled mice); Lgr5-
creERT2/PIK3CA
H1047R
/Tomato: 4 days n=3, 4 weeks n=3, 8 weeks n=6 and 13 weeks n=5 technical 
replicates (each 1-2 pooled mice)). i, Representative images of 7 days tracing (left n=4 mice; right 
n=2 mice). Scale bar 100 μm, magnification 50 μm, Bar graphs means ±s.e.m. two-sided unpaired 
student`s t-test, *P<0.05. NS=not significant. 
 
 
 
 
Extended Data Figure 6-3│Gating scheme for FACS experiments 
Representative FACS plots of a, K8-creERT2/Tomato, b, K8-creERT2/PIK3CA
H1047R
/Tomato, c, 
Lgr5-creERT2/PIK3CA
WT
, and d, Lgr5-creERT2/PIK3CA
H1047R
 animals 4 weeks after Tamoxifen 
injection. The gating strategy shown illustrates the elimination of doublets, dead cells (DAPI
high
), and 
white blood cells (CD45
positive
) and the sorting of Tomato- or GFP-positive mammary epithelial subsets 
(basal CD24
low
Sca1
negative
, luminal CD24
high
Sca1
negative
; luminal CD24
high
Sca1
positive
). 
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Extended Data Figure 6-4│K8-creERT2/Tomato and PIK3CAH1047R/Tomato labeling in the 
mammary gland 
a, Scheme depicting time line of tracing experiments. b, Representative images and FACS 
quantifications of K8-creERT2/Tomato and K8-creERT2/PIK3CA
H1047R
/Tomato mammary glands 4 
days post Tamoxifen (24 h after the last Tamoxifen injection) (upper panel: immunofluorescence n=5 
mice, FACS: n=7 technical replicates (each 1-2 pooled mice); lower panel: immunofluorescence n=3 
mice, FACS: n=3 technical replicates (each 1 mouse)). Scale bar 100 μm; magnifications 20 μm. c, 
Representative FACS plots of 4-week Tomato tracing. d, Percentage of total Tomato-positive cells in 
mammary glands. (K8-creERT2/Tomato: 4 days n=7, 4 and 8 weeks n=4, 13 weeks n=5 technical 
replicates (each 1-3 pooled mice); K8-creERT2/PIK3CA
H1047R
/Tomato: 4 days n=3, 4 and 8 weeks 
n=4 and 13 weeks n=3 technical replicates (each 1-2 pooled mice)). Bar graphs means ±s.e.m. 
*P<0.05; two-sided unpaired student`s t-test. 
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Extended Data Figure 6-5│Tracing of GFP-positive mammary subsets 
a, Percentage of GFP-labeled cells in K8-creERT2/PIK3CA
H1047R
 versus K8-creERT2/PIK3CA
WT
 
animals 4 days post Tamoxifen (24 h after the last Tamoxifen injection) (n=3 technical replicates, 2 
mice per genotype). b,d, Representative FACS plots and percentage of GFP-positive cells in 
mammary gland subsets and total mammary epithelial cells 4 and 8-11 weeks post Tamoxifen. c,e, Bar 
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graphs showing total numbers of GFP-positive cells and numbers of GFP-positive cells in basal 
(CD24
low
Sca1
negative
) and luminal (CD24
high
Sca1
negative
; CD24
high
Sca1
positive
) subsets of Lgr5-
creERT2/PIK3CA
H1047R
 (c) and K8-creERT2/PIK3CA
H1047R
 (e) mammary epithelial cells (b,c: 4 
weeks: non-induced control n=3, control n=9, PIK3CA
WT
 n=3, PIK3CA
H1047R
 n=9 sortings with each 
1-4 pooled mice, 8-11 weeks: non-induced control n=3, control n=3, PIK3CA
WT
 n=3, PIK3CA
H1047R
 
n=4 sortings with each 1-4 pooled mice; d,e: 4 weeks: PIK3CA
WT
 and  PIK3CA
H1047R
 n=3 sortings 
with each 1-5 pooled mice, 8-11 weeks: PIK3CA
WT
 n=4, PIK3CA
H1047R
 n=5-6 sortings with each 1-4 
pooled mice). Bar graphs, means ±s.e.m; two-sided unpaired student`s t-test, *P<0.05; NS=not 
significant. 
 
 
 
 
 
Extended Data Figure 6-6│Expression of PIK3CAH1047R induces Akt phosphorylation 
Immunoblot and quantification of lysates from K8-creERT2 control, PIK3CA
WT
 and PIK3CA
H1047R
 
mammary glands 4 weeks post Tamoxifen for p110α, pAkt, Akt, pan Keratin and Erk2 (loading 
control). Protein levels were normalized to pan Keratin for normalization of epithelial content. Bar 
graphs depict fold change over control lysate. Bar graph means ±s.d. two-sided unpaired student`s t-
test, *P<0.006; NS= not significant. 
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Extended Data Figure 6-7│Expression of basal and luminal lineage-genes in PIK3CAH1047R 
subsets 
a, Expression heat maps of selected luminal and basal genes (left: Lgr5-creERT2/PIK3CA
H1047R
 versus 
control; right K8-creERT2/PIK3CA
H1047R
 versus control). Myo: myoepithelial; SC: stem cell-enriched; 
LP: luminal progenitors; LM: mature luminal cells. b,c Expression profiles of basal and luminal 
lineage-genes in mammary subsets of (b) Lgr5-creERT2/PIK3CA
H1047R
 compared to Lgr5-creERT2 
control and (c) K8-creERT2/PIK3CA
H1047R
 compared to K8-creERT2 control animals. The QRT-PCR 
results are representative of 2-3 experiments of 4 pooled animals of each genotype. Bar graphs means 
±s.e.m. two-sided unpaired student`s t-test, *P<0.05,. NS=not significant. N.d.=not detected. 
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Extended Data Figure 6-8│Luminal PIK3CAH1047R cells repopulate a mammary gland 
Number of outgrowths in cleared-fat pad transplantation of (a) GFP-negative Lgr5-creERT2 control 
and GFP-positive Lgr5-creERT2/PIK3CA
H1047R
-expressing luminal subsets (CD24
high
Sca1
negative
) and 
GFP-negative K8-creERT2 control and GFP-positive K8-creERT2/PIK3CA
H1047R
-expressing luminal 
subsets (left, CD24
high
Sca1
negative
 and right, CD24
high
Sca1
positive
) (b). Representative carmine-stained 
whole mounts (bottom). Scale bar 500 μm. c, Representative immuno-stained sections. Scale bar 50 
μm. Data from 3 independent experiments (a-c). d, Percentage of K14-, K8/18- and double-positive 
(K14/K8/18) colonies derived from Lgr5-creERT2/PIK3CA
H1047R
, Lgr5-creERT2 control (left; pooled 
data from n=4 independent experiments (1-5 pooled mice)), K8-creERT2/PIK3CA
H1047R
 and K8-
creERT2 control subsets (right; pooled data from n=3 independent experiments (1-5 pooled mice)). 
Total number of quantified colonies is shown. e, Representative images of colonies. Arrowheads 
indicate K8/18- (white), K14- (yellow) and double-positive (blue) colonies. Scale bar 500 μm. f, 
Number of colonies derived from basal and luminal cells from Lgr5- and K8-creERT2/PIK3CA
H1047R
 
and control mice. (left: pooled data from 3 independent sortings  (each 1-5 pooled animals), total n=8 
(control), n=10 (mutant) technical replicates for basal subset, n=9 (control), n=5 (mutant) technical 
replicates for luminal CD24
high
Sca1
negative
 subset and n=8 (control), n=4 (mutant) technical replicates 
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for luminal CD24
high
Sca1
positive
 subset. Right: pooled data from 2 independent sortings (each 1-5 
pooled animals), total n=8 (control), n=10 (mutant) technical replicates for basal subset, n=5 
(control), n=10 (mutant) technical replicates for luminal CD24
high
Sca1
negative
 subset and n=6 (control), 
n=9 (mutant) technical replicates for luminal CD24
high
Sca1
positive
 subset). 500 cells were seeded for 
each replicate. A colony was defined as a cell cluster of >5 cells. Bar graphs means ±s.e.m. Two-sided 
unpaired student’s t-test. *P<0.05. g, Bar graph showing number of spheres derived from FVB-control 
and PIK3CA
H1047R
-expressing luminal (CD24
high
Sca1
negative
/
positive
) mammary cells over three passages 
(p1,2,3). Representative data (3 replicates, n=4 mice per genotype) from two independent 
experiments. Bar graphs means ±s.d. *P<0.02, two-sided unpaired student’s t-test. h, Representative 
images of spheres derived from CD24
high
Sca1
negative 
cells in passage one (P1) and three (P3). Scale bar 
100 μm. NS=not significant. N.d.=not determined. 
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Extended Data Figure 6-9│PIK3CAH1047R-evoked tumors express basal and luminal markers 
a, Representative FACS plots of Lgr5-creERT2/PIK3CA
H1047R
 and K8-creERT2/PIK3CA
H1047R
 tumors 
(n=3). b, Percentages of total GFP-positive cells and GFP-positive basal (CD24
low
Sca1
negative
) and 
luminal (CD24
high
Sca1
negative/positive
) subsets of Lgr5-creERT2 and K8-creERT2/PIK3CA
H1047R
-tumors 
(n=3). Bar graph means ±s.e.m. NS= not significant; two-sided unpaired student`s t-test c, 
Immunostaining for basal and luminal markers on serial sections of a multi-nodular rosette-type 
adenomyoepithelioma (Lgr5-creERT2/PIK3CA
H1047R
) and adenomyoepithelioma (K8-
creERT2/PIK3CA
H1047R
). Scale bar 100 μm; magnification 50 μm. d, Quantification of basal- and 
luminal-lineage markers of Lgr5-creERT2 and K8-creERT2/PIK3CA
H1047R
 tumors. Each dot 
represents one tumor (upper panel: K8/18, K14 and SMA n=15, K5 n=14, ER n=10, PR n=9, p63 
n=8; lower panel: K8/18, K14, SMA and K5 n=15, ER, PR and p63 n=10). All Lgr5-
creERT2/PIK3CA
H1047R
 tumors and 8/10 and 6/10 of K8-creERT2/PIK3CA
H1047R
 tumors show more 
than 1% of ER- and/or PR-positive cells, respectively. Bar graph means ±s.d. e, Representative H&E-
stainings of tumor phenotypes. Scale bar 100 μm. f, Percentage of benign and malignant mammary 
tumors. 
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Extended Data Figure 6-10│Expression profiling of K8- and Lgr5-creERT2/PIK3CAH1047R 
mammary tumors 
a, Principle component analysis and dendogram of a hierarchical clustering of gene expression profiles 
from 10 K8- and 10 Lgr5-CreER
T2
/PIK3CA
H1047R
 tumors and 2–3 reference mammary glands. Each 
dot indicates one sample. Circles represent K8-CreER
T2
 and squares represent Lgr5-CreER
T2
 animals 
expressing PIK3CA
H1047R
 (filled symbols) or not (open symbols). b, Heat map of the top 1,000 genes 
that vary between K8-CreER
T2
/PIK3CA
H1047R
 and Lgr5-CreER
T2
/PIK3CA
H1047R
 tumors and The 
Cancer Genome Atlas (TCGA) human breast cancer gene signatures. 
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Unpublished Data Figure 6-1 │Long-term tracing of control mammary glands 
FACS quantifications of Tomato-positive epithelial basal (CD24
low
Sca1
negative
) and luminal 
(CD24
high
Sca1
negative/positive
) subsets from a, Lgr5-creERT2/Tomato control mice (n=1 technical 
replicate with 3 pooled mice) and b, K8-creERT2/Tomato (n=4 technical replicates with each 2-3 
pooled mice) 20-28 weeks after Tamoxifen injection.  
 
 
 
Unpublished Data Figure 6-2 │Expression of PIK3CAH1047R leads to double-positive mammary 
cells 
Representative images (left) and quantifications (right) of Tomato-positive sorted cells from K8-
creERT2/Tomato and K8-creERT2/PIK3CA
H1047R
/Tomato mammary glands 4 weeks post Tamoxifen 
injection stained for luminal K8/18 (green) and basal K14 (red) and K5 (white) markers. Merged (left) 
and single channels (right) are shown. K8-creERT2/Tomato n=1545 and K8-
creERT2/PIK3CA
H1047R
/Tomato n=872 counted cells from 3 independent FACS-sortings. Scale bar 20 
μm. Unpaired student`s t-test P<0.02.  
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Unpublished Data Figure 6-3 │ K8-creERT2 control basal cells repopulate a mammary gland 
Number of outgrowths in cleared-fat pad transplantation of GFP-negative K8-creERT2 control basal 
subsets (CD24
low
Sca1
negative
) (left) and representative carmine-stained whole mount (1000 cells 
condition) (right). Scale bar 500 μm. Data from one transplantation experiment with FACS-sorted 
cells from 4 pooled mice. 
  
Results Part II 
73 
 
6.4 Discussion 
The PI3K pathway is frequently deregulated in cancer but the effect on cell fate and lineage 
commitment in pre-neoplastic cells and the effect of its expression in subpopulations of the 
mammary gland remained ill-defined. Here, we show that expression of PIK3CA
H1047R
 
dedifferentiates lineage-restricted epithelial cells into a multipotent stem-like state from which 
cells further differentiate, revealing a mechanism by which heterogeneous mixed-lineage 
tumors may develop (Figure 6-5). Evidence comes from in vivo genetic lineage tracing, gene 
expression analyses and functional assays showing that expression of PIK3CA
H1047R
 in 
lineage-restricted basal or luminal mammary cells results in labeling of both basal and luminal 
cell lineages in pre-neoplastic mammary glands, in an increase of mammary repopulating 
capacity and in the formation of heterogeneous mammary tumors expressing basal and 
luminal markers. Furthermore, our study shows that the tumor cell-of-origin influences the 
frequency of malignant mammary tumors. 
 
 
Figure 6-5 │ Model of the effect of PIK3CAH1047R on cell fate in pre-neoplastic mammary glands 
a, Under physiological conditions Lgr5-positive basal cells contribute to the basal lineage in the adult 
mammary gland (black arrows). Upon expression of PIK3CA
H1047R
 cells dedifferentiate into 
multipotent stem-like cells from which cells further differentiate to basal and luminal mammary 
epithelial cells, contributing to mostly mixed-lineage benign tumors (blue arrows). b, K8-positive 
luminal cells contribute to the homeostasis of luminal cells in the adult mammary gland (black 
arrows). Upon expression of PIK3CA
H1047R
 cells dedifferentiate into multipotent stem-like cells from 
which cells further differentiate to basal and luminal mammary epithelial cells, contributing to mostly 
mixed-lineage malignant tumors (red arrows). 
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The observation that PIK3CA
H1047R
 expression evokes luminal and basal progeny 
derived from Lgr5-positive basal and from K8-positive luminal cells, respectively, suggests 
that cells undergo dedifferentiation, a process in which cells revert back in hierarchy, or 
transdifferention, a process in which cells differentiate into another lineage without going 
through early cellular states in hierarchy. The increase of mammary repopulating and sphere-
forming capacity and the increase of double-positive cells in PIK3CA
H1047R
-mutant cells 
suggest that cells dedifferentiate.  
GFP driven by the Lgr5-promoter was found in a rare luminal subset of the control 
gland (Extended Data Fig. 6-5b,c), as shown previously (Van Keymeulen et al., 2011). 
Conceivably, such rare cells expand due to PIK3CA
H1047R
 and form the luminal GFP-positive 
population. Though, we observed multi-lineage labeling upon PIK3CA
H1047R
 expression in a 
basal as well as a luminal cell-driven model. An alternative possibility that we cannot firmly 
exclude is that Lgr5- and K8-positive populations contain rare bipotent subsets that are 
quiescent or not efficiently labeled in physiological conditions and are, therefore, not detected 
by lineage tracing but may expand upon PIK3CA
H1047R
 expression.  
Lgr5 marks stem cells in small intestine, colon (Barker et al., 2007), hair follicle (Jaks 
et al., 2008), and stomach (Barker et al., 2010). Moreover, overexpression of LGR5 has been 
found in several cancers (Uchida et al., 2010), indicating an important effect of Lgr5 on 
tumorigenesis. Surprisingly, expression of PIK3CA
H1047R
 under control of the Lgr5-creERT2 
promoter caused exclusively mammary tumors with 100% penetrance and frequent benign 
histotypes. Lgr5-positive cells were identified previously as multipotent stem cells fueling 
tumor growth in APC-deleted intestinal adenomas (Schepers et al., 2012). Remarkably, we 
found no evidence of gastrointestinal cancers in PIK3CA-mutant mice, suggesting that 
PIK3CA
H1047R
 is a tumor-initiating mutation in breast rather than in intestine. Alternatively, 
cancer initiation and progression triggered by mutant PIK3CA might be slower in the intestine 
compared to the breast and therefore, could not be identified before the end point. Different 
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wiring diagrams in adult stem cells of distinct tissues may make some cells more prone to 
tumorigenesis than others upon mutation of PIK3CA. Further studies of the nature of Lgr5-
positive cells in the breast compared to other tissues are needed.  
The fundamental questions of which mammary cells are susceptible to which 
combination of oncogenes and how this impinges on tumor progression and aggressiveness 
warrant further investigation. Understanding these dynamic relationships is paramount for 
understanding tumor heterogeneity and for identifying prognostic and predictive biomarkers. 
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6.5 Materials and methods 
Mice. Lgr5-creERT2 mice (C57BL/6) were generated and provided by B. Kinzel and J. 
Tchorz (Kinzel et al., 2014). Mice were backcrossed to the FVB background and used in this 
study. K8-creERT2 mice (CD-1) were provided by C. Blanpain (Van Keymeulen et al., 
2011). The generation of PIK3CA
H1047R
 and PIK3CA
WT
 (pure FVB) was described previously 
(Meyer et al., 2011; Meyer et al., 2013). Tomato-reporter animals (C57BL/6) were provided 
by B. Roska. For lineage-tracing studies, mice of a mixed background (FVB/CD-1/C57BL/6 
and FVB/C57BL/6) were used. For studies without a Tomato-reporter, mice with a pure FVB 
background (Lgr5-creERT2 model) or mixed FVB/CD-1 background (K8-creERT2 model) 
were used. Mouse colonies were maintained in the animal facility of the Friedrich Miescher 
Institute for Biomedical Research and experiments were carried out in accordance with Swiss 
national guidelines on animal welfare and the regulations of the Canton of Basel Stadt, 
Switzerland. 
 
Targeting Tomato and/or GFP expression. Adult 7- to 8-week-old mice were induced by 
intraperitoneal injection of Tamoxifen (2 mg/25 g of body weight) for three consecutive days 
(Sigma, diluted in sunflower seed oil, Sigma) to activate cell-specific expression of the Cre 
recombinase and thus expression of Tomato and/or the PIK3CA
H1047R or /WT
 transgene. Tomato 
and/or GFP were expressed in recombined cells derived from Lgr5-positive or K8-positive 
cells, respectively. For the Lgr5 model, after Cre induction, GFP expression was derived from 
both Lgr5 promoter activity and PIK3CA
H1047R
 expression. 
 
Histology and immunostaining. Tumors and dissected mammary glands were spread on a 
glass slide and fixed in 20% formalin for 24 h at 4°C. Samples were then processed, 
embedded in paraffin and sectioned (3 μm). Immunofluorescence studies were performed 
using a Ventana DiscoveryUltra instrument (Roche Diagnostics) following the RUO 
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Discovery Universal method. Briefly, slides were pretreated with CC1 for 40 min and then 
incubated with primary antibodies for 1 h at 37°C. After washing, secondary antibodies were 
incubated for 32 min at 37°C. Slides were then washed with reaction buffer (three times), 
PBS (two times) and then incubated with DAPI (1 μg/ml) for 5 min. Finally, slides were 
rinsed with PBS (three times) and mounted in Mount Fluor (ProTaqs). The following 
antibodies were used: anti-keratin8/18 (guinea-pig, 1:200, Fitzgerald, 20R-CP004), anti-RFP 
(rabbit, 1:500, Rockland, 600-401379), anti-keratin14 (chicken, 1:500, Covance, Sig3476), 
anti-p63 (mouse, 1:500, Thermo Scientific, ma121871), anti-keratin5 (rabbit, 1:500, abcam, 
ab52635), anti-chicken Alexa Fluor 488, anti-chicken Alexa Fluor 568, anti-guinea pig Alexa 
Fluor 488, anti-mouse Alexa Fluor 488, anti-rabbit Alexa Fluor 647. All Alexa secondary 
antibodies were obtained from Molecular Probes (Invitrogen). Immunohistochemistry 
experiments were performed for keratin 14, keratin 8/18, GFP, and p63 using a Ventana 
DiscoveryXT instrument (Roche Diagnostics) following the Research IHC DAB Map XT 
procedure. Slides were treated with a mild CC1 and incubated with the primary antibodies for 
1 h at 37°C. Following brief washes, biotinylated donkey-anti-rabbit and biotinylated anti-
guinea-pig, respectively, were applied for 32 min at 37°C. For mouse-anti p63 detection, a 
monoclonal rabbit-anti-mouse antibody was applied for 32 min at 37°C, followed by 
incubation with a polymer anti-rabbit conjugated with HRP (ImmPRESS anti-rabbit 
peroxidase, Vector Laboratories) for 32 min at 37°C. Finally, sections were counterstained 
with hematoxylin II and bluing reagent (4 min). Staining against ERα-, SMA- and keratin 5 
was performed by deparaffinization followed by antigen retrieval with citrate buffer and 
quenching with PBS+3% H2O2. Slides were then blocked with PBS+2,5% normal goat serum 
and primary antibodies incubated overnight at 4°C in PBS+1% BSA+ 0.5% Tween-20. After 
brief washes, secondary antibodies were then incubated in PBS+1% BSA for 30 min at RT. 
Signals were enhanced using the Vectastain ABC system and visualized with 3,3`-
diaminobenzidine (DAB; Sigma). Hematoxylin was used as counterstain. Anti-PR-staining 
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was performed without antigen retrieval. The following antibodies were used: anti-keratin 
8/18 (guinea-pig, 1:500, Fitzgerald, 20R-CP004), anti-keratin 14 (rabbit, 1:500, Thermo 
Scientific, Rb9020), anti-p63 (mouse, 1:1000, Thermo Scientific, ma121871), anti-keratin 5 
(rabbit, 1:1000, abcam, ab52635), anti-SMA (rabbit, 1:500, Thermo Scientific, Rb9010), anti-
ERα (rabbit, 1:1000, Santa Cruz, sc-542), anti-PR (rabbit, 1:200, Thermo Scientific, 
Rm9102), anti-GFP (rabbit, 1:50, Invitrogen, A11122), Secondary antibodies were 
biotinylated anti-rabbit IgG (1:200, Jackson Immunoresearch), biotinylated anti-guinea pig 
IgG (1:200; Vector Laboratories), and biotinylated anti-mouse IgG (1:200; Abcam). 
Hematoxylin and eosin staining was performed using standard protocols. 
 
Microscopy image acquisition. For immunofluorescence, images of stained sections were 
captured using a Zeiss Z1 wide-field fluorescent microscope, 5x/0.13, 10x/0.45 or 20x/0.8 
(Plan-APOCHROMAT) objectives, an AxioCamMRc camera (1’024 x 1’024, pixel size 6.45 
μm) and an Axiocam506 camera (2’752 x 2’208, pixel size 4.54 μm). Whole-mount 
fluorescent mammary gland and tumors sections were imaged on the Zeiss Axio Scan.Z1 
slide scanner, (ORCA-Flash4.0 camera, 2’048 x 2’048, pixel size 6.5 μm). Representative 
images were cropped and processed using the ZenBlue software. For immunohistochemistry, 
stained sections were examined using a Nikon E600 Eclipse brightfield microscope (20x/0.5 
and 40x/0.75 objectives) and images captured with a Nikon DXM1200 camera (2’592 x 
1’944, pixel size 6.7 μm) using the IMS acquisition software. All images were scaled 
appropriately. 
 
Quantification of immunohistochemistry. Five representative images of 8-15 tumors of 
each genotype were captured with a Nikon E600 Eclipse brightfield microscope (20x/0.5 
objective) and positively stained tumor areas, luminal cells, and total epithelial cells 
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quantified with Image J (Fiji). Evaluation of tissue sections was performed blindly by two 
independent investigators. 
 
Quantification of double-positive tumor epithelial area. 10 tumors from each model were 
stained with anti-keratin14, anti-keratin5, anti-keratin8/18, anti-rabbit Alexa Fluor 647, anti-
chicken Alexa Fluor 568, and anti-guinea pig Alexa Fluor 488. Whole-mount tumor sections 
were scanned using the Zeiss Axio Scan Z1 slide scanner. For computational reasons, the 
whole images of tumors were first tiled and the channels split using the ZenBlue software and 
Matlab. Images were then processed using Ilastik (Sommer et al., 2011), an interactive 
supervised Machine Learning toolkit, and the subsequent prediction maps were treated with 
batch functions written with the Matlab programing language. For the statistical analysis 
shown in Fig. 6-4b, a total of 23 regions of tumors were subsequently tiled into 14’872 
squared images of 1’024x1’024 pixels. In a second step, data from a set of 9 selected tiles 
were generated by annotating a few regions representative of the predefined classes. For each 
of the three channels the training data were processed using the four phenotype classes: 
‘1.background’, ‘2.fluorescent marker (Alexa Fluor 488, 568 or 647)’, ‘3.blood cells’, and 
‘4.Stroma’. After annotation of the different pixels of the different classes by brush stroke, 
features of the labeled pixels and their local neighborhood are used to train a Random Forest 
classifier. In a third step, the inferred classifier was used to predict all the tiles in a batch 
process. The last step implemented in Matlab determined the masks for all the channels and 
tiles. In order to perform the analysis on relevant tiles, i.e. tiles sufficiently covered by tissue, 
we performed a k-mean clustering on a set of statistical features extracted from the tiles. This 
enabled us to suppress tiles that were merely in the background or those that contained non-
epithelial structures. For each tile, the fluorescent marker mask corresponded to pixels having 
a probability above 50% in the class ‘fluorescent marker (Alexa)’. In addition, a non-tissue 
mask was calculated by the mean of morphological filters on the union of background, blood 
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cells and stroma classes. The mask for tissue represented the complement image of the non-
tissue mask. We calculated on each tile the ratio between the areas of pixels in the mask of the 
fluorescent marker and those in the tissue mask. Finally, the distribution of double-labelled 
fluorescent marker within the whole tumor epithelial area was represented in Fig. 6-4b. 
 
Preparation of mammary single-cell suspensions and labeling. Mammary glands were 
dissected and intra-mammary lymph nodes removed. To obtain mammary organoids, 
mammary glands were processed as described previously (Meier-Abt et al., 2013; Sleeman et 
al., 2006). To obtain single mammary epithelial cells, organoids were washed in serum-free 
Leibowitz L15-medium (Gibco) and digested with Hyclone HyQTase (Thermo Scientific). 
Single cells were washed and filtered through a 40-μm cell strainer (BD Falcon) and counted; 
10
6 
cells/ml were stained with the following antibodies: PE-Cy7-CD45 (Biolegend; clone 30-
F11), APC-Sca1 (Biolegend; clone E13-161.7), PerCP-Cy5.5-CD24 (Biolegend; clone 
M1/69), PE-CD49f (BD-Pharmingen), Alexa700-CD24 (Novus Biologicals; clone M1/69), 
and DAPI (2 µg/ml, Invitrogen). 
 
Flow cytometry. FACS was carried out with a BD FACSAria III (Becton Dickinson) using a 
100-μm nozzle. Cells were gated based on their forward- and sideward-scatter. Pulse-width 
was used to exclude doublets. DAPI-negative/CD45-negative cells were gated for Tomato or 
GFP. CD24, Sca1, and CD49f subsets were then gated on GFP-positive epithelium. Tomato-
positive cells were gated using only CD24, CD45, and Sca1 antigens. The same numbers of 
living cells were recorded in each condition. FACS data were analyzed using FlowJo (Tree 
Star). Total cell numbers were determined by enumerating the total epithelial content after 
single-cell isolation and calculating back based on the percentages obtained from antibody-
staining, sorting, and FlowJo analysis. Cell numbers were subsequently normalized to one 
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animal (3-9 independent FACS-experiments of 1-5 pooled animals per time point were 
quantified; ±s.e.m.; P<0.05, student`s t-test). 
 
In vitro colony formation assay and quantification. Freshly sorted cells of each 
subpopulation (500 cells) were plated as previously described (Meier-Abt et al., 2013). Seven 
days later, the colonies were fixed with acetone/methanol (1:1), washed, blocked with 2.5% 
normal goat serum and stained with anti-keratin8/18 (guinea-pig, 1:500, Fitzgerald, 20R-
CP004), anti-keratin14 (rabbit, 1:500, Thermo Scientific, Rb9020), DAPI (2 µg/ml, 
Invitrogen), anti-guinea-pig Alexa Fluor 488 and anti-rabbit Alexa Fluor 647 (1:1000, 
Invitrogen). Colonies were imaged using the Zeiss Z1 wide-field fluorescent microscope 
(5x/0.13 DIC). Colonies were defined as a cluster of more than five cells. The number of 
colonies per well was determined manually. Colonies containing more than 20% of 
keratin8/18/keratin14 double-positive cells were defined as “double-positive”.  
 
In vitro mammosphere culture. Mammosphere cultures were performed as described 
previously (Cicalese et al., 2009). Freshly sorted subsets (luminal CD24
high
Sca1
negative
 and 
CD24
high
Sca1
positive
) cells from adult FVB and uninduced PIK3CA
H1047R
 females were plated 
at 20’000 cells/ml in 6-well ultra-low attachment plates (Falcon) in DMEM/F12 medium 
(Gibco) supplemented with 5 µg/ml insulin, 0.5 µg/ml hydrocortisone, 2% B27 (Invitrogen), 
20 ng/ml EGF and bFGF (BD Biosciences), and cholera toxin (Sigma) and cultured at 37°C in 
5% CO2. After 5 days, mammospheres were collected and dissociated into single cells using 
HYQtase (Gibco) and counted. Luminal subsets from FVB control and PIK3CA
H1047R
 animals 
were subsequently treated with TAT-Cre (Millipore) (0.5 µM) at a density of 20’000 cells/ml 
in 4 ml overnight at 37°C in 5% CO2. The next morning, the medium was replaced and cells 
were cultured for 72 h at 37°C in 5% CO2 to allow for maximal recombination and expression 
of PIK3CA
H1047R
. After 72 h, PIK3CA
H1047R
-GFP
positive/negative 
cells were sorted and plated into 
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24-well ultralow attachment plates in medium (described above) supplemented with 2% 
Matrigel (growth factor reduced; BD; 356230) at a density of 1’000 cells/well. Control and 
PIK3CA
H1047R
 spheres from each subset were enumerated every 7 days, at which point spheres 
were dissociated and re-plated at a density of 1’000 cells/well. 
 
Mammary fat pad transplantation. For limiting dilution transplantation, freshly sorted cells 
from Lgr5-creERT2 control and Lgr5-creERT2/PIK3CA
H1047R
 animals (pure FVB 
background) and from K8-creERT2 control and K8-creERT2/PIK3CA
H1047R
 F1-hybrid 
(FVB/CD-1) littermates were used. Sorted cells were resuspended in limiting dilution 
numbers in PBS+2% FCS with 25% Matrigel (growth factor reduced; BD; 356230) and 
injected in 20-μl volumes into inguinal glands of 3-week-old FVB females that had been 
cleared of endogenous mammary epithelium (Deome et al., 1959). Cells from control and 
from PIK3CA
H1047R
 animals were injected in the same animal on opposite sides. After 8 
weeks, glands of the recipients were removed for evaluation. Glands were spread on a glass 
slide and fixed in Carnoy`s fixative overnight. Whole mount staining with carmine alum was 
performed as previously described (Meier-Abt et al., 2013) and scanned with an Epson 1600 
Pro scanner. An outgrowth was defined as an epithelial structure composed of ducts arising 
from a central point with lobules and/or terminal end buds (Shackleton et al., 2006). 
Frequencies of mammary-repopulating-units between different cell populations were 
calculated and statistically compared using the Extreme Limiting Dilution Analysis (ELDA) 
(Hu and Smyth, 2009) online tool (http://bioinf.wehi.edu.au/software/elda/). 
 
Immunoblotting. Lysates from mammary glands were prepared by lysing cryo-homogenized 
mammary gland powder in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1x protease inhibitor cocktail 
(Complete Mini, Roche), 0.2 mMol/L sodium orthovanadate, 20 mM sodium fluoride and 1 
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mMol/L phenylmethylsulfonyl fluoride. Lysates (30 – 80 µg) were subjected to SDS-PAGE, 
transferred to PVDF membranes (Immobilon-P, Millipore) and blocked for 1 h at room 
temperature with 5% milk or BSA in PBS-0.05% Tween 20. Membranes were then incubated 
overnight with primary antibodies (1:200 – 1:3000) and exposed to secondary HRP-coupled 
anti-mouse or anti-rabbit antibodies at 1:5’000–10’000 for 1 h at room temperature. Results 
are representative of at least three different experiments. The following antibodies were used: 
anti-AKT pan (Cell Signaling), anti-pAKT (Ser473, Cell Signaling), anti-p110α (Cell 
Signaling), anti-ERK2 (Santa Cruz) and anti-Keratin pan (SantaCruz). Blot densities were 
quantified using ImageJ and normalized to pan-Keratin for epithelial content. 
 
RNA isolation. For pre-neoplastic gene expression profiling, mammary epithelial subsets 
were FACS sorted as described above into extraction buffer and total RNA from 250 or 2’000 
sorted cells isolated using an Arcturus PicoPure RNA Isolation Kit (Life Technologies). 
Subsets of pooled mammary glands of 2-3 estrus-synchronized animals (confirmed by vaginal 
smear) per genotype in three independent sortings were collected for microarray analysis. 
RNA from mammary subsets of four animals per genotype was collected for QRT-PCR. For 
tumor gene expression profiling and expression of Lgr5 in the mammary gland, total RNA 
from 50 mg cryo-homogenized tumor tissue or nipple and distal area of mammary glands 
were extracted using the TRIzol method (Life Technologies) according to the manufacturer’s 
instructions. Genomic DNA was removed by DNAse I digestion (Qiagen) and RNA purified 
using an RNeasy Plus Mini Kit (Qiagen). RNA concentration was measured with a Nanodrop 
1000 machine and RNA quality assessed using an Agilent 2100 bioanalyzer and RNA Pico 
Chips or RNA Nano Chips. 
 
Microarray. Total RNA from 250 sorted cells (pre-neoplastic Lgr5), 2’000 sorted cells (pre-
neoplastic K8) or 100 ng from tumor tissue was used as the input for synthesis of amplified 
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cDNA with the NuGen Ovation Pico WTA System (NuGen Inc.). The resulting double-
stranded cDNA was fragmented and labeled using the Affymetrix GeneChip WT Terminal 
Labeling kit (Affymetrix). Affymetrix Gene Chip Mouse gene 1.0 ST microarrays were 
hybridized according to the GeneChip Whole Transcript (WT) Sense Target Labeling Assay 
Manual (Affymetrix) with a hybridization time of 16 h. Scanning was performed with 
Affymetrix GCC Scan Control Software v. 3.0.0.1214 on a GeneChip Scanner 3000 7 G with 
autoloader. 
 
Normalization and analysis of mammary epithelial subset microarray data. The arrays 
for GEO GSE40875 (Meier-Abt et al.), GSE59870 (Fig. 6-2a), and GSE65411 (Fig. 6-2b) 
datasets were RMA normalized using the bioconductor package affy (R3.0.1/Bioconductor 
2.13). Heatmaps with unscaled normalized expression values for selected genes were plotted 
with the heatmap.2 function of the gplots package. Differential gene expression for the 
comparison of mature luminal (LM) or luminal progenitor (LP) versus myoepithelial (MYO) 
cells was calculated with limma. The function topTable was used to select the top 300 
upregulated genes as luminal mature versus myoepithelial UP (Luminal_Mature UP, MEIER-
ABT) and luminal progenitors versus myoepithelial UP (Luminal_progenitors UP, MEIER-
ABT), and the top 300 upregulated genes as myoepithelial versus luminal mature UP 
(Myoepithelial UP, MEIER-ABT). Signatures 
LIM_MAMMARY_LUMINAL_MATURE_DN, 
LIM_MAMMARY_LUMINAL_MATURE_UP, 
LIM_MAMMARY_LUMINAL_PROGENITOR_DN, 
LIM_MAMMARY_LUMINAL_PROGENITOR_UP, 
LIM_MAMMARY_STEM_CELL_DN and LIM_MAMMARY_STEM_CELL_UP were 
downloaded from http://www.broadinstitute.org/gsea/msigdb/search.jsp in gmt format, 
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combined with the signatures described above, and used in the PGSEA and smcPlot functions 
of the Bioconductor PGSEA package. 
 
QRT-PCR. RNA was converted into cDNA using SuperScript III Reverse Transcriptase 
(Invitrogen). Quantitative real-time PCR was performed on unamplified cDNA normalized to 
the number of sorted cells for each subset (6’000-10’000 sorted cells). Taqman-probes (Life 
technologies) and Taqman Universal PCR Mastermix (Applied Biosystems) were applied. 
The following Taqman-probe IDs were used: Krt14 Mm00516879_m1, Krt5 
Mm01305291_g1, Lgr5 Mm00438890_m1, Vim Mm01333430_m1, Krt8 Mm00835759_m1, 
Krt18 Mm01601702_g1, Gata3 Mm00484683_m1, Elf5 Mm00468732_m1, Csn2 
Mm04207885_m1, Axin2 Mm00443610_m1, and PIK3CA Hs00907957_m1. Cycling was 
performed with StepOne Plus Real-time PCR Systems (Applied Biosystems). The results are 
representative of three QRT-PCR experiments of pooled mammary subsets from four animals 
of each genotype. Results of Csn2 (CD24
high
Sca1
negative/positive
) and Krt14 (CD24
high
Sca1
positive
) 
from K8-CreERT2/PIK3CA
H1047R
 cells and of Krt5 and Lgr5 (CD24
high
Sca1
negative
) from Lgr5-
CreERT2/PIK3CA
H1047R
 cells are representative of two experiments. Statistical data analysis 
was performed using deltaCT-values.  
 
Normalization and analysis of tumor mouse microarray data. Mouse Affymetrix 
microarrays (GSE59872) were background corrected, quantile normalized, and log2 transcript 
cluster expression values calculated using the rma() function of the Bioconductor package 
“oligo” (Carvalho and Irizarry, 2010). Transcript cluster identifiers were mapped to Entrez 
Gene identifiers using the Bioconductor package “mogene10sttranscriptcluster.db”, and 
transcript clusters associated with none or multiple genes were removed. Where multiple 
transcript clusters were associated with a single e, that with the maximal variance across 
samples was selected; this resulted in a total number of 20’365 transcript clusters with unique 
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gene assignments. Principal component analysis was performed on log2 expression values 
from which the mean over samples had been subtracted for each gene. Hierarchical clustering 
of samples was performed using (1-r) as distance metric, with r being the Pearson’s 
correlation coefficient for log2 expression values between each pair of samples. The 
clustering dendrogram was visualized using the “dendextend” R package. 
 
Analysis of human TCGA breast cancer data and comparison to mouse. Human breast 
cancer expression data and corresponding clinical data (Cancer Genome Atlas, 2012) were 
obtained from https://tcga-data.nci.nih.gov/docs/publications/brca_2012/, corresponding to 
the November 11, 2011 data freeze that contains 522 tumor samples with clinical annotation. 
Human gene symbols were mapped to Entrez Gene identifiers and genes selected that are one-
to-one homologues between human and mouse according to Homologene (build 68, 
downloaded from ftp://ftp.ncbi.nlm.nih.gov/pub/HomoloGene/build68/ (Coordinators, 2014)) 
and that were measured on both human and mouse experimental platforms; this resulted in 
13’969 genes. In order to reduce technical differences between human and mouse samples, all 
samples were scaled to a standard deviation of 1, and the within-special mean was subtracted 
from each gene. Heatmap and clustering of the combined human and mouse expression data 
were performed using the function aheatmap() from the R package "NMF" (Gaujoux and 
Seoighe, 2010) on the top 1’000 genes ranked by variance across human samples. Mouse 
samples were compared to human PAM50 tumor subtypes (Normal, LumA, LumB, Her2 and 
Basal) by calculating Pearson's correlation coefficients for each mouse sample against the 
averages of all human samples within each subtype. 
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Survival analysis. Tumor incidence was determined by palpation. Kaplan-Meier plots were 
generated using the survival calculation tool from Graphpad Prism and significance calculated 
using the Log-rank test. 
Statistical data analysis. The number of mice was calculated by performing power analysis 
using data from small pilot experiments. Values represent the means ±s.e.m (standard error of 
the mean) or ±s.d. (standard deviation). Depending on the type of experiments, data were 
tested using unpaired student’s t-test or Log-rank test. *P<0.05 was considered statistically 
significant. The experiments were not randomized. 
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7 | Concluding remarks and perspectives  
Current mouse models of mutant PIK3CA are contributing to a better understanding of breast 
cancer pathogenesis associated with alterations in the PI3K pathway. By using transgenic 
animals expressing PIK3CA
H1047R
 and PIK3CA
E545K
 mutations, we unraveled that 
PIK3CA
H1047R
 is a more potent inducer of mammary tumors than PIK3CA
E545K
, what might 
explain the higher frequency of PIK3CA
H1047R
 mutations in human breast cancer. Future 
investigations are needed to decipher further potential distinct downstream signaling in 
E545K and H1047R-expressing mutants to better understand and explain differences in 
potency.  
Moreover, by using in situ genetic lineage tracing, gene expression analyses and 
functional assays, we show that PIK3CA
H1047R
 causes dedifferentiation of mammary cells to a 
multipotent stem-like state, which may be a mechanism by which heterogeneity develops in 
breast cancer. Additionally, we revealed that the cell-of-origin dictates the frequency of 
malignant tumor lesions, as the expression of PIK3CA
H1047R
 in luminal mammary epithelial 
cells causes more frequently aggressive mammary tumors compared to expression in basal 
mammary epithelial cells.         
These findings lead to further questions. What is the mechanism underlying the 
observed dedifferentiation to a multipotent stem-like state? Expression of PIK3CA
H1047R
 
modulates gene expression. This might be caused by regulation or activation of transcriptional 
factors, co-factors and/or epigenetic remodelers which may impinge on chromatin structure 
and eventually unlock multipotency programs. During mammary gland development dynamic 
changes occur in the mammary epigenome involving polycomb-group-complexes (PRC) and 
DNA methylation (Pal et al., 2013; Rijnkels et al., 2010). Also cancer hallmarks were 
described to be controlled by posttranslational modifications of histones and methylation of 
DNA. Epigenetic remodeling and genetic alterations may work cooperatively to promote 
tumor initiation and progression in breast cancer (Shen and Laird, 2013; Stefansson and 
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Esteller, 2013). It was previously shown that activated Akt phosphorylates the PRC2 member 
EZH2 at an inhibitory site leading to reduction of methylated H3K27 sites (Cha et al., 2005). 
Moreover, epigenetic silencing was found to be mediated by the PI3K-pathway in breast 
cancer (Zuo et al., 2011). Therefore, it would be of profound interest to investigate whether 
PIK3CA
H1047R
 oncogene-induced dedifferentiation is triggered by epigenetic events.  
We did not find metastasis in animals expressing PIK3CA
H1047R
 or PIK3CA
E545K
 under 
various promoters (WAPiCre, CAGs-creERT2, Lgr5-creERT2, K8-creERT2, K14-cre). 
Similarly, other studies rarely report metastasis in these mouse models (please see section 
3.5.3). It would be of interest to investigate whether additional genetic alterations are required 
for metastasis in a mutant PIK3CA context. Conceivably, metastatic spread might be a slow 
process in these models and therefore could not be found before the end point. 
Transplantation studies would be helpful to investigate the role of mutant PIK3CA in 
metastasis.   Alternatively, expression of mutant PIK3CA in other mammary epithelial cell 
subtypes, which were not tested yet, may cause metastasis.   
Oncogene-induced multipotency and the importance of the cell-of-origin on tumor 
phenotype were shown in this study by using PIK3CA
H1047R
. PTEN, a negative regulator of 
the PI3K-pathway, was shown to be essential in lineage fate determination and restriction of 
activation of hematopoietic stem cells (Zhang et al., 2006). Moreover, distinct molecular 
signatures that are predictive of human patient outcome were reported in Pten inactivated 
prostate tumors from basal or luminal origins. Pten deletion in luminal prostate cells evokes 
more aggressive tumors compared to its expression in basal cells (Wang et al., 2013). 
Furthermore, previous lineage-tracing approaches show that basal prostate cells differentiate 
into luminal cells upon Pten loss suggesting that deregulation of epithelial differentiation is a 
critical step for tumor initiation (Choi et al., 2012). Little is known whether other PIK3CA 
mutations (e.g. E545K) or oncogenes and tumor suppressors also influence cell fate decisions. 
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Further lineage-tracing studies in distinct mammary epithelial subpopulations expressing 
different tumor-initiating lesions could answer this question.    
We and others now show that the cell-of-origin dictates the tumor phenotype, 
molecular subtype and clinical outcome. Mammary tumors arising from luminal epithelial 
cells cluster more frequently with basal-like cancers. Moreover, luminal to basal cell fate 
changes were shown to have a poorer disease-free survival (Koren et al., 2015; Van 
Keymeulen et al., 2015).  It is yet unknown whether the cellular origin of breast cancer could 
predict treatment success. The influence of the cell-of-origin on response to treatment should 
be the focus of future investigations.  
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10.1 Abbreviations 
3D Three-dimensional 
APC Adenomatous polyposis coli 
CAF Cancer-associated fibroblast 
CAGs Modified chicken β-actin promoter 
CD24 Cluster of differentiation 24/heat stable antigen CD24 
CD29 Cluster of differentiation 29/Integrin beta-1  
CD45 Cluster of differentiation 45/Protein tyrosine phosphatase, receptor type C 
CD49f Cluster of differentiation 49f/Integrin alpha-6 
CD61 Cluster of differentiation 29/Integrin beta-3 
CDK4 Cyclin-dependent kinase 4 
Cre-ERT2 Tamoxifen inducible activation of Cre-recombinase 
CSC Cancer stem cell 
Ctrl Control 
DAPI 4′,6-Diamidin-2-phenylindol 
EGFP Enhanced Green fluorescent protein 
EMT Epithelial-mesenchymal transition 
EpCAM Epithelial cell adhesion molecule 
ER Estrogen receptor 
ERK Extracellular-signal-regulated kinase 
ES cell Embryonic stem cell 
EZH2 Enhancer of zeste homolog 2  
FACS Fluorescence-activated cell sorting 
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GPCR G-protein-coupled receptor 
GTP Guanosine-5'-triphosphate 
h  Hour 
HA  Hemagglutinin 
HER2 Human epidermal growth factor receptor 2 
HMEC Human mammary epithelial cell 
ICD Invasive ductal carcinoma 
IRES Internal ribosome entry site 
IRS Insulin receptor substrate  
K14 Keratin 14 
K5 Keratin 5 
K8 Keratin 8 
Lgr5 Leucine-rich repeat-containing G-protein coupled receptor 5 
LSD1 Lysin-specific demethylase 1 
MaSC Mammary stem cell 
MMTV Mouse mammary tumor virus 
NS Not significant 
PDK1 Phosphoinositide-dependent kinase 1  
PDX  Patient-derived xenograft 
PGK  Phosphoglycerate kinase 
PI3K Phosphoinositol 3-kinase 
PI-4-P Phosphatidylinositol-4-phosphate  
PIP2 Phosphatidylinositol 4,5-bisphosphate  
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PR  Progesterone receptor 
Appendices 
112 
 
PTEN Phosphatase and Tensin homolog 
PyMT Polyomavirus middle T 
RMCE Recombinase-mediated cassette exchange 
RTK Receptor tyrosine kinase 
rtTA Tetracycline transactivator protein 
s.d. Standard deviation 
s.e.m. Standard error of the mean 
Sca1 Stem cell antigen 1 
SMA Smooth muscle actin 
Stat3 Signal transducer and activator of transcription 3 
TCGA The cancer genome atlas 
WAP Whey acidic protein 
Wnt1 Wingless-type  member 1 
ZEB1 Zinc finger E-box-binding homeobox 1 
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The phosphoinositide 3-kinase (PI3K) signaling pathway is crucial for cell
growth, proliferation, metabolism, and survival, and is frequently deregu-
lated in human cancer, including ~ 70% of breast tumors. PIK3CA, the
gene encoding the catalytic subunit p110a of PI3K, is mutated in ~ 30% of
breast cancers. However, the exact mechanism of PIK3CA-evoked breast
tumorigenesis has not yet been defined. Genetically engineered mouse mod-
els are valuable for examining the initiation, development and progression
of cancer. Transgenic mice harboring hotspot mutations in p110a have
helped to elucidate breast cancer pathogenesis and increase our knowledge
about molecular and cellular alterations in vivo. They are also useful for
the development of therapeutic strategies. Here, we describe current mouse
models of mutant PIK3CA in the mammary gland, and discuss differences
in tumor latency and pathogenesis.
Introduction
Phosphoinositide 3-kinases (PI3Ks) belong to a family
of lipid kinases involved in metabolism, growth, prolif-
eration, and survival signaling. Class Ia PI3Ks phos-
phorylate the 3-hydroxyl group of phosphatidylinositol
4,5-bisphosphate, resulting in the production of the
second messenger phosphatidylinositol 3,4,5-trisphos-
phate. This recruits and activates several signaling
proteins, including AKT and PDK1, leading to the
activation of their downstream effectors. PI3K action
is reversed by the PTEN phosphatase [1,2]. PI3Ks are
heterodimers of regulatory (p85a, p50a, p55a, p85b,
and p55c) and catalytic (p110a, p110b, p110c, and
p110d) subunits [2,3].
Genomic alterations of components of the PI3K
pathway are found in ~ 70% of breast cancers [4]. The
gene PIK3CA encodes the catalytic subunit p110a, and
its amplification and/or mutation is associated with
several kinds of human solid tumors [5–9]. Activating
somatic mutations in PIK3CA are present in ~ 30% of
human breast cancers at all stages [5,8,10–12]. In 47%
of these cases, mutations occur in the kinase domain;
the most frequent one is H1047R in exon 20. In 33%
of these cases, mutations occur in the helical domain;
the most frequent ones are E545K and E542K in
exon 9 [8,13]. These mutations lead to a constitutively
active enzyme with oncogenic capacity in cell culture
[14–16]. Alterations in PIK3CA are found at similar
frequencies in pure ductal carcinoma in situ, ductal
carcinoma in situ adjacent to invasive ductal carci-
noma, and in invasive ductal carcinoma, indicating
that PIK3CA mutations occur early in carcinoma
development [17]. In addition, mutant p110a has been
found in distinct human breast cancer subtypes, such
as estrogen receptor (ER)a-positive, progesterone
Abbreviations
CK, cytokeratin; ER, estrogen receptor; MMTV-Cre, Cre driven by the mouse mammary tumor virus long terminal repeat; MMTV, mouse
mammary tumor virus; MMTV-Cre, Cre driven by the mouse mammary tumor virus long terminal repeat promoter; PI3K, phosphoinositide
3-kinase; PR, progesterone receptor; WAPi-Cre, Cre driven by the whey acidic protein promoter.
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receptor (PR)-positive, human epidermal growth fac-
tor 2 (HER2)/Neu-positive and triple-negative breast
cancers [12,18], but the correlation between PIK3CA
mutations and pathological parameters remains con-
troversial [5,12,19–25]. Also, assessment of the clinical
outcome associated with these hotspot mutations
showed contradictory results: some studies reported
poor prognosis in breast cancer patients harboring
PIK3CA exon 20 [26,27] or exon 9 mutations [10],
whereas others reported favorable prognosis with
improved overall survival in patients with exon 20
mutations [10,22]. Notably, PIK3CA mutations were
shown to reduce the efficacy of HER2-targeted and
ER-targeted therapies [28–30].
Adding to the list of mammary tumor mouse models
[31], several groups have generated transgenic mice
expressing PIK3CA H1047R in the mammary gland
[32–36]. In contrast to mouse models such as Neu, Myc
or polyoma middle T-antigen, which evoke tumors
with a very specific phenotype, PIK3CA H1047R
mutant mice have heterogeneous tumors. These new
models should not only help to delineate the cellular
and molecular mechanisms of action of mutant p110a
in vivo, but also improve our understanding of tumor
initiation, development and progression in breast
cancer, provide a resource for the development of can-
cer therapies, and help to elucidate mechanisms of
resistance to current PI3K pathway inhibitors.
Tumor formation in PIK3CA H1047R
mutant mice
Transgenic mice expressing the amino acid substitution
H1047R in the mammary gland were generated in
order to model mutant PIK3CA breast cancer
(Table 1; Fig. 1). For conditional mammary-specific
expression of human PIK3CA or murine Pik3ca
H1047R, two different promoters were used to drive
Cre recombinase expression. First, Cre driven by the
mouse mammary tumor virus (MMTV) long terminal
repeat (MMTV-Cre) promoter results in mosaic
expression of mutant PIK3CA/Pik3ca in differentiated
mammary luminal cells and progenitor cells, and in
other organs, depending on the MMTV-Cre line [35,37
–41]. Second, Cre driven by the whey acidic protein
promoter (WAPi-Cre) [42] (Fig. 1A) results in expres-
sion of mutant PIK3CA in alveolar progenitor cells
and differentiated secretory luminal cells [34]. Tetracy-
cline-inducible promoter systems (combined with
MMTV-rtTA [43]; Fig. 1B) were also used to drive
overexpression of H1047R, leading to a seven-fold to
eight-fold change in expression of mutant PIK3CA as
compared with Pik3ca [33]. Other groups have used a
knock-in system to express endogenous levels of Pik3ca
H1047R under the control of the native promoter
(combined with MMTV-Cre [35,36,39,41]) (Fig. 1C,D).
Meyer et al. found mammary tumor-independent
high lethality (~ 75%) in MMTV-Cre PIK3CA
H1047R mice. Although the cause of death could not
be identified, promoter leakiness leading to expression
of PIK3CA H1047R in other tissues was suggested
[34]. Using two different MMTV-Cre lines [37–39] to
induce expression of PIK3CA H1047 (Fig. 1E), Adams
et al. found that some MMTV-CrelineA Pik3ca
H1047R and MMTV-CreNLST Pik3ca H1047R mice
reached endpoint (lethargy, impaired breathing, tumor)
independently of mammary tumors [32]. These obser-
vations raise concerns about whether MMTV-Cre is
the optimal promoter system with which to study
PIK3CA-induced mammary cancer in mice.
Each of these systems leads to the development of
heterogeneous mammary tumors. The most prominent
phenotypes, adenosquamous carcinoma and adeno-
myoepithelioma, express ERa, as well as basal [e.g.
cytokeratin (CK)5 and CK14) and luminal (e.g. CK8
and CK18) markers. The Pik3ca H1047R knock-in
models of Yuan et al. and Tikoo et al. led mostly to
hormone receptor-positive fibroadenomas (76.9% and
45%, respectively) or sarcomas (42.5%). Other histo-
pathological features, such as adenocarcinoma, carci-
nosarcoma, and osteosarcoma, were also observed
[35,36] (Table 1). Heterogeneity, a feature of human
breast cancer, was also reported in mouse models of
Pten inactivation [44,45]. In another study, however,
loss of PTEN resulted only in adenomyoepithelioma
[46] (for a review of PTEN mouse models, see [47]).
Nulliparous WAPi-Cre PIK3CA H1047R animals
developed tumors at an average of 219 days (K.S. and
M.B.A., unpublished data), and nulliparous MMTV-
Cre Pik3ca knock-in H1047R animals developed
tumors at an average of 484 and 492 days [35,36].
Notably, tumor latencies in parous WAPi-Cre PIK3CA
H1047R animals were, on average, 140 days [34], and
those in MMTV-Cre Pik3ca knock-in H1047R animals
were 392 and 465 days [35,36], showing that pregnancy
accelerates tumorigenesis in these models. An increase
in the number of H1047R-expressing cells after preg-
nancy and a delay in involution (days 2 and 8), owing
to a reduced number of apoptotic cells, were observed
in WAPi-Cre H1047R mice [34].
Tumor formation was also investigated by using
MMTV-driven expression of nonmutated p110a fused to
a Src myristolyation sequence (Fig. 1F), which results in
the recruitment of p110a to the membrane and constitu-
tive activation of PI3K signaling (MMTV-MYR-p110a).
Transgenic mice developed heterogeneous ER-positive
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mammary tumors, but at a frequency lower than in mice
expressing mutant PIK3CA [48].
Synergism between PIK3CA H1047R
and p53 alterations
Whole-exome capture and sequencing of mammary
tumors from MMTV-Cre knock-in Pik3ca H1047R
mice of various histotypes has revealed greater increases
in somatic mutations in spindle cell tumors (~ 44–88)
and adenocarcinoma (~ 4–61) than in fibroadenoma
(~ 2–13) [36]. Moreover, comparative genomic hybridi-
zation-array profiling showed a greater accumulation of
chromosomal copy number alterations in spindle cell
tumors than in adenocarcinoma and fibroadenoma [36].
Functional validation and examination of the clinical
relevance of these secondary genomic alterations are
now warranted.
Table 1. Summary of current mouse models of PIK3CA alterations. a-SMA, a-smooth muscle actin.
Mouse model Mean age at tumor onset Pathology Ref.
WAPi-Cre PIK3CA H1047R
(transgenic model; Fig. 1A)
Parous: 140.3  6.9 days
(= 36.8  4.9 days after delivery)
Nulliparous: 219  12 days
Adenosquamous carcinoma (54.6%),
adenomyoepithelioma (22.7%, PR+),
adenocarcinoma with squamous metaplasia
(13.6%), adenocarcinoma (9.1%)
(all ER+, CK14+, CK18+, and CK14/CK18+)
[34]
MMTV-Cre PIK3CA
H1047R (transgenic model;
Fig. 1A)
214  22.6 days Adenomyoepithelioma (100%) (ER+, PR+,
CK14+, CK18+, and a-SMA+)
[34]
MMTV-rtTA TetO-PIK3CA H1047R
(inducible transgenic model;
Fig. 1B)
7 months Adenocarcinoma and adenosquamous
carcinoma
[33]
MMTV-Cre Pik3ca H1047R
(knock-in model; Fig. 1C)
Parous: 465 days
Nulliparous: 492 days
Fibroadenoma (76.9%), adenocarcinoma
(15.4%) (both CK5+, CK18+, ER+ and PR+);
spindle cell neoplasia (7.7%) (ER–, PR–,
CK5–, CK18+, vimentin+)
[36]
MMTV-Cre Pik3ca H1047R
(knock-in model; Fig. 1D)
Parous: 393 days
Nulliparous: 484 days
Benign fibroadenoma (45%), carcinosarcoma
(both ER+, CK5/CK6+, CK8/CK18+, CK5/CK8+,
CK8/E-cadherin+) or sarcoma (42.5%);
adenosquamous carcinoma (10%) (CK5/CK6+,
CK8–, E-cadherin–); osteosarcoma (2.5%)
[35]
MMTV-CreNLST Pik3ca H1047R
(transgenic model; Fig. 1E)
5 months Adenosquamous carcinoma (51%) (ER+, CK8+,
CK14+, CK8/CK14+, CK8/CK14, N-cadherin+,
vimentin+, Atf3+, CK10+, b-catenin+),
adenomyoepithelioma (45%) (ER+, CK8+,
CK14+, N-cadherin+, Atf3+, desmin+, b-catenin+),
spindle cell tumors (1%), poorly differentiated
adenocarcinoma (3%)
[32]
MMTV CreNLST Pik3ca H1047R;
p53 fl/+ (transgenic model)
< 5 months Spindle cell/EMT tumors (33%) (ER+,
CK8+, CK14+, N-cadherin+, desmin+),
adenosquamous carcinoma (52%)
(ER+, CK8+, CK14+, CK8/CK14+,
CK8/CK14, N-cadherin+, desmin,
CK10+), radial scar type lesions (10%) and
poorly differentiated adenocarcinoma
(5%) (ER+, CK8+, CK14+, CK8/CK14+,
CK8/CK14)
[32]
MMTV-MYR-p110a (Fig. 1F)
and MMTV-MYR-p110a; p53+/
(transgenic model)
Not reported Nulliparous: adenosquamous carcinoma.
Parous: 66% adenosquamous carcinoma,
34% carcinoma (all ER+, cathepsin D+)
[48]
MMTV-MYR-p110a; CDK4(R24C)
(transgenic model)
Not reported Nulliparous: adenosquamous carcinoma, papillary
adenocarcinoma, carcinoma, sarcoma
Parous: adenosquamous carcinoma, complex
adenocarcinoma, carcinoma, sarcoma
(all ER+ except sarcoma)
[48]
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Some human breast tumors harbor alterations in
PIK3CA in combination with mutant p53 [18,49,50].
p53 mutations (R245H, A135V, and I192N) were
among the secondary mutations identified by Yuan
et al. [36] in adenocarcinoma and spindle cell neopla-
sia. It is likely that these mutations prevented the
well-established p53-dependent tumor suppression.
Notably, Pik3ca mutant mouse models were used to
investigate the interaction of Pik3ca H1047R and p53
[32,36]. Heterozygosity in p53 was shown to accelerate
tumor onset in MMTV-Cre Pik3ca H1047R mice [32].
The tumor histotype in double mutants consisted
mostly of ER-positive, CK14-positive and CK8-posi-
tive spindle cell tumors that express epithelial–mesen-
chymal transition markers, or adenosquamous
carcinoma [32] (Table 1).
p53 has been found to be inactivated in MMTV-
MYR-p110a-evoked tumors, suggesting that p53 loss
is important for tumorigenesis in this model. Consis-
tently, no difference was found in tumor latency or
tumor phenotype between MMTV-MYR-p110a mice
in a heterozygous p53 background and MMTV-MYR-
p110a mice [48]. Notably, MMTV-MYR-p110a mice
in an inactive retinoblastoma (pRB) background
(CDK4 R24C knock-in line [51,52]) showed enhanced
mammary tumorigenesis. These data suggest that
PIK3CA H1047R-evoked tumor suppression mecha-
nisms can be circumvented by inactivation of either
p53 or pRB [48].
PIK3CA H1047R mutations and
metastasis
Mouse models with an altered PI3K pathway can
increase our understanding of breast cancer progres-
sion and metastatic spread. Metastases were reported
in Pten heterozygous mice: one study found a meta-
static tumor in the regional lymph node of one mouse,
and three other mice had lung metastases. Their mor-
phological appearance was similar to that of the pri-
mary tumor [44]. In contrast, metastases are rarely
found in PIK3CA/Pik3ca H1047R mouse models.
There is only one report of isolated lung metastasis in
MMTV-CreNLST Pik3ca H1047R mice [32]. However,
PIK3CA mutations occur at high frequencies in meta-
static human breast cancer [21]. Surprisingly, onco-
genic PIK3CA-driven breast tumors have a longer
time to recurrence after surgery [21], and some clinical
X Promoter Exon 1 Intron SA PGK-neo tpA Pik3ca H1047R bpa Intron Exon 2
ROSA26 Locus
Cre recombinaseMMTV promoter
TetO HA-PIK3CA H1047R LuciferaseIRESXrtTAMMTV promoter
X
Cre recombinaseMMTV promoter
Cre recombinaseWAP promoter
STOP
ROSA26 Locus
HA-PIK3CA H1047R IRES2 EGFPCAGS promoter
X Exon 17 Exon 18 Exon 19 Exon 20   polyA 4x Transcriptionalstop cassette Pik3ca H1047RCre recombinaseMMTV promoter
X Exon 17 Exon 18 Exon 19 Exon 20  STOP Pik3ca H1047RCre recombinaseMMTV promoter
MYR-p110αMMTV promoter
A
B
C
D
E
F
Fig. 1. Schematic overview of constructs that were used to generate mutant PIK3CA/Pik3ca models. Triangles represent loxp sites. (A)
WAPi-Cre PIK3CA H1047R and MMTV-Cre PIK3CA H1047R models [34]. (B) MMTV-rtTA TetO-PIK3CA H1047R model [33]. (C) MMTV-Cre
Pik3ca H1047R model [36]. (D) MMTV-Cre Pik3ca H1047R model [35]. (E) MMTV-CreNLST Pik3ca H1047R model [32]. (F) MMTV-MYR-p110a
model [48]. EGFP, enhanced green fluorescent protein; HA, hemagglutinin; IRES, internal ribosome entry site; PGK, phosphoglycerate
kinase; SA, splice acceptor sequence.
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studies reported a good prognosis [10,22]. These obser-
vations may mean that mutant PIK3CA results in a
selective advantage for breast cancer cells at the pri-
mary site, but not during metastatic progression and
colonization of distant sites. The analysis of PIK3CA
status in a large number of metastatic lesions, circulat-
ing tumor cells and matched primary tumors should
clarify this ‘PIK3CA paradox’ [53]. An alternative
explanation is that patients with mutations in PIK3CA
respond well to the current standard of care, resulting
in this apparent paradox.
Constitutively active PI3K signaling, in association
with further genomic alterations, induces mammary
cancer in mice, suggesting a causative role for PIK3CA
mutations in breast tumorigenesis. Additional gain-of-
function or loss-of-function genomic alterations may
also contribute to metastasis in breast tumor progres-
sion. The identification of these synergistic oncogenic
pathways is of paramount importance for the elucida-
tion of the ‘wiring diagram’ of tumor cells with
PIK3CA mutations.
Therapeutic strategies and resistance
in mutant PIK3CA mouse models
At least 26 PI3K pathway-targeting compounds are
currently undergoing over 150 cancer-related clinical
trials [54]. PIK3CA mouse models also serve as a valu-
able tool for testing anticancer drugs [55,56]. A test of
the efficacy of the PI3K inhibitor GDC-0941 by Yuan
et al. showed a decline in tumor growth in spindle cell
tumors with Pik3ca H1047R and p53 mutations [36].
These mouse models have already proved useful for
investigating resistance mechanisms. For example,
PIK3CA H1047R-driven tumors were shown to recur
after PIK3CA H1047R inactivation in a PI3K-depen-
dent or PI3K-independent manner [33]. Tumor sur-
vival in c-MET-elevated tumors was shown to depend
on an active endogenous PI3K pathway, whereas
c-MYC elevation contributed to oncogene indepen-
dence and GDC-0941 resistance [33].
The PI3K-independent recurrence of PIK3CA
H1047R-initiated mammary tumors shows how impor-
tant it is to investigate associated pathways involved
in tumor formation that may result in escape from
treatment. Their delineation should pave the way for
the development of mechanism-based combination
therapies.
Future perspectives
Current mouse models of mutant PIK3CA are
contributing to a better understanding of breast cancer
pathogenesis associated with alterations in the PI3K
pathway. So far, characterization of PIK3CA H1047R-
evoked tumors has clarified some pathophysiological
aspects, but has also raised further relevant questions.
Tumor heterogeneity and the observation that
PIK3CA H1047R mutants develop CK5/CK14-positive
and CK8/CK18-positive mammary carcinomas [32,34–
36] suggest either a luminal and basal tumor cell of
origin or the dedifferentiation of cell lineage-commit-
ted tumor cells to multipotent progenitors that then
give rise to CK5/CK14-positive and CK8/CK18-posi-
tive cells. Consistent with the latter possibility, Tikoo
et al. found that expression of Pik3ca H1047R results
in expansion of the luminal progenitor population.
Furthermore, the putative mammary stem cell-enriched
basal population and the luminal progenitors of
mutants show enhanced colony-forming ability and a
larger colony size [35], but the molecular mechanisms
underlying these effects have not yet been defined. The
current mouse models do not definitively answer the
question of what causes heterogeneity in PIK3CA
H1047R-evoked tumors and which cell type gives rise
to which subtype of mammary cancer. However, line-
age-tracing experiments should provide further infor-
mation about the cell of origin and cellular hierarchy
in tumors.
There have been few studies of synergistic pathways
contributing to tumor progression in vivo, especially
metastatic spread, and to resistance to therapy. Such
investigations should lead to an increase in our under-
standing of tumor relapse and therapy failure, and
should help to define targets for preventing PIK3CA-
driven tumor initiation and progression.
Acknowledgements
We thank members of the Bentires-Alj laboratory for
fruitful discussions. Research conducted in the labora-
tory of M. Bentires-Alj is supported by the Novartis
Research Foundation, the European Research Council
(ERC starting grant 243211-PTPsBDC), the Swiss
Cancer League, and the Krebsliga Beider Basel.
References
1 Cantley LC (2002) The phosphoinositide 3-kinase
pathway. Science 296, 1655–1657.
2 Yuan TL & Cantley LC (2008) PI3K pathway
alterations in cancer: variations on a theme. Oncogene
27, 5497–5510.
3 Zhao L & Vogt PK (2008) Class I PI3K in oncogenic
cellular transformation. Oncogene 27, 5486–5496.
2762 FEBS Journal 280 (2013) 2758–2765 ª 2013 The Authors Journal compilation ª 2013 FEBS
Mouse models of PIK3CA mutations S. Koren and M. Bentires-Alj
4 Miller TW, Rexer BN, Garrett JT & Arteaga CL (2011)
Mutations in the phosphatidylinositol 3-kinase pathway:
role in tumor progression and therapeutic implications
in breast cancer. Breast Cancer Res 13, 224. doi: 10.
1186/bcr3039.
5 Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J,
Szabo S, Konishi H, Karakas B, Blair BG, Lin C et al.
(2004) The PIK3CA gene is mutated with high
frequency in human breast cancers. Cancer Biol Ther 3,
772–775.
6 Kadota M, Sato M, Duncan B, Ooshima A, Yang HH,
Diaz-Meyer N, Gere S, Kageyama S, Fukuoka J,
Nagata T et al. (2009) Identification of novel gene
amplifications in breast cancer and coexistence of gene
amplification with an activating mutation of PIK3CA.
Cancer Res 69, 7357–7365.
7 Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat
RR, Borgen PI & Boyd J (2005) Frequent mutation of
the PIK3CA gene in ovarian and breast cancers. Clin
Cancer Res 11, 2875–2878.
8 Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J,
Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ
et al. (2004) High frequency of mutations of the
PIK3CA gene in human cancers. Science 304, 554. doi:
10.1126/science.1096502.
9 Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z,
Chatterjee A, Goldenberg D, Gollin SM, Sukumar S
et al. (2005) Somatic mutation and gain of copy
number of PIK3CA in human breast cancer. Breast
Cancer Res 7, R609–R616.
10 Barbareschi M, Buttitta F, Felicioni L, Cotrupi S,
Barassi F, Del Grammastro M, Ferro A, Dalla Palma
P, Galligioni E & Marchetti A (2007) Different
prognostic roles of mutations in the helical and kinase
domains of the PIK3CA gene in breast carcinomas.
Clin Cancer Res 13, 6064–6069.
11 Miller TW (2012) Initiating breast cancer by PIK3CA
mutation. Breast Cancer Res 14, 301. doi:10.1186/
bcr3103.
12 Saal LH, Holm K, Maurer M, Memeo L, Su T,
Wang X, Yu JS, Malmstrom PO, Mansukhani M,
Enoksson J et al. (2005) PIK3CA mutations correlate
with hormone receptors, node metastasis, and
ERBB2, and are mutually exclusive with PTEN
loss in human breast carcinoma. Cancer Res 65,
2554–2559.
13 Bader AG, Kang S, Zhao L & Vogt PK (2005)
Oncogenic PI3K deregulates transcription and
translation. Nat Rev Cancer 5, 921–929.
14 Bader AG, Kang S & Vogt PK (2006) Cancer-specific
mutations in PIK3CA are oncogenic in vivo. Proc Natl
Acad Sci USA 103, 1475–1479.
15 Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann
SM, Pearline RV, Cantley LC & Brugge JS (2005)
Breast cancer-associated PIK3CA mutations are
oncogenic in mammary epithelial cells. Cancer Res 65,
10992–11000.
16 Zhao JJ, Liu Z, Wang L, Shin E, Loda MF & Roberts
TM (2005) The oncogenic properties of mutant
p110alpha and p110beta phosphatidylinositol 3-kinases
in human mammary epithelial cells. Proc Natl Acad Sci
USA 102, 18443–18448.
17 Miron A, Varadi M, Carrasco D, Li H, Luongo L,
Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S et al.
(2010) PIK3CA mutations in in situ and invasive breast
carcinomas. Cancer Res 70, 5674–5678.
18 Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C,
Treilleux I, Tabone E, Puisieux A & Wang Q (2012)
Mutational characterization of individual breast
tumors: TP53 and PI3K pathway genes are frequently
and distinctively mutated in different subtypes. Breast
Cancer Res Treat 132, 29–39.
19 Campbell IG, Russell SE, Choong DY, Montgomery
KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson
RB & Phillips WA (2004) Mutation of the PIK3CA
gene in ovarian and breast cancer. Cancer Res 64,
7678–7681.
20 Dunlap J, Le C, Shukla A, Patterson J, Presnell A,
Heinrich MC, Corless CL & Troxell ML (2010)
Phosphatidylinositol-3-kinase and AKT1 mutations
occur early in breast carcinoma. Breast Cancer Res
Treat 120, 409–418.
21 Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M,
Bandaru R, Liu W, Hackl W, Barrett JC & Gardner H
(2011) PIK3CA mutations may be discordant between
primary and corresponding metastatic disease in breast
cancer. Clin Cancer Res 17, 667–677.
22 Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M,
Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald
W et al. (2009) PIK3CA mutation associates with
improved outcome in breast cancer. Clin Cancer Res
15, 5049–5059.
23 Li H, Zhu R, Wang L, Zhu T, Li Q, Chen Q, Wang H
& Zhu H (2010) PIK3CA mutations mostly begin to
develop in ductal carcinoma of the breast. Exp Mol
Pathol 88, 150–155.
24 Li SY, Rong M, Grieu F & Iacopetta B (2006)
PIK3CA mutations in breast cancer are associated with
poor outcome. Breast Cancer Res Treat 96, 91–95.
25 Perez-Tenorio G, Alkhori L, Olsson B, Waltersson
MA, Nordenskjold B, Rutqvist LE, Skoog L & Stal O
(2007) PIK3CA mutations and PTEN loss
correlate with similar prognostic factors and are not
mutually exclusive in breast cancer. Clin Cancer Res
13, 3577–3584.
26 Lai YL, Mau BL, Cheng WH, Chen HM, Chiu
HH & Tzen CY (2008) PIK3CA exon 20 mutation
is independently associated with a poor prognosis
in breast cancer patients. Ann Surg Oncol 15,
1064–1069.
FEBS Journal 280 (2013) 2758–2765 ª 2013 The Authors Journal compilation ª 2013 FEBS 2763
S. Koren and M. Bentires-Alj Mouse models of PIK3CA mutations
27 Mangone FR, Bobrovnitchaia IG, Salaorni S, Manuli
E & Nagai MA (2012) PIK3CA exon 20 mutations are
associated with poor prognosis in breast cancer
patients. Clinics 67, 1285–1290.
28 Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M,
Nijkamp W, Beijersbergen RL, Valero V, Seoane J,
Bernards R et al. (2008) Phosphatidylinositol 3-kinase
hyperactivation results in lapatinib resistance that is
reversed by the mTOR/phosphatidylinositol 3-kinase
inhibitor NVP-BEZ235. Cancer Res 68, 9221–9230.
29 Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai
M & Minami H (2010) Association between gain-of-
function mutations in PIK3CA and resistance to
HER2-targeted agents in HER2-amplified breast cancer
cell lines. Ann Oncol 21, 255–262.
30 Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC,
Olivares MG, Sanchez V, Dugger TC, de Matos Granja
N, Narasanna A et al. (2009) Inhibition of mammalian
target of rapamycin is required for optimal antitumor
effect of HER2 inhibitors against HER2-overexpressing
cancer cells. Clin Cancer Res 15, 7266–7276.
31 Borowsky AD (2011) Choosing a mouse model:
experimental biology in context – the utility and
limitations of mouse models of breast cancer. Cold
Spring Harbor Perspect Biol 3, a009670. doi: 10.1101/
cshperspect.a009670.
32 Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ,
Wong RG, Wang W, Wright KL, Lane TF,
Zacksenhaus E et al. (2011) Cooperation between
Pik3ca and p53 mutations in mouse mammary tumor
formation. Cancer Res 71, 2706–2717.
33 Liu P, Cheng H, Santiago S, Raeder M, Zhang F,
Isabella A, Yang J, Semaan DJ, Chen C, Fox EA et al.
(2011) Oncogenic PIK3CA-driven mammary tumors
frequently recur via PI3K pathway-dependent and
PI3K pathway-independent mechanisms. Nat Med 17,
1116–1120.
34 Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff
RD & Bentires-Alj M (2011) Luminal expression of
PIK3CA mutant H1047R in the mammary gland induces
heterogeneous tumors. Cancer Res 71, 4344–4351.
35 Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P,
Pelzer R, Hare L, Shackleton M, Humbert P & Phillips
WA (2012) Physiological levels of Pik3ca(H1047R)
mutation in the mouse mammary gland results in
ductal hyperplasia and formation of ERalpha-positive
tumors. PLoS One 7, e36924.
36 Yuan W, Stawiski E, Janakiraman V, Chan E, Durinck
S, Edgar KA, Kljavin NM, Rivers CS, Gnad F, Roose-
Girma M et al. (2012) Conditional activation of Pik3ca
(H1047R) in a knock-in mouse model promotes
mammary tumorigenesis and emergence of mutations.
Oncogene 32, 318–326.
37 Soriano P (1999) Generalized lacZ expression with the
ROSA26 Cre reporter strain. Nat Genet 21, 70–71.
38 Srinivas S, Watanabe T, Lin CS, William CM, Tanabe
Y, Jessell TM & Costantini F (2001) Cre reporter
strains produced by targeted insertion of EYFP and
ECFP into the ROSA26 locus. BMC Dev Biol 1, 4. doi:
10.1186/1471-213X-1-4.
39 Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-
Boris A, Garrett L, Li M, Furth PA & Hennighausen L
(1997) Cre-mediated gene deletion in the mammary
gland. Nucleic Acids Res 25, 4323–4330.
40 Andrechek ER, White D & Muller WJ (2005)
Targeted disruption of ErbB2/Neu in the mammary
epithelium results in impaired ductal outgrowth.
Oncogene 24, 932–937.
41 Wagner KU, McAllister K, Ward T, Davis B, Wiseman
R & Hennighausen L (2001) Spatial and temporal
expression of the Cre gene under the control of the
MMTV-LTR in different lines of transgenic mice.
Transgenic Res 10, 545–553.
42 Wintermantel TM, Mayer AK, Schutz G & Greiner EF
(2002) Targeting mammary epithelial cells using a
bacterial artificial chromosome. Genesis 33, 125–130.
43 Gunther EJ, Belka GK, Wertheim GB, Wang J,
Hartman JL, Boxer RB & Chodosh LA (2002) A novel
doxycycline-inducible system for the transgenic analysis
of mammary gland biology. FASEB J 16, 283–292.
44 Stambolic V, TsaoMS, Macpherson D, Suzuki A,
ChapmanWB &Mak TW (2000) High incidence of breast
and endometrial neoplasia resembling human Cowden
syndrome in pten+/–mice. Cancer Res 60, 3605–3611.
45 Li G, Robinson GW, Lesche R, Martinez-Diaz H,
Jiang Z, Rozengurt N, Wagner KU, Wu DC, Lane TF,
Liu X et al. (2002) Conditional loss of PTEN leads to
precocious development and neoplasia in the mammary
gland. Development 129, 4159–4170.
46 Dourdin N, Schade B, Lesurf R, Hallett M, Munn RJ,
Cardiff RD & Muller WJ (2008) Phosphatase and
tensin homologue deleted on chromosome 10 deficiency
accelerates tumor induction in a mouse model of ErbB-
2 mammary tumorigenesis. Cancer Res 68, 2122–2131.
47 HollanderMC, Blumenthal GM&Dennis PA (2011)
PTEN loss in the continuum of common cancers, rare
syndromes andmousemodels.Nat Rev Cancer 11, 289–301.
48 Renner O, Blanco-Aparicio C, Grassow M, Canamero
M, Leal JF & Carnero A (2008) Activation of
phosphatidylinositol 3-kinase by membrane localization
of p110alpha predisposes mammary glands to
neoplastic transformation. Cancer Res 68, 9643–9653.
49 Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi
D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A,
Campani D et al. (2006) PIK3CA mutation and
histological type in breast carcinoma: high frequency
of mutations in lobular carcinoma. J Pathol 208,
350–355.
50 Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y,
Monden M & Noguchi S (2007) Clinicopathologic
2764 FEBS Journal 280 (2013) 2758–2765 ª 2013 The Authors Journal compilation ª 2013 FEBS
Mouse models of PIK3CA mutations S. Koren and M. Bentires-Alj
analysis of breast cancers with PIK3CA mutations in
Japanese women. Clin Cancer Res 13, 408–414.
51 Quereda V, Martinalbo J, Dubus P, Carnero A &
Malumbres M (2007) Genetic cooperation between
p21Cip1 and INK4 inhibitors in cellular senescence and
tumor suppression. Oncogene 26, 7665–7674.
52 Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S,
Malumbres M & Barbacid M (2001) Wide spectrum of
tumors in knock-in mice carrying a Cdk4 protein
insensitive to INK4 inhibitors. EMBO J 20, 6637–6647.
53 Meyer DS & Bentires-Alj M (2010) Can
phosphatidylinositol 3-kinase/mammalian target of
rapamycin inhibition ERase them all? Breast Cancer
Res 12, 315. doi: 10.1186/bcr2718.
54 Sheppard K, Kinross KM, Solomon B, Pearson RB &
Phillips WA (2012) Targeting PI3 kinase/AKT/mTOR
signaling in cancer. Crit Rev Oncog 17, 69–95.
55 Courtney KD, Corcoran RB & Engelman JA (2010)
The PI3K pathway as drug target in human cancer.
J Clin Oncol 28, 1075–1083.
56 Engelman JA, Chen L, Tan X, Crosby K, Guimaraes
AR, Upadhyay R, Maira M, McNamara K, Perera
SA, Song Y et al. (2008) Effective use of PI3K and
MEK inhibitors to treat mutant Kras G12D and
PIK3CA H1047R murine lung cancers. Nat Med 14,
1351–1356.
FEBS Journal 280 (2013) 2758–2765 ª 2013 The Authors Journal compilation ª 2013 FEBS 2765
S. Koren and M. Bentires-Alj Mouse models of PIK3CA mutations
OPEN
SHORT COMMUNICATION
Expression of PIK3CA mutant E545K in the mammary
gland induces heterogeneous tumors but is less potent than
mutant H1047R
DS Meyer1,4,5, S Koren1,4, C Leroy1,2, H Brinkhaus1, U Mu¨ller1, I Klebba1,6, M Mu¨ller2, RD Cardiff3 and M Bentires-Alj1
The phosphoinositide 3-kinase (PI3K) signaling cascade is a key mediator of cellular growth, survival and metabolism and is
frequently subverted in human cancer. The gene encoding for the alpha catalytic subunit of PI3K (PIK3CA) is mutated and/or
ampliﬁed in B30% of breast cancers. Mutations in either the kinase domain (H1047R) or the helical domain (E545K) are most
common and result in a constitutively active enzyme with oncogenic capacity. PIK3CAH1047R was previously demonstrated to induce
tumors in transgenic mouse models; however, it was not known whether overexpression of PIK3CAE545K is sufﬁcient to induce
mammary tumors and whether tumor initiation by these two types of mutants differs. Here, we demonstrate that expression of
PIK3CAE545K in the mouse mammary gland induces heterogenous mammary carcinomas but with a longer latency than
PIK3CAH1047R-expressing mice. Our results suggest that the helical domain mutant PIK3CAE545K is a less potent inducer of mammary
tumors due to less efﬁcient activation of downstream Akt signaling.
Oncogenesis (2013) 2, e74; doi:10.1038/oncsis.2013.38; published online 30 September 2013
Subject Categories: Cellular oncogenes
Keywords: PIK3CA; PI3K; breast cancer
INTRODUCTION
The phosphoinositide 3-kinase (PI3K) pathway is a key regulator of
cell growth, proliferation, metabolism and survival and is often
found to be hyperactivated in human cancer.1,2 The most
common aberrations of the PI3K pathway include mutation
and/or ampliﬁcation of PIK3CA,3–7 the gene encoding the
alpha catalytic subunit of the kinase (p110a), loss of expression
of the PTEN phosphatase that reverses PI3K action, acti-
vation downstream of oncogenic receptor tyrosine kinases and
mutation/ampliﬁcation of Akt.1 Hyperactivation of the PI3K
pathway increases tumorigenicity by reducing cell death and
increasing cell proliferation, migration, invasion, metabolism and
angiogenesis.1,2 It also enhances resistance to chemotherapy.8
The majority of mutations in PIK3CA occur at two ‘hotspots’
within the kinase (H1047R) and helical domains (E542K and E545K)
of p110a.6,9 These mutations lead to a constitutively active
enzyme, transform cells in vitro, and enhance tumorigenicity in
xenograft models.10–13 Notably, different mechanisms underlie the
gain-of-function activities of helical- and kinase domain mutants.
While PIK3CAE545K is independent of binding to the adaptor
molecule p85 but requires interaction with Ras-GTP, the
PIK3CAH1047R mutant is highly dependent on p85 for its
oncogenic capacity but independent of Ras-GTP.14
PIK3CA gain-of-function mutations are found inB30% of human
breast cancers3,6,15–17 and most likely occur at an early stage of
breast carcinoma development, as suggested by the similar
mutation frequencies in PIK3CA found in pure ductal carcinoma
in situ, ductal carcinoma in situ adjacent to invasive ductal
carcinoma, and invasive ductal carcinoma.18 Evaluation of the
clinical outcome of genomic alterations in PIK3CA has produced
contradictory results.15,19,20 However, these studies showed that
alterations in different exons of PIK3CA have varying impacts on
tumor development and progression and, therefore, differ in
prognostic value. For example, both mutations are associated with
lower grade and hormone receptor-positive tumors, but
PIK3CAH1047R mutants are strongly associated with lymph-node
negativity and PIK3CAE545K mutants with older age at diagnosis,
indicating the different oncogenic potentials of the H1047R and
E545K mutations.19 This is further supported by the different
frequencies of E545K (B6%) and H1047R (B15%) mutations in
breast cancer.17,21 In vivo transplantation assays have demonstrated
PIK3CAH1047R to be more potent in inducing tumors10 but another
study found no trend,12 and the exact impact of these mutations
on breast cancer has remained controversial.
We and others have reported that expression of PIK3CAH1047R in
the mammary gland induces heterogeneous tumors.22–25 To
determine which PIK3CA mutant shows higher oncogenic
activity in vivo, we generated a novel conditional mouse model
expressing PIK3CAE545K. We have demonstrated that PIK3CAE545K
induces heterogeneous mammary tumors that express basal and
luminal markers but is a less potent oncogene in vivo than
PIK3CAH1047R.
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RESULTS AND DISCUSSION
Expression of PIK3CAE545K but not wild-type PIK3CA induces
mammary tumors
We and others have shown that PIK3CAH1047R induces mouse
mammary carcinomas.22–25 To test whether overexpression of
wild-type human PIK3CA (PIK3CAwt) or PIK3CAE545K also induces
mammary tumors, we generated novel transgenic mice that
conditionally express PIK3CAwt or PIK3CAE545K (Figure 1a). To
achieve equivalent transgene expression, we integrated PIK3CAwt
or PIK3CAE545K into the ROSA26 locus using recombinase-
mediated cassette exchange.26 Correct integration of the target
cassettes was conﬁrmed in the resulting PIK3CAwt and PIK3CAE545K
lines (Figure 1b, left). PIK3CAwt and PIK3CAE545K animals were then
crossed to WAPiCre mice in which expression of recombinase Cre
is controlled by the whey acidic protein (WAP) promoter, which is
mainly active in secretory mammary epithelial cells, and expres-
sion of the transgenes conﬁrmed (Figure 1b, right).27–30 This
enabled us to directly compare the kinetics of tumor onset in
PIK3CAwt and PIK3CAE545K mice, and the previously reported
WAPiCre PIK3CAH1047R mice.22
The resulting bi-transgenic WAPiCre PIK3CAwt and WAPiCre
PIK3CAE545K female mice were impregnated to achieve maximal
Cre-mediated recombination and the pups removed 1 day after
delivery. All WAPiCre PIK3CAE545K mice developed mammary tumors
on average 80 (±10) days after delivery, whereas parous WAPiCre
PIK3CAwt mice did not form tumors within 520 days (Figure 1c). This
indicates that overexpression of wild-type PIK3CA itself is insufﬁcient
to induce mammary tumors. Of note, the latency to tumor onset
in WAPiCre PIK3CAE545K animals was signiﬁcantly longer than that
observed previously for WAPiCre PIK3CAH1047R mice (36 (±4.9)
days).22 We also crossed PIK3CAE545K and PIK3CAH1047R lines to
CAGs-CreERT2 mice that express a tamoxifen-inducible Cre/
estrogen receptor (ER) fusion protein under the control of a
modiﬁed b-actin promoter; this results in the expression of Cre-ER in
virtually all cells. Unexpectedly, bi-transgenic CAGs-Cre PIK3CAE545K
and PIK3CAH1047R mice died by the age of 4 months even when no
tamoxifen was administered. Although we were unable to identify
the exact cause of death, we concluded that leakiness of the CAGs-
CreERT2 system caused premature and deleterious PIK3CAE545K or
PIK3CAH1047R expression in various tissues of these mice (DSM and
MB-A, unpublished observations).
To compare the tumor-initiating potential of the two different
PIK3CA mutants, we then transplanted pieces of mammary gland
tissue from CAGs-CreERT2 PIK3CAE545K or PIK3CAH1047R donor mice
previously treated with tamoxifen into cleared fat pads of Balb/c
mice. The mammary glands reconstituted by either CAGs-CreERT2
PIK3CAE545K or PIK3CAH1047R-derived epithelium were hyperplastic
(data not shown) and eventually formed tumors after 229 (±17,
PIK3CAH1047R) and 336 days (±20, PIK3CAE545K), respectively
(Figure 1d). As observed in the WAPiCre mouse cohorts,
PIK3CAE545K was signiﬁcantly less potent than PIK3CAH1047R in
the induction of mammary carcinomas, which is a possible
explanation for the lower frequency of E542K/E545K mutations in
human breast cancer.17,21
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Figure 1. Overexpression of PIK3CA mutant PIK3CAE545K but not PIK3CAwt induces mammary tumors. (a) Schematic of the constructs used for
generating transgenic mice conditionally expressing human wild-type and mutant 5’-terminally HA-tagged PIK3CA. Vectors were constructed in
which the PIK3CA cDNA is flanked by a floxed STOP cassette upstream and an IRES2-EGFP reporter element downstream. The transgene is driven
by a modified chicken b-actin (CAGs) promoter. The vector was introduced into a modified Rosa26 locus of Balb/c mouse embryonic stem cells
by recombinase-mediated cassette exchange. (b) Southern blot of genomic DNA from PIK3CAE545K and PIK3CAwt transgenic mice (left) and
immunoblots of lysates from mammary glands isolated 12h after onset of involution from WAPiCre control, WAPiCre PIK3CAwt and WAPiCre
PIK3CAE545K mice (each n¼ 3) probed for HA. Erk2 levels were used as a control for equal loading (right). (c) Kaplan–Meier plot showing tumor
onset in parous WAPiCre PIK3CAwt (n¼ 8) and WAPiCre E545K (n¼ 16) mice. The mice were impregnated and the pups weaned 1 day after
delivery. WAPiCre PIK3CAwt mice did not develop palpable tumors within 520 days whereas mice expressing PIK3CAE545K developed tumors on
average 80 (±10) days after delivery. (d) Seven-week-old CAGs-CreERT2 PIK3CAE545K and PIK3CAH1047R donor mice were treated with tamoxifen
on 3 consecutive days for transgene induction and fragments of glands were transplanted into cleared fat pads of three-week-old Balb/c
recipient mice. Kaplan–Meier curves show tumor onset in recipient Balb/c mice transplanted with CAGs-CreERT2 PIK3CAE545K- (n¼ 10) or CAGS-
CreERT2 PIK3CAH1047R-derived mammary glands (n¼ 10). Balb/c mice developed palpable tumors on average 336 (±20) days (PIK3CAE545K) or 229
(±17) days (PIK3CAH1047R) after transplantation; P¼ 0.0033.
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WAPiCre PIK3CAE545K-evoked mammary tumors are heterogeneous
Examination of 30 WAPiCre PIK3CAE545K-derived tumors identiﬁed
6 distinct histotypes. By far the most prevalent tumor pheno-
type was adenosquamous carcinoma (60%) (Figures 2a and b),
which was also the most common histotype formed by
WAPiCre PIK3CAH1047R mice (54.6%).22 Adenocarcinomas (23.3%)
and carcinomas (6.7%) were also observed albeit at lower
frequencies (Figures 2a and b). An adenocarcinoma with
squamous metaplasia (3.3%), an adenomyoepithelioma (3.3%)
and spindle cell tumor (3.3%) were observed in one tumor only
(Figures 2a and b). The low frequency of adenomyoepithelioma in
WAPiCre PIK3CAE545K mice is in stark contrast to the WAPiCre
PIK3CAH1047R animals, in which adenomyoepitheliomas accounted
for B23% of the tumors.22 A further discrepancy between mice
expressing PIK3CAE545K or PIK3CAH1047R was the complete absence
of diffuse and invasive adenocarcinomatosis in WAPiCre
PIK3CAE545K-derived glands, a histological feature that was
displayed by all tumor-surrounding tissue in WAPiCre
PIK3CAH1047R mice.22
The PIK3CAE545K-induced tumors were stained for luminal
cytokeratin 18 (K18), basal/myoepithelial cytokeratin 14 (K14),
and myoepithelial a-smooth muscle actin (a-SMA) markers. The
most frequent histotypes, adenosquamous carcinoma and ade-
nocarcinoma, were positive for both luminal K18 and basal K14
(Figure 2c). In tumors of the adenosquamous carcinoma type, the
relative tumor areas positive for K18 and K14 were B35% and
B39%, respectively (Figure 2d) and largely negative for a-SMA
(o1%) (Figure 2d). WAPiCre PIK3CAE545K-evoked adenosquamous
carcinomas also stained positive for ER (B8% of the tumor cells)
and displayed a high proportion of Ki-67-positive cells (B35%)
(Figures 2c and d). The relative tumor areas and cells positive for
K14, K18, a-SMA, ER and Ki-67 were very similar to those observed
in PIK3CAH1047R-driven adenosquamous carcinomas.22 However,
the number of apoptotic cells staining positively for cleaved
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Figure 2. WAPiCre PIK3CAE545K-evoked tumors are heterogeneous and express basal and luminal cytokeratins. (a) Diagram showing relative
abundance of adenosquamous carcinoma (60%, red), adenocarcinoma (23.3%, green), carcinoma (6.7%, purple), adenocarcinoma with
squamous metaplasia (3.3%, dark blue), adenomyoepithelioma (3.3%, light blue) and spindle cell tumor (3.3%, orange) among tumors (n ¼ 30)
from parous WAPiCre PIK3CAE545K mice. (b) H&E-stained tumor sections of the indicated histotypes from parous WAPiCre PIK3CAE545K mice. The
top-left image shows a representative adenosquamous carcinoma with glands and squamous features. The top-right image shows an
adenocarcinoma; the arrows indicate the gland lumen. The glands are lined by malignant epithelium. The center-left image shows an
adenocarcinoma with squamous metaplasia; the asterisk shows an area with glands and the arrow indicates areas of metaplasia. The center-
right image shows a spindle cell tumor with possible osseous metaplasia, intense pink stroma and large cells in the interstices. The bottom
image shows an adenomyoepithelioma. Scale bar¼ 100 mm. (c) Immunostaining for K14, K18, a-SMA, ER, Ki67 and cleaved caspase-3. Scale
bars¼ 50 mm. (d) Quantification of immunostaining for K18, K14, a-SMA, ER, Ki67 and cleaved caspase-3 isolated from parous WAPiCre
PIK3CAE545K-evoked adenosquamous carcinomas (n¼ 8). The data are presented as percentages of positive tumor area and tumor cells.
Histological features of WAPiCre PIK3CAE545K-evoked adenosquamous carcinomas are compared with those of WAPiCre PIK3CAH1047R-evoked
adenosquamous carcinomas previously reported.22
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caspase-3 was higher in PIK3CA PIK3CAE545K-evoked adeno-
squamous carcinomas (B7%) (Figures 2c and d) than those
derived from WAPiCre H1047R mice (B1%),22 indicating that
PIK3CAH1047R is a more potent suppressor of apoptosis than
PIK3CAE545K in mammary tumors.
In summary, both PIK3CAE545K and PIK3CAH1047R produced K14/
K18-positive tumors of various histotypes, with the adenosqua-
mous carcinoma type being the most common in both transgenic
models. However, differences between the mouse models
included low abundance of adenomyoepitheliomas and the
absence of adenocarcinomatosis in WAPiCre PIK3CAE545K mice.
The variations in tumor histotypes and the discrepancy in tumor
latency in WAPiCre PIK3CAE545K and PIK3CAH1047R mice suggest
that different mechanisms underlie tumor initiation by these
mutants. To gain a mechanistic insight that might explain these
differences, we investigated whether pregnancy accelerates tumor
onset in WAPiCre PIK3CAE545K as it does in WAPiCre PIK3CAH1047R
mice.22 Pregnancy accelerated tumor onset in WAPiCre
PIK3CAE545K mice, reducing latency from 228±15 days in
nulliparous to 165±10 days in parous mice (Figure 3a). Interest-
ingly, pregnancy appeared to accentuate the difference in tumor
latency between WAPiCre PIK3CAE545K and PIK3CAH1047R mice,
shown by 32 days difference in nulliparous vs 48 days difference
in parous mice (Figure 3a).22 We showed previously that a
pregnancy-induced delay in mammary gland involution accounts,
at least in part, for accelerated tumor kinetics in parous vs
nulliparous PIK3CAH1047R mice.22 Thus, we hypothesized here that
the longer tumor latency of parous WAPiCre PIK3CAE545K
compared with parous WAPiCre PIK3CAH1047R animals is the
result of a less-pronounced involution delay. Comparison of
WAPiCre PIK3CAE545K and WAPiCre PIK3CAH1047R glands 15 days
after weaning revealed a dramatic delay in involution compared
with control animals (Figure 3b). The relative gland area occupied
by epithelial cells was the same in WAPiCre PIK3CAE545K and
PIK3CAH1047R mice and signiﬁcantly larger than in WAPiCre control
glands (Figure 3c). Similarly, there was no difference in the
number of apoptotic or proliferating cells in glands expressing
either of the PIK3CA mutations (Figure 3d). Interestingly, glands
from WAPiCre PIK3CAwt mice, which did not form tumors,
displayed normal involution and numbers of apoptotic and
proliferating cells similar to the controls (Figure 3), indicating that
the delay in involution is caused by mutant PIK3CA rather than by
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Figure 3. Pregnancy accelerates PIK3CA-evoked tumorigenesis and PIK3CA mutants delay mammary gland involution. (a) Kaplan–Meier curves
showing tumor onset in parous WAPiCre PIK3CAE545K (n¼ 16) and nulliparous WAPiCre PIK3CAE545K (n¼ 6) animals. Parous WAPiCre PIK3CAE545K
mice developed palpable tumors on average after 165 (±10) days whereas nulliparous mice developed tumors on average after 228 (±15)
days (PIK3CAE545K); P¼ 0.0023. (b) Representative images of whole mount (top panels), magnification of whole mount (center panels) and H&E
(lower panels) staining of involuting glands from WAPiCre control, WAPiCre PIK3CAwt, WAPiCre PIK3CAE545K and WAPiCre PIK3CAH1047R mice as
indicated. The glands were isolated 15 days after removal of the pups. Scale bar¼ 1 cm (whole mounts). Scale bar¼ 100 mm (H&E sections).
(c) Bar graph showing relative epithelium to total gland area of involution at day 15 in whole mounts prepared from WAPiCre control (n¼ 3),
WAPiCre PIK3CAwt (n¼ 4), WAPiCre PIK3CAE545K (n¼ 4) and WAPiCre PIK3CAH1047R (n¼ 2). Means±s.d. are shown; P¼ 0.001 (WAPiCre vs
WAPiCre PIK3CAE545K); P¼ 0.01 (WAPiCre vs WAPiCre PIK3CAH1047R); P¼ 0.46 (WAPiCre PIK3CAE545K vs WAPiCre PIK3CAH1047R).
(d) Immunostaining for Ki67 and cleaved caspase-3 of day 15 involuting glands from WAPiCre control, WAPiCre PIK3CAE545K and
WAPiCreH1047R mice (upper panels). Scale bar¼ 50mm. Quantification of Ki67- and cleaved caspase-3-positive cells (lower panels). Means±s.e.m.
are shown. *For Ki67-positive cells: P¼ 2.18 10 5 (WAPiCre vs WAPiCre PIK3CAE545K), P¼ 2.90 10 7 (WAPiCre vs WAPiCre PIK3CAH1047R).
For cleaved caspase-3-positive cells: P¼ 6.55 10 3 (WAPiCre vs WAPiCre PIK3CAE545K). NS¼not significant.
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overexpression of the transgene. In summary, PIK3CAE545K and
PIK3CAH1047R transgene expression caused a dramatic but
comparable delay in involution and, therefore, involution does
not explain the different tumor kinetics observed in parous vs
nulliparous mice expressing these mutations.
Comparison of lysates from WAPiCre PIK3CAE545K- and WAPiCre
PIK3CAH1047R-derived mammary glands and tumors showed
equal expression of p110a in tumors from both transgenic
models (Figure 4a). Despite the enhanced oncogenic potential
of the PIK3CAH1047R mutant, no differences in activation of the
PI3K/Akt or the Erk pathways were observed in the tumors
(Figure 4a). Similarly, a more detailed analysis of Akt1 and Akt2
isoform-speciﬁc phosphorylation revealed no difference between
PIK3CAE545K- and WAPiCre PIK3CAH1047R-induced signaling
(Figure 4b). Conceivably, by the time mammary tumors were
established, numerous secondary mutations had resulted in a
tumor heterogeneity that compromises the detection of
potentially subtle differences in oncogenic signaling induced by
either PIK3CA mutant. To circumvent this, we investigated
molecular signaling events in mutant PIK3CA-expressing epithelial
cells at an early pre-neoplastic stage. Protein lysates from
mammary glands isolated 12 h after the onset of involution
revealed increased activation of Akt and decreased phosphoryla-
tion of the signal transducer and activator of transcription (STAT) 3
in mutant relative to control glands. Notably, both hyperactivation
of Akt and hypoactivation of STAT3 were more pronounced in
PIK3CAH1047R than in PIK3CAE545K glands (for pAkt P¼ 2.5 10 4;
for pSTAT3 P¼ 0.047) (Figure 4c).
In summary, we found that overexpression of PIK3CAE545K in a
transgenic mouse model potently induces heterogeneous mammary
tumors whereas overexpression of wild-type PIK3CA does not.
Notably, although PIK3CAE545K evokes tumors with 100% penetrance
it is a weaker inducer of mammary tumors than PIK3CAH1047R in two
independent mouse models in which mutant PIK3CA is either driven
by the WAP or by the CAGs promoter. This may explain the lower
frequency of helical vs kinase domain mutations in human breast
cancer.13 We found differences in Akt and STAT3 activation in pre-
neoplastic mammary glands from PIK3CAE545K and PIK3CAH1047R
transgenic mice that may explain the longer tumor latency observed
in WAPiCre PIK3CAE545K compared with WAPiCre PIK3CAH1047R mice.
The novel transgenic mouse models reported here provide
excellent tools to further dissect the activities of different PIK3CA
mutants in tumor initiation in vivo and to investigate drug responses
to the ever-increasing number of PI3K pathway inhibitors.
MATERIALS AND METHODS
Transgenic mice
We constructed a vector with a transcriptional STOP sequence ﬂanked by
loxP sites upstream of the 5’-terminally HA-tagged human PIK3CA cDNA
(Addgene, Cambridge, MA, USA) and an IRES2-EGFP reporter element
(pIRES2-EGFP vector; Clontech, Mountain View, CA, USA). The resulting
construct was introduced into the modiﬁed Rosa26 locus of Balb/c mouse
embryonic stem cells by recombinase-mediated cassette exchange as
described earlier.22 Chimeric mice were backcrossed to Balb/c mice and
transgenic mice identiﬁed by genotyping.22
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Figure 4. WAPiCre PIK3CAE545K involuting glands show reduced pAkt and increased pSTAT3 compared with WAPiCre PIK3CAH1047R at 12 h of
involution. (a) Immunoblots of lysates from WAPiCre PIK3CAE545K and WAPiCre PIK3CAH1047R mammary tumors probed for the indicated
proteins. (b) Lysates of mammary tumors from WAPiCre PIK3CAE545K and WAPiCre PIK3CAH1047R mice were first immunoprecipitated with
antibodies against either Akt1 or Akt2 and then probed for total Akt or S473 pAkt (upper panels). Bar graph showing relative levels of S473
pAkt normalized to total Akt in Akt1 or Akt2 immunoprecipitates (lower panel). (c) Lysates of mammary glands isolated 12 h after onset of
involution from WAPiCre control, WAPiCre PIK3CAH1047R and WAPiCre PIK3CAE545K mice (each n¼ 3) probed for p110a, pAkt, Akt, pSTAT3, STAT3
and ERK2 as a loading control (upper panels). Bar graphs showing relative amounts of pAkt (normalized to total Akt), pSTAT3 (normalized to
total STAT3) and p110a (normalized to ERK2) in lysates of WAPiCre control, WAPiCre PIK3CAH1047R and WAPiCre PIK3CAE545K mammary glands
(lower panels). *WAPiCre vs WAPiCre PIK3CAH1047R: For pAkt P¼ 3.8 10 5; for pSTAT3 P¼ 0.002; for p110a P¼ 0.007. WAPiCre vs WAPiCre
PIK3CAE545K: For pAkt P¼ 1.8 10 4; for pSTAT3 P¼ 0.02; for p110a P¼ 8.8 10 5. WAPiCre PIK3CAH1047R vs WAPiCre PIK3CAE545K: for pAkt
P¼ 2.5 10 4; for pSTAT3 P¼ 0.047; for p110a P¼ 0.7. NS¼not significant.
PIK3CA E545K induces mammary carcinomas
DS Meyer et al
5
& 2013 Macmillan Publishers Limited Oncogenesis (2013), 1 – 6
Immunoblotting
Protein lysates were extracted from inguinal mammary glands or tumors
using LB buffer (50mM Tris–HCl pH8, 150mM NaCl, 1% NP-40) supplemented
with 0.5mM sodium orthovanadate. Anti-p110a, anti-pAKT (Ser473), anti-Akt,
anti-pERK1/2 (Thr202/Tyr204), anti-ERK1/2, anti-pS6 (Ser235/236), anti-S6, anti-
Akt1, anti-Akt2, anti-pSTAT3 (Tyr705) and anti-STAT3 antibodies were
purchased from Cell Signaling Technology, Danvers, MA, USA.
Immunohistochemistry
The following antibodies were used: K14 (Thermo Scientiﬁc, , Waltham, MA,
USA, RB-9020, 1:100), K18 (Fitzgerald, Acton, MA, USA, #GP11, 1 : 200), ER
(Santa Cruz, , Dallas, TX, USA, SC-542, 1:1000), a-SMA (Thermo Scientiﬁc, RB-
9010, 1:500), cleaved caspase-3 (Cell Signaling, #9661, 1:100) Ki-67 (Thermo
Scientiﬁc, RB-9106, 1:50).
Southern blotting
Genomic DNA from mouse tails was digested with 8U of AvrII enzyme (New
England BioLabs (NEB), Ipswich, MA, USA) and separated on a 1% agarose
gel. A DIG-labeled DNA probe targeting the neomycin resistance cassette
was ampliﬁed using the PCR DIG Probe Synthesis Kit (Roche, Basel,
Switzerland) and the primers 5’-ATGGGATCGGCCATTGAACAAGAT-3’ and 5’-
CGGCCATTTTCCACCATGATAT-3’.
CONFLICT OF INTEREST
M Mueller is a Novartis employee. All the other authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We thank members of the Bentires-Alj laboratory for advice and discussions. Research
in the laboratory of MB-A is supported by the Novartis Research Foundation, the
European Research Council (ERC starting grant 243211-PTPsBDC), the Swiss Cancer
League and the Krebsliga Beider Basel.
REFERENCES
1 Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme.
Oncogene 2008; 27: 5497–5510.
2 Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;
129: 1261–1274.
3 Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al. The PIK3CA
gene is mutated with high frequency in human breast cancers. Cancer Biol Ther
2004; 3: 772–775.
4 Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N et al.
Identiﬁcation of novel gene ampliﬁcations in breast cancer and coexistence of
gene ampliﬁcation with an activating mutation of PIK3CA. Cancer Res 2009; 69:
7357–7365.
5 Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI et al. Frequent
mutation of the PIK3CA gene in ovarian and breast cancers. Clinical cancer
research: an ofﬁcial journal of the American Association for Cancer Research 2005;
11: 2875–2878.
6 Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. High frequency of
mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
7 Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z et al. Somatic mutation and gain
of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005; 7:
R609–R616.
8 Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z et al. Gene
alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance
(review). Int J Oncol 2012; 40: 639–644.
9 Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and
translation. Nat Rev Cancer 2005; 5: 921–929.
10 Bader AG, Kang S, Vogt PK. Cancer-speciﬁc mutations in PIK3CA are oncogenic
in vivo. Proc Natl Acad Sci USA 2006; 103: 1475–1479.
11 Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al. Breast
cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Cancer Res 2005; 65: 10992–11000.
12 Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties
of mutant p110alpha and p110beta phosphatidylinositol 3-kinases
in human mammary epithelial cells. Proc Natl Acad Sci USA 2005; 102:
18443–18448.
13 Koren S, Bentires-Alj M. Mouse models of PIK3CA mutations: one mutation
initiates heterogeneous mammary tumors. FEBS J 2013; 280: 2758–2765.
14 Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of
phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
Proc Natl Acad Sci USA 2008; 105: 2652–2657.
15 Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M et al.
Different prognostic roles of mutations in the helical and kinase domains of the
PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13: 6064–6069.
16 Miller TW. Initiating breast cancer by PIK3CA mutation. Breast Cancer Res 2012;
14: 301.
17 Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. PIK3CA mutations correlate
with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive
with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554–2559.
18 Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ et al. PIK3CA mutations in
in situ and invasive breast carcinomas. Cancer Res 2010; 70: 5674–5678.
19 Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK et al. PIK3CA
mutation associates with improved outcome in breast cancer. Clin Cancer Res
2009; 15: 5049–5059.
20 Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20 mutation
is independently associated with a poor prognosis in breast cancer patients.
Ann Surg Oncol 2008; 15: 1064–1069.
21 Cancer Genome Atlas Network. Comprehensive molecular portraits of human
breast tumours. Nature 2012; 490: 61–70.
22 Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff RD, Bentires-Alj M. Luminal
expression of PIK3CA mutant H1047R in the mammary gland induces hetero-
geneous tumors. Cancer Res 2011; 71: 4344–4351.
23 Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, Wong RG et al. Cooperation
between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer
Res 2011; 71: 2706–2717.
24 Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A et al. Oncogenic
PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent
and PI3K pathway-independent mechanisms. Nat Med 2011; 17: 1116–1120.
25 Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R et al. Physiological
levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in
ductal hyperplasia and formation of ERalpha-positive tumors. PLoS One 2012; 7:
e36924.
26 Tchorz JS, Kinter J, Muller M, Tornillo L, Heim MH, Bettler B. Notch2 signaling
promotes biliary epithelial cell fate speciﬁcation and tubulogenesis during bile
duct development in mice. Hepatology 2009; 50: 871–879.
27 Wintermantel TM, Mayer AK, Schutz G, Greiner EF. Targeting mammary epithelial
cells using a bacterial artiﬁcial chromosome. Genesis 2002; 33: 125–130.
28 Boulanger CA, Wagner KU, Smith GH. Parity-induced mouse mammary epithelial
cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression.
Oncogene 2005; 24: 552–560.
29 Booth BW, Boulanger CA, Smith GH. Alveolar progenitor cells develop in mouse
mammary glands independent of pregnancy and lactation. J Cell Physiol 2007;
212: 729–736.
30 Bruno RD, Smith GH. Functional characterization of stem cell activity in the mouse
mammary gland. Stem Cell Rev 2011; 7: 238–247.
Oncogenesis is an open-access journal published by Nature Publishing
Group. This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-nd/3.0/
PIK3CA E545K induces mammary carcinomas
DS Meyer et al
6
Oncogenesis (2013), 1 – 6 & 2013 Macmillan Publishers Limited
LETTER
doi:10.1038/nature14669
PIK3CAH1047R induces multipotency and
multi-lineage mammary tumours
Shany Koren1, Linsey Reavie1, Joana Pinto Couto1, Duvini De Silva1, Michael B. Stadler1,2, Tim Roloff1, Adrian Britschgi1,
Tobias Eichlisberger1, Hubertus Kohler1, Olulanu Aina3, Robert D. Cardiff3 & Mohamed Bentires-Alj1
The adult mouse mammary epithelium contains self-sustained cell
lineages that form the inner luminal and outer basal cell layers,
with stem and progenitor cells contributing to its proliferative and
regenerative potential1–4. A key issue in breast cancer biology is the
effect of genomic lesions in specific mammary cell lineages on
tumour heterogeneity and progression. The impact of transform-
ing events on fate conversion in cancer cells of origin and thus their
contribution to tumour heterogeneity remains largely elusive.
Using in situ genetic lineage tracing and limiting dilution trans-
plantation, we have unravelled the potential of PIK3CAH1047R, one
of themost frequentmutations occurring in human breast cancer5,
to induce multipotency during tumorigenesis in the mammary
gland. Here we show that expression of PIK3CAH1047R in lineage-
committed basal Lgr5-positive and luminal keratin-8-positive cells
of the adult mouse mammary gland evokes cell dedifferentiation
into a multipotent stem-like state, suggesting this to be a mech-
anism involved in the formation of heterogeneous, multi-lineage
mammary tumours. Moreover, we show that the tumour cell of
origin influences the frequency of malignant mammary tumours.
Our results define a key effect of PIK3CAH1047R on mammary cell
fate in the pre-neoplastic mammary gland and show that the cell
of origin of PIK3CAH1047R tumours dictates their malignancy,
thus revealing a mechanism underlying tumour heterogeneity
and aggressiveness.
The mammary gland epithelium is composed of two major cell
lineages: the luminal layer contains cells expressing keratin 8/18
(K8/18) and the basal layer with cells expressing K5/14 and/or smooth
muscle actin (SMA) and/or p63 (ref. 6).
Multipotent cells that generate both the luminal and basal lineages
are found in the mouse embryonic mammary gland1,7 but their exist-
ence in the adult gland is still under debate. Studies using serial trans-
plantation into clearedmammary fat pad supposed the existence in the
adult mouse mammary gland of multipotent stem cells with myo-
epithelial features8–11. Arguably, these assays reflected the regenerative
potential of the transplanted cells rather than their properties in situ1–3.
Lineage-tracing studies, which permit targeted expression of a fluor-
escent reporter in a given cell and its progeny, showed that tissue
homeostasis is maintained by unipotent luminal K8/18-positive and
basal K5/14/Lgr5-positive stem cells after birth. Lineage tracing of
K8/18, K5/14 and Lgr5 progeny found no evidence for the presence
of multipotent stem cells in the adult mammary gland1 but did not
exclude the possibility that rare cells not targeted by these reporters, or
only at a very low frequency, havemultipotent potential.While tracing
of the progeny of axin-2-positive cells showed the presence of multi-
potent stem cells during puberty and pregnancy, this and other studies
revealed that the basal and luminal lineages are self-sustained in the
adult virgin gland2–4. By contrast, recent three-dimensional whole-
mount imaging12 and the identification of the Procr-positive subset13
argue for the presence of multipotent stem cells in the adult virgin
mouse mammary gland, thus reopening the debate.
The phosphatidylinositol 3-kinase (PI3K) pathway is activated in
,70% of breast cancers. Several mechanisms may account for the
activation of this pathway in cancer, including amplification and/or
activating mutations of the PIK3CA gene that encodes the p110a
catalytic subunit of PI3K found in 20–40% of breast cancers5,14. The
most recurrent mutation, H1047R, leads to constitutive PI3K signal-
ling and heterogeneous mammary tumours15–17. Despite frequent
alterations of the PI3K pathway in breast cancer, its impact on lineage
organization during tumorigenesis and the importance of the cell of
origin for heterogeneity and aggressiveness of PI3K-driven tumours
has remained unclear.
To address the effects ofmutant PIK3CAH1047R on basal- or luminal-
lineage-restricted cells, we performed lineage tracing in adult Lgr5-
CreERT2/Tomato-reporter and K8-CreERT2/Tomato-reporter mice
with or without PIK3CAH1047R (Extended Data Fig. 1a)16. Moreover,
we used Lgr5- and K8-CreERT2/PIK3CAH1047R or PIK3CA wild-type
(PIK3CAWT) animals16,18 for tracing of the green fluorescent protein
(GFP) reporter, and Lgr5-CreERT2 and K8-CreERT2 mice as controls
(Extended Data Fig. 1b). As previously reported1,19, we found Lgr5
activity only in a subset of basal cells in the nipple area of the mam-
mary gland (Extended Data Fig. 2a–e). We further assessed the effects
of PIK3CAH1047R expression on the distribution of mammary subpo-
pulations by fluorescence-activated cell sorting (FACS) on isolated
mammary epithelial cells labelled with CD24 and Sca1, which were
shown to enrich for luminal (CD24HiSca12, CD24HiSca11) and basal
(CD24LoSca12) cells10,20 (Extended Data Fig. 3). Four days lineage
tracing confirmed Tomato labelling of basal cells in Lgr5-CreERT2/
Tomato and Lgr5-CreERT2/PIK3CAH1047R/Tomato and of luminal
cells in K8-CreERT2/Tomato and K8-CreERT2/PIK3CAH1047R/
Tomato animals (Extended Data Figs 2b, f and 4a, b). We further
performed 4-, 8- and 13-week lineage tracing. The distribution of
Tomato-labelled subsets in Lgr5-CreERT2/Tomato glands did not
change with time where the progeny of Lgr5-positive cells was mostly
of basal origin (Fig. 1a, b andExtendedData Fig. 2g, h). InK8-CreERT2/
Tomato mice, labelling was restricted to the luminal subset, marking
mostly mature CD24HiSca11 in 4 weeks and mostly CD24HiSca12
luminal progenitors in 13 weeks tracing, indicating the targeting of a
long-term unipotent luminal subset (Fig. 1a, c and Extended Data Fig.
4c, d). By contrast, expression of PIK3CAH1047R in Lgr5-CreERT2/
PIK3CAH1047R/Tomato and K8-CreERT2/PIK3CAH1047R/Tomatomice
resulted in labelling of both the luminal and the basal compartments
(Fig. 1b, c and Extended Data Figs 2g, h, 4c, d). PIK3CAH1047R-evoked
multi-lineage labelling was not observed at 4–7 days after tamoxifen
induction (Extended Data Figs 2f, i and 4b). Since PIK3CAH1047R/WT
targeting vectors contain an internal ribosome entry site (IRES)–GFP
construct, we also used GFP as a readout of transgene expression.
At 4 days after tamoxifen induction, K8-CreERT2/PIK3CAWT and
K8-CreERT2/PIK3CAH1047R glands expressed similar levels of GFP,
indicating similar Cre recombination efficiency. In both models,
4- and 8–11-week lineage tracing revealed an increase in GFP-labelled
1Friedrich Miescher Institute for Biomedical Research (FMI), 4058 Basel, Switzerland. 2Swiss Institute of Bioinformatics, 4058 Basel, Switzerland. 3Department of Pathology, Center for Comparative
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basal and luminal subsets in PIK3CAH1047R compared with PIK3CAWT
animals that showed lineage-restricted GFP labelling, consistent with
higher PI3K pathway activation (Extended Data Figs 5 and 6). These
results suggest that expression of PIK3CAH1047R in basal- or luminal-
restricted mammary cells triggers lineage plasticity and cell expansion.
Next, we assessed the effects of PIK3CAH1047R on global gene
expression in the pre-neoplastic gland. Microarray and quantitative
polymerase chain reaction with reverse transcription (qRT–PCR)
analyses were performed on mammary epithelial cell subpopulations
from Lgr5-CreERT2 control versus Lgr5-CreERT2/PIK3CAH1047R and
K8-CreERT2 control versus K8-CreERT2/PIK3CAH1047R animals.
Genes expressed differentially between subpopulations of control and
mutant mice were compared with subpopulation signatures that have
been previously described21,22. We found enrichment of luminal pro-
genitor signature genes in the basal Lgr5-CreERT2/PIK3CAH1047R sub-
set and in the newly formed basal K8-CreERT2/PIK3CAH1047R subset.
Enrichment of myoepithelial signature genes was found in the newly
formed luminal Lgr5-CreERT2/PIK3CAH1047R and in the K8-CreERT2/
PIK3CAH1047R luminal subsets (Fig. 2a, b and Extended Data Fig. 7).
Mammary cells co-expressing basal and luminal markers in neoplastic
areas confirmed that PIK3CAH1047R induces cell plasticity (Fig. 2c).
We addressed how lineage plasticity is evoked by PIK3CAH1047R in
functional assays. Limiting dilution transplantation revealed an
increase in the mammary-repopulating capacity of basal cells from
Lgr5-CreERT2/PIK3CAH1047R and K8-CreERT2/PIK3CAH1047R mice
compared with the respective controls (Fig. 3a). The GFP-negative
basal CD24LoSca12 population from K8-CreERT2 mice comprises
the bulk of basal cells (myoepithelial and mammary-repopulating
cells)10,20, explaining the lack of outgrowths at the number of cells
transplanted.PIK3CAH1047R-expressing luminal cells also had repopu-
lating capacity (Extended Data Fig. 8a, b). All outgrowths expressed
luminal and basal markers (Fig. 3b and Extended Data Fig. 8c). In
colony formation assays, PIK3CAH1047R increased the percentage of
double-positive (K14/K8/18) colonies derived from the newly formed
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Figure 1 | Mutant PIK3CA inducesmammary cell plasticity. a, Timeline for
lineage-tracing studies.b, c, Representative images of 4-, 8- and 13-week tracing
and FACS quantification of Tomato-positive epithelial basal (CD24LoSca12)
and luminal (CD24HiSca12/1) subsets from Lgr5-CreERT2/Tomato
(b, immunofluorescence: left n5 3,middle n5 11, right n5 6mice; FACS: left
n5 4 technical replicates (each 1–3 pooled mice), middle n5 3 technical
replicates (each 1–2 pooled mice), right n5 3 technical replicates (each 1
mouse)), Lgr5-CreERT2/PIK3CAH1047R/Tomato (b, immunofluorescence: left
n5 3, middle n5 10, right n5 4 mice; FACS: left n5 3 technical replicates
(each 1–2 pooledmice), middle n5 6 technical replicates (each 1mouse), right
n5 5 technical replicates (each 1–2 pooled mice)), K8-CreERT2/Tomato
(c, immunofluorescence: left n5 4, middle n5 8, right n5 5 mice; FACS: left
n5 4 technical replicates (each 1–3 pooled mice), middle n5 4 technical
replicates (each 1–2 pooled mice), right n5 5 technical replicates (each 1
mouse)) and K8-CreERT2/PIK3CAH1047R/Tomato animals (c, immunofluo-
rescence: left n5 4, middle n5 4, right n5 3 mice; FACS: left n5 4 technical
replicates (each 1–2 pooled mice), middle n5 4, right n5 3 technical
replicates (each 1 mouse)). White arrowheads indicate luminal and yellow
arrowheads indicate basal Tomato-labelled cells. Scale bars, 100mm, 20mm
(magnifications). Bar graphs show means6 standard error of the mean
(s.e.m.); two-sided unpaired Student’s t-test; *P, 0.05; NS, not significant.
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luminal (Lgr5-CreERT2/PIK3CAH1047R) and basal cells (K8-CreERT2/
PIK3CAH1047R). PIK3CAH1047R-expressing subsets overcame lineage
restriction, giving rise to both lineages, albeit at low frequencies.
Moreover, basal cells from Lgr5- and K8-CreERT2/PIK3CAH1047R
animals showed increased colony formation capacity (Extended Data
Fig. 8d–f). In mammosphere cultures, PIK3CAH1047R increased the
sphere-forming capacity of luminal cells. While control cells formed
sphereswith a hollow lumen after passaging,PIK3CAH1047R-expressing
cells formed filled spheres, indicating the accumulation of less differ-
entiated cells (Extended Data Fig. 8g, h). Altogether, these data suggest
that PIK3CAH1047R evokes cell dedifferentiation to amultipotent stem-
like state, from which cells further differentiate into both cell lineages.
Expression of PIK3CAH1047R in Lgr5- and K8-positive cells induced
mammary tumours on average after 108 and 78 days, respectively.
Control and PIK3CAWT animals developed no tumours (Fig. 4a).
FACS analysis of GFP-positive tumour cells revealed a similar distri-
bution of cancer subpopulations, with an accumulation of the
CD24HiSca12 subset. PIK3CAH1047R-evoked mammary tumours
expressed basal and luminal markers (Extended Data Fig. 9a–d).
Additionally, cells double positive for basal and luminal markers were
found (Fig. 4b). These results suggest that PIK3CAH1047R-evoked cell
plasticity results in multi-lineage tumours and that expression of basal
and luminal markers is not an indicator of the origin of mammary
cancers. It has been proposed that basal-like mammary tumours may
originate from luminal cells23,24. Therefore, any inference of the cell of
origin from the differentiation state of the tumour can be misleading.
Histological analysis showed heterogeneous phenotypes and
differences in malignancy between both models. Lgr5-CreERT2/
PIK3CAH1047Rmice formed unique benignmulti-nodular rosette-type
adenomyoepitheliomas, aggressive adenosquamous carcinomas with
pilosebaceous differentiation and carcinosarcomas. K8-CreERT2/
PIK3CAH1047R mice mainly developed aggressive adenosquamous
carcinoma, carcinosarcomas that infiltrated the surrounding tissue,
adenocarcinomas and benign adenomyoepitheliomas. These results
show that PIK3CAH1047R mostly evokes benign tumours (74%) with
high intratumour heterogeneity when expressed in Lgr5-positive cells,
in contrast to the mostly aggressive mammary tumours (62%) with a
distinctive infiltrative densely fibrotic phenotype seen when the cell of
origin is K8-positive (Fig. 4c and Extended Data Fig. 9e, f).
Microarray analysis, principle component analysis and hierarchical
clustering of tumours revealed a single cluster of Lgr5-CreERT2/
PIK3CAH1047R and three clusters of K8-CreERT2/PIK3CAH1047R
tumours. We found no correlation between tumour phenotype and
clustering, probably owing to intratumour heterogeneity. We com-
pared tumour expression profiles to different human breast cancer
subtypes5. The majority (7/10) of the K8-CreERT2/PIK3CAH1047R
tumours correlated best with themalignant basal-like, HER2-enriched
and luminal-B profiles, whereas 3/10 clustered with benign luminal-A
and normal-like breast cancers. Lgr5-CreERT2/PIK3CAH1047R
tumours resembled benign (2/10) but also malignant subtypes (3/10).
However, 5/10 showed no similarity to a single subtype but were equi-
distant from all, representing the high intratumour heterogeneity
in this model (Fig. 4d and Extended Data Fig. 10). The fact that
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Figure 2 | Activation of PIK3CAH1047R leads to expression of basal- and
luminal-lineage genes. a, b, Plots indicating enrichment of gene expression
from FACS-sorted Lgr5-CreERT2/PIK3CAH1047R versus Lgr5-CreERT2
control (a) andK8-CreERT2/PIK3CAH1047R versus K8-CreERT2 control subsets
(b) in signatures of mammary subpopulations from refs 21, 22. Microarray
was performed 4 weeks after tamoxifen induction on basal CD24LoSca12 and
luminal CD24HiSca12/1 subsets of pooled mammary glands of 2–3 oestrus-
synchronized animals from three independent sortings. c, Representative
images of immunostaining for basal (K14, red; K5, white) and luminal (K8/18,
green) markers on mammary glands 4 weeks after tamoxifen treatment (n5 3
mice). White arrowheads indicate double-positive cells. Scale bars, 100mm,
20mm (magnifications).
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Figure 3 | Expression of PIK3CAH1047R evokes multipotent stem-like cells.
a, Number of outgrowths in cleared-fat-pad transplantation of GFP-positive
(Lgr5-positive) control and PIK3CAH1047R-expressing basal subsets (top).
Outgrowths of GFP-negative control and GFP-positive PIK3CAH1047R-
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condition). Scale bars, 50mm (top three rows), 500mm (bottom row).
a, b, Pooled data from three independent experiments.
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K8-CreERT2/PIK3CAH1047R tumours but not Lgr5-CreERT2/
PIK3CAH1047R tumours clustered mostly with malignant breast can-
cers that have a poor prognosis is consistent with the histopathologi-
cal results and suggests that, in the presence of the same initiating
oncogenic mutation, the cell of origin dictates the frequency of
aggressive tumours.
GFP driven by the Lgr5 promoter was found in a rare luminal subset
of the control gland (ExtendedData Fig. 5b, c), as shownpreviously1. It
is unlikely that such rare cells expand due to PIK3CAH1047R and form
the luminal GFP-positive population. We observed multi-lineage
labelling upon PIK3CAH1047R expression in a basal and a luminal
cell-driven model. An alternative possibility that we cannot firmly
exclude is that Lgr5- and K8-positive populations contain rare bipo-
tent subsets that are quiescent or not efficiently labelled in physio-
logical conditions and are, therefore, not detected by lineage tracing
but may expand upon PIK3CAH1047R expression.
We show that expression of PIK3CAH1047R dedifferentiates lineage-
restricted epithelial cells into a multipotent stem-like state fromwhich
cells further differentiate, revealing a mechanism by which heterogen-
eousmixed-lineage tumours may develop. Furthermore, we show that
the tumour cell of origin influences the frequency of malignant mam-
mary tumours. The fundamental questions of which mammary cells
are susceptible to which combination of oncogenes and how this
impinges on tumour progression and aggressiveness warrant further
investigation. Understanding these dynamic relationships is para-
mount for understanding tumour heterogeneity and for identifying
prognostic and predictive biomarkers.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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Figure 4 | The frequency of malignant tumour
lesions is dictated by the cell of origin. a, Kaplan–
Meier plots depicting tumour onset in Lgr5-
CreERT2/PIK3CAH1047R (average 108 days; n5 15)
and K8-CreERT2/PIK3CAH1047R (average 78 days;
n5 15) mice compared with PIK3CAWT and
control animals after tamoxifen injection (top,
n5 14; bottom, n5 9 and n5 12, respectively).
*P, 0.0001, log-rank test. b, Representative
images of immunostaining and quantification of
double-positive epithelial area in Lgr5-CreERT2/
PIK3CAH1047R and K8-CreERT2/PIK3CAH1047R
tumours (n5 10). Yellow arrowheads indicate
double-positive cells. Scale bars, 100 mm (right),
20mm (left, magnification). Graphs show
means6 standard deviation (s.d.); two-sided
unpaired Student’s t-test; *P5 0.0002; NS, not
significant. c, Pie chart showing phenotypes of
tumours evoked in Lgr5-CreERT2/PIK3CAH1047R
(n5 50) and K8-CreERT2/PIK3CAH1047R (n5 29)
animals.d, Clustered heatmap showing correlation
coefficients between human breast cancer profiles
and ten K8- and Lgr5-CreERT2/PIK3CAH1047R
mouse mammary tumours. Ctrl, control; Lum,
luminal.
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METHODS
Mice. Lgr5-CreERT2 mice (C57BL/6) were generated and provided by B. Kinzel
and J. Tchorz25. Mice were backcrossed to the FVB background and used in this
study. K8-CreERT2mice (CD-1)were provided byC. Blanpain1. The generation of
PIK3CAH1047R and PIK3CAWT (pure FVB) was described previously16,18. Tomato-
reporter animals (C57BL/6) were provided by B. Roska. For lineage-tracing stud-
ies, mice of a mixed background (FVB/CD-1/C57BL/6 and FVB/C57BL/6) were
used. For studies without a Tomato reporter, mice with a pure FVB background
(Lgr5-CreERT2 model) or mixed FVB/CD-1 background (K8-CreERT2 model)
were used. Mouse colonies were maintained in the animal facility of the
Friedrich Miescher Institute for Biomedical Research and experiments were car-
ried out in accordance with Swiss national guidelines on animal welfare and the
regulations of the canton of Basel-Stadt, Switzerland.
Targeting Tomato and/or GFP expression. Adult 7- to 8-week-old female mice
were induced by intraperitoneal injection of tamoxifen (Sigma; 2 mg per 25 g of
body weight) for three consecutive days (diluted in sunflower seed oil, Sigma) to
activate cell-specific expression of the Cre recombinase and thus expression of
Tomato and/or the PIK3CAH1047R or WT transgene. Tomato and/or GFP were
expressed in recombined cells derived from Lgr5-positive or K8-positive cells,
respectively. For the Lgr5 model, after Cre induction, GFP expression was derived
from both Lgr5 promoter activity and PIK3CAH1047R expression.
Histology and immunostaining. Tumours and dissected mammary glands were
spread on a glass slide and fixed in 20% formalin for 24 h at 4 uC. Samples were
then processed, embedded in paraffin and sectioned (3mm). Immunofluorescence
studies were performed using a Ventana DiscoveryUltra instrument (Roche
Diagnostics) following the RUODiscovery Universal method. Briefly, slides were
pretreated with CC1 for 40min and then incubated with primary antibodies for
1 h at 37 uC. After washing, secondary antibodies were incubated for 32min at
37 uC. Slides were then washed with reaction buffer (three times), PBS (two times)
and then incubated with DAPI (1mgml21) for 5min. Finally, slides were rinsed
with PBS (three times) and mounted in Mount Fluor (ProTaqs). The following
antibodies were used: anti-keratin 8/18 (guinea-pig, 1:200, Fitzgerald, 20R-
CP004), anti-RFP (rabbit, 1:500, Rockland, 600-401379), anti-keratin 14 (chicken,
1:500, Covance, Sig3476), anti-p63 (mouse, 1:500, Thermo Scientific, ma121871),
anti-keratin 5 (rabbit, 1:500, Abcam, ab52635), anti-chickenAlexa Fluor 488, anti-
chicken Alexa Fluor 568, anti-guinea pig Alexa Fluor 488, anti-mouse Alexa Fluor
488, anti-rabbit Alexa Fluor 647. All Alexa secondary antibodies were obtained
from Molecular Probes (Invitrogen). Immunohistochemistry experiments were
performed for keratin 14, keratin 8/18, GFP, and p63 using a Ventana
DiscoveryXT instrument (Roche Diagnostics) following the Research IHC DAB
Map XT procedure. Slides were treated with a mild CC1 and incubated with the
primary antibodies for 1 h at 37 uC. After brief washes, biotinylated donkey-anti-
rabbit and biotinylated anti-guinea-pig, respectively, were applied for 32min at
37 uC. For mouse-anti p63 detection, a monoclonal rabbit-anti-mouse antibody
was applied for 32min at 37 uC, followed by incubation with a polymer anti-rabbit
conjugated with horseradish peroxidase (HRP) (ImmPRESS anti-rabbit peroxi-
dase, Vector Laboratories) for 32min at 37 uC. Finally, sections were counter-
stained with haematoxylin II and bluing reagent (4 min). Staining against ERa,
SMA and keratin 5 was performed by deparaffinization followed by antigen
retrieval with citrate buffer and quenching with PBS plus 3% H2O2. Slides were
then blocked with PBS plus 2.5% normal goat serum and primary antibodies
incubated overnight at 4 uC in PBS plus 1% BSA plus 0.5% Tween-20. After brief
washes, secondary antibodies were then incubated in PBS plus 1% BSA for 30min
at room temperature. Signalswere enhanced using theVectastainABC system and
visualized with 3,39-diaminobenzidine (DAB; Sigma). Haematoxylin was used as
counterstain. Anti-PR staining was performed without antigen retrieval. The fol-
lowing antibodies were used: anti-keratin 8/18 (guinea-pig, 1:500, Fitzgerald, 20R-
CP004), anti-keratin 14 (rabbit, 1:500, Thermo Scientific, Rb9020), anti-p63
(mouse, 1:1,000, Thermo Scientific, ma121871), anti-keratin 5 (rabbit, 1:1,000,
Abcam, ab52635), anti-SMA (rabbit, 1:500, Thermo Scientific, Rb9010), anti-
ERa (rabbit, 1:1,000, Santa Cruz, sc-542), anti-PR (rabbit, 1:200, Thermo
Scientific, Rm9102), anti-GFP (rabbit, 1:50, Invitrogen, A11122). Secondary anti-
bodies were biotinylated anti-rabbit IgG (1:200, Jackson Immunoresearch), bio-
tinylated anti-guinea pig IgG (1:200; Vector Laboratories) and biotinylated anti-
mouse IgG (1:200;Abcam).Haematoxylin and eosin stainingwas performedusing
standard protocols.
Microscopy image acquisition. For immunofluorescence, images of stained
sections were captured using a Zeiss Z1 wide-field fluorescent microscope,
35/0.13, 310/0.45 or 320/0.8 (Plan-APOCHROMAT) objectives, an
AxioCamMRc camera (1,0243 1,024, pixel size 6.45mm) and an Axiocam506
camera (2,7523 2,208, pixel size 4.54mm). Whole-mount fluorescent mammary
gland and tumours sections were imaged on the Zeiss Axio Scan.Z1 slide scanner
(ORCA-Flash4.0 camera, 2,0483 2,048, pixel size 6.5mm). Representative images
were cropped and processed using the ZenBlue software. For immunohistochem-
istry, stained sections were examined using a Nikon E600 Eclipse brightfieldmicro-
scope (320/0.5 and 340/0.75 objectives) and images captured with a Nikon
DXM1200 camera (2,5923 1,944, pixel size 6.7mm) using the IMS acquisition
software. All images were scaled appropriately.
Quantification of immunohistochemistry. Five representative images of 8–15
tumours of each genotype were captured with a Nikon E600 Eclipse brightfield
microscope (320/0.5 objective) and positively stained tumour areas, luminal cells,
and total epithelial cells quantified with Image J (Fiji). Evaluation of tissue sections
was performed blindly by two independent investigators.
Quantification of double-positive tumour epithelial area. Ten tumours from
each model were stained with anti-keratin 14, anti-keratin 5, anti-keratin 8/18,
anti-rabbit Alexa Fluor 647, anti-chicken Alexa Fluor 568, and anti-guinea-pig
Alexa Fluor 488. Whole-mount tumour sections were scanned using the Zeiss
Axio Scan Z1 slide scanner. For computational reasons, the whole images of
tumours were first tiled and the channels split using the ZenBlue software and
Matlab. Images were then processed using Ilastik26, an interactive supervised
machine learning toolkit, and the subsequent prediction maps were treated with
batch functions written with the Matlab programing language. For the statistical
analysis shown in Fig. 4b, a total of 23 regions of tumours were subsequently tiled
into 14,872 squared images of 1,0243 1,024 pixels. In a second step, data from a
set of nine selected tiles were generated by annotating a few regions representative
of the predefined classes. For each of the three channels the training data were
processed using the four phenotype classes: ‘1.background’, ‘2.fluorescent marker
(Alexa 488, 568 or 647)’, ‘3.blood cells’, and ‘4.Stroma’. After annotation of the
different pixels of the different classes by brush stroke, features of the labelled
pixels and their local neighbourhood are used to train a Random Forest classifier.
In a third step, the inferred classifier was used to predict all the tiles in a batch
process. The last step implemented in Matlab determined the masks for all the
channels and tiles. To perform the analysis on relevant tiles, that is, tiles sufficiently
covered by tissue, we performed a k-means clustering on a set of statistical features
extracted from the tiles. This enabled us to suppress tiles that were merely in the
background or those that contained non-epithelial structures. For each tile, the
fluorescentmarkermask corresponded to pixels having a probability above 50% in
the class ‘fluorescent marker (Alexa)’. In addition, a non-tissue mask was calcu-
lated by the mean ofmorphological filters on the union of background, blood cells
and stroma classes. The mask for tissue represented the complement image of the
non-tissuemask.We calculated on each tile the ratio between the areas of pixels in
the mask of the fluorescent marker and those in the tissue mask. Finally, the
distribution of double-labelled fluorescent marker within the whole tumour epi-
thelial area was represented in Fig. 4b.
Preparation of mammary single-cell suspensions and labelling. Mammary
glands were dissected and intra-mammary lymph nodes removed. To obtain
mammary organoids, mammary glands were processed as described prev-
iously20,21. To obtain single mammary epithelial cells, organoids were washed in
serum-free Leibowitz L15-medium (Gibco) and digested with Hyclone HyQTase
(Thermo Scientific). Single cells were washed and filtered through a 40-mm cell
strainer (BD Falcon) and counted; 106 cells perml were stained with the following
antibodies: PE-Cy7-CD45 (Biolegend; clone 30-F11), APC-Sca1 (Biolegend;
clone E13-161.7), PerCP-Cy5.5-CD24 (Biolegend; clone M1/69), PE-CD49f
(BD-Pharmingen), Alexa700-CD24 (Novus Biologicals; clone M1/69) and
DAPI (2mgml21, Invitrogen).
Flow cytometry. FACS was carried out with a BD FACSAria III (Becton
Dickinson) using a 100-mm nozzle. Cells were gated based on their forward-
and sideward-scatter. Pulse-width was used to exclude doublets. DAPI-negative/
CD45-negative cells were gated for Tomato or GFP. CD24, Sca1 and CD49f
subsets were then gated on GFP-positive epithelium. Tomato-positive cells were
gated using only CD24, CD45 and Sca1 antigens. The same numbers of living cells
were recorded in each condition. FACS data were analysed using FlowJo (Tree
Star). Total cell numbers were determined by enumerating the total epithelial
content after single-cell isolation and calculating back based on the percentages
obtained from antibody staining, sorting and FlowJo analysis. Cell numbers were
subsequently normalized to one animal (3–9 independent FACS experiments
of 1–5 pooled animals per time point were quantified;6 s.e.m.; P, 0.05,
Student’s t-test).
In vitro colony formation assay and quantification. Freshly sorted cells of each
subpopulation (500 cells) were plated as previously described21. Seven days later,
the colonies were fixed with acetone/methanol (1:1), washed, blocked with 2.5%
normal goat serum and stained with anti-keratin 8/18 (guinea pig, 1:500,
Fitzgerald, 20R-CP004), anti-keratin 14 (rabbit, 1:500, Thermo Scientific,
Rb9020), DAPI (2 mgml21, Invitrogen), anti-guinea-pig Alexa Fluor 488 and
anti-rabbit Alexa Fluor 647 (1:1,000, Invitrogen). Colonies were imaged using
the Zeiss Z1 wide-field fluorescent microscope (35/0.13 DIC). Colonies were
LETTER RESEARCH
G2015 Macmillan Publishers Limited. All rights reserved
defined as a cluster of more than five cells. The number of colonies per well was
determinedmanually. Colonies containingmore than 20% of keratin 8/18/keratin
14 double-positive cells were defined as ‘double-positive’.
In vitro mammosphere culture. Mammosphere cultures were performed as
described previously27. Freshly sorted subsets (luminal CD24HiSca12 and
CD24HiSca11) from adult FVB and uninduced PIK3CAH1047R females were
plated at 20,000 cells per ml in 6-well ultra-low attachment plates (Falcon) in
DMEM/F12 medium (Gibco) supplemented with 5mgml21 insulin, 0.5mgml21
hydrocortisone, 2%B27 (Invitrogen), 20 ngml21 EGF andbFGF (BDBiosciences)
and cholera toxin (Sigma), and cultured at 37 uC in 5% CO2. After 5 days, mam-
mospheres were collected and dissociated into single cells using HYQtase (Gibco)
and counted. Luminal subsets from FVB control and PIK3CAH1047R animals
were subsequently treated with TAT-Cre (Millipore) (0.5 mM) at a density of
20,000 cells per ml in 4 ml overnight at 37 uC in 5% CO2. The next morning,
the medium was replaced and cells were cultured for 72 h at 37 uC in 5% CO2 to
allow for maximal recombination and expression of PIK3CAH1047R. After 72 h,
PIK3CAH1047R-GFP1/2 cells were sorted and plated into 24-well ultra-low attach-
ment plates in medium (described earlier) supplemented with 2% Matrigel
(growth factor reduced; BD, 356230) at a density of 1,000 cells per well. Control
and PIK3CAH1047R spheres from each subset were enumerated every 7 days,
at which point spheres were dissociated and re-plated at a density of 1,000 cells
per well.
Mammary fat pad transplantation. For limiting dilution transplantation, freshly
sorted cells fromLgr5-CreERT2 control andLgr5-CreERT2/PIK3CAH1047R animals
(pure FVB background) and from K8-CreERT2 control and K8-CreERT2/
PIK3CAH1047R F1-hybrid (FVB/CD-1) littermates were used. Sorted cells were
resuspended in limiting dilution numbers in PBS plus 2% FCS with 25%
Matrigel (growth factor reduced; BD, 356230) and injected in 20-ml volumes into
inguinal glands of 3-week-old FVB females that had been cleared of endogenous
mammary epithelium28. Cells from control and from PIK3CAH1047R animals were
injected in the same animal on opposite sides. After 8 weeks, glands of the reci-
pients were removed for evaluation. Glands were spread on a glass slide and fixed
in Carnoy`s fixative overnight. Whole-mount staining with carmine alum was
performed as previously described21 and scannedwith an Epson 1600 Pro scanner.
An outgrowth was defined as an epithelial structure composed of ducts arising
from a central point with lobules and/or terminal end buds8. Frequencies of
mammary-repopulating units between different cell populations were calculated
and statistically compared using the Extreme LimitingDilutionAnalysis (ELDA)29
online tool (http://bioinf.wehi.edu.au/software/elda/).
Immunoblotting. Lysates from mammary glands were prepared by lysing cryo-
homogenized mammary gland powder in RIPA buffer (50 mM Tris-HCl pH 8,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented
with 13 protease inhibitor cocktail (Complete Mini, Roche), 0.2mM sodium
orthovanadate, 20mM sodium fluoride and 1mMphenylmethylsulfonyl fluoride.
Lysates (30–80mg) were subjected to SDS–PAGE, transferred to PVDF mem-
branes (Immobilon-P, Millipore) and blocked for 1 h at room temperature with
5% milk or BSA in PBS/0.05% Tween 20. Membranes were then incubated over-
night with primary antibodies (1:200–1:3,000) and exposed to secondary HRP-
coupled anti-mouse or anti-rabbit antibodies at 1:5,000–10,000 for 1 h at room
temperature. Results are representative of at least three different experiments. The
following antibodies were used: anti-AKT pan (Cell Signaling), anti-pAKT
(Ser473, Cell Signaling), anti-p110a (Cell Signaling), anti-ERK2 (Santa Cruz)
and anti-keratin pan (SantaCruz). Blot densities were quantified using ImageJ
and normalized to pan-keratin for epithelial content.
RNA isolation. For pre-neoplastic gene expression profiling, mammary epithelial
subsets were FACS sorted as described earlier into extraction buffer and total RNA
from 250 or 2,000 sorted cells was isolated using an Arcturus PicoPure RNA
Isolation Kit (Life Technologies). Subsets of pooled mammary glands of 2–3
oestrus-synchronized animals (confirmed by vaginal smear) per genotype in three
independent sortingswere collected formicroarray analysis. RNA frommammary
subsets of four animals per genotypewas collected for qRT–PCR. For tumour gene
expression profiling and expression of Lgr5 in the mammary gland, total RNA
from 50mg cryo-homogenized tumour tissue or nipple and distal area of mam-
mary glands were extracted using the TRIzol method (Life Technologies) accord-
ing to the manufacturer’s instructions. Genomic DNA was removed by DNase I
digestion (Qiagen) and RNA purified using an RNeasy Plus Mini Kit (Qiagen).
RNA concentration was measured with a Nanodrop 1000 machine and RNA
quality assessed using an Agilent 2100 bioanalyzer and RNA Pico Chips or
RNA Nano Chips.
Microarray. Total RNA from 250 sorted cells (pre-neoplastic Lgr5), 2,000 sorted
cells (pre-neoplastic K8) or 100 ng from tumour tissue was used as the input for
synthesis of amplified cDNA with the NuGen Ovation Pico WTA System
(NuGen). The resulting double-stranded cDNA was fragmented and labelled
using the Affymetrix GeneChip WT Terminal Labelling kit (Affymetrix).
Affymetrix Gene ChipMouse gene 1.0 STmicroarrays were hybridized according
to the GeneChip Whole Transcript (WT) Sense Target Labelling Assay Manual
(Affymetrix) with a hybridization time of 16 h. Scanning was performed with
Affymetrix GCC Scan Control Software v. 3.0.0.1214 on a GeneChip Scanner
3000 7 G with autoloader.
Normalization and analysis of mammary epithelial subset microarray data.
The arrays for Gene Expression Omnibus accession numbers GSE40875 (ref. 21),
GSE59870 (Fig. 2a) andGSE65411 (Fig. 2b) data sets were RMAnormalized using
the bioconductor package affy (R3.0.1/Bioconductor 2.13). Heat maps with
unscaled normalized expression values for selected genes were plotted with the
heatmap.2 function of the gplots package. Differential gene expression for the
comparison of mature luminal (LM) or luminal progenitor (LP) versus myoe-
pithelial (MYO) cells was calculated with limma. The function topTable was
used to select the top 300 upregulated genes as luminal mature versus myoepithe-
lial UP (Luminal_Mature UP, MEIER-ABT) and luminal progenitors versus
myoepithelial UP (Luminal_progenitors UP, MEIER-ABT), and the top 300
upregulated genes as myoepithelial versus luminal mature UP (Myoepithelial
UP, MEIER-ABT). Signatures LIM_MAMMARY_LUMINAL_MATURE_DN,
LIM_MAMMARY_LUMINAL_MATURE_UP, LIM_MAMMARY_LUMINAL_
PROGENITOR_DN, LIM_MAMMARY_LUMINAL_PROGENITOR_UP, LIM_
MAMMARY_STEM_CELL_DN and LIM_MAMMARY_STEM_CELL_UP were
downloaded from http://www.broadinstitute.org/gsea/msigdb/search.jsp in gmt
format, combined with the signatures described earlier, and used in the PGSEA
and smcPlot functions of the Bioconductor PGSEA package.
qRT–PCR. RNA was converted into cDNA using SuperScript III Reverse
Transcriptase (Invitrogen). Quantitative real-time PCR was performed on unam-
plified cDNA normalized to the number of sorted cells for each subset (6,000–
10,000 sorted cells). Taqman probes (Life Technologies) and Taqman Universal
PCR Mastermix (Applied Biosystems) were applied. The following Taqman
probe identifiers were used: Krt14 Mm00516879_m1, Krt5 Mm01305291_g1,
Lgr5 Mm00438890_m1, Vim Mm01333430_m1, Krt8 Mm00835759_m1, Krt18
Mm01601702_g1, Gata3 Mm00484683_m1, Elf5 Mm00468732_m1, Csn2
Mm04207885_m1 and Axin2 Mm00443610_m1. Cycling was performed with
StepOne Plus Real-time PCR Systems (Applied Biosystems). The results are rep-
resentative of three qRT–PCR experiments of pooled mammary subsets from
four animals of each genotype. Results of Csn2 (CD24HiSca12/1) and Krt14
(CD24HiSca11) from K8-CreERT2/PIK3CAH1047R cells and of Krt5 and Lgr5
(CD24HiSca12) from Lgr5-CreERT2/PIK3CAH1047R cells are representative of
two experiments. Statistical data analysis was performed using DCT values.
Normalization and analysis of tumour mouse microarray data. Mouse
Affymetrix microarrays (Gene Expression Omnibus accession number GSE59872)
were background corrected, quantile normalized, and log2 transcript cluster express-
ion values were calculated using the rma() function of the Bioconductor package
‘‘oligo’’30. Transcript cluster identifiers weremapped to Entrez Gene identifiers using
the Bioconductor package ‘‘mogene10sttranscriptcluster.db’’, and transcript clusters
associated with none or multiple genes were removed. Where multiple transcript
clusters were associated with a single gene that with the maximal variance across
samples was selected; this resulted in a total number of 20,365 transcript clusters with
unique gene assignments. Principal component analysis was performed on log2
expression values from which the mean over samples had been subtracted for each
gene. Hierarchical clustering of samples was performed using (12 r) as distance
metric, with r being the Pearson’s correlation coefficient for log2 expression values
between each pair of samples. The clustering dendrogram was visualized using the
‘‘dendextend’’ R package.
Analysis of human TCGA breast cancer data and comparison to mouse.
Human breast cancer expression data and corresponding clinical data5
were obtained from https://tcga-data.nci.nih.gov/docs/publications/brca_2012/,
corresponding to the 11 November, 2011 data freeze that contains 522 tumour
samples with clinical annotation. Human gene symbols were mapped to Entrez
Gene identifiers and genes selected that are one-to-one homologues between
human and mouse according to Homologene (build 68, downloaded from ftp://
ftp.ncbi.nlm.nih.gov/pub/HomoloGene/build68/31) and that were measured
on both human and mouse experimental platforms; this resulted in 13,969
genes. To reduce technical differences between human and mouse samples,
all samples were scaled to a standard deviation of 1, and the within-species
mean was subtracted from each gene. Heat map and clustering of the combined
human and mouse expression data were performed using the function aheat-
map() from the R package ‘‘NMF’’32 on the top 1,000 genes ranked by variance
across human samples. Mouse samples were compared with human PAM50
tumour subtypes (Normal-like, Luminal A, Luminal B, HER2-enriched and
Basal-like) by calculating Pearson’s correlation coefficients for each mouse
sample against the averages of all human samples within each subtype.
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Survival analysis.Tumour incidencewas determined by palpation. Kaplan–Meier
plots were generated using the survival calculation tool fromGraphpad Prism and
significance was calculated using the log-rank test.
Statistical data analysis.Thenumber ofmicewas calculated byperformingpower
analysis using data from small pilot experiments. Values represent the means6
s.e.m. or 6s.d. Depending on the type of experiments, data were tested using
unpaired Student’s t-test or log-rank test. *P, 0.05 was considered statistically
significant. The experiments were not randomized.
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Extended Data Figure 1 | Scheme depicting mouse lines generated for
lineage-tracing studies. a, Lgr5-CreERT2 (ref. 25) or K8-CreERT2 (ref. 1)
animals were crossed to transgenic lox-STOP-lox PIK3CAH1047R 16 and/or
Tomato-reportermice, generating Lgr5-CreERT2/Tomato, K8-CreERT2/Tomato,
Lgr5-CreERT2/PIK3CAH1047R/Tomato and K8-CreERT2/PIK3CAH1047R/Tomato
animals for lineage-tracing studies. Lgr5-CreERT2/Tomato and
K8-CreERT2/Tomato animals were used as controls. b, Lgr5-CreERT2 (ref. 25)
and K8-CreERT2 (ref. 1) animals were crossed to lox-STOP-lox PIK3CAH1047R
(ref. 16) or PIK3CAWT (ref. 18) animals. Lgr5-CreERT2 and K8-CreERT2
animals were used as controls. Tamoxifen injection induces PIK3CAH1047R,
PIK3CAWT and/or Tomato expression.
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Extended Data Figure 2 | Lgr5-CreERT2/Tomato and PIK3CAH1047R/
Tomato labelling in the mammary nipple area. a, Lgr5 expression in the
nipple and distal area of Lgr5-CreERT2 glands (n5 3mice). b, Tracing scheme.
c, d, Representative images of mammary glands after 4 weeks tracing (n5 3
mice for each genotype). Scale bars, 2mm, 100mm (magnifications). e, Repre-
sentative haematoxylin and eosin staining of an Lgr5-CreERT2/PIK3CAH1047R
mammary gland with a tumour. Scale bar, 500mm. LN, lymph node.
f, Representative images, FACS plots and quantification of 4 days tracing (24 h
after the last tamoxifen injection) (top: immunofluorescence: n5 3 mice;
FACS: n5 5 technical replicates (each 1–2 pooled mice); bottom:
immunofluorescence: n5 3 mice; FACS: n5 3 technical replicates (each 1
mouse)). Scale bars, 100mm; 20mm (magnifications). g, Representative FACS
plots of 4-week tracing. h, Percentage of total Tomato-positive cells in the
tracing experiments (Lgr5-CreERT2/Tomato: 4 days n5 5, 4weeksn5 4, 8 and
13 weeks n5 3 technical replicates (each 1–2 pooled mice); Lgr5-CreERT2/
PIK3CAH1047R/Tomato: 4 days n5 3, 4 weeks n5 3, 8 weeks n5 6 and 13
weeks n5 5 technical replicates (each 1–2 pooled mice)). i, Representative
images of 7 days tracing (left n5 4 mice; right n5 2 mice). Scale bars, 100mm,
50mm (magnifications). Bar graphs show means6 s.e.m.; two-sided unpaired
Student’s t-test; *P, 0.05; NS, not significant.
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Extended Data Figure 3 | Gating scheme for FACS experiments.
a–d, Representative FACS plots of K8-CreERT2/Tomato (a), K8-CreERT2/
PIK3CAH1047R/Tomato (b), Lgr5-CreERT2/PIK3CAWT (c) and Lgr5-CreERT2/
PIK3CAH1047R (d) animals 4 weeks after tamoxifen injection. The gating
strategy shown illustrates the elimination of doublets, dead cells (DAPIHi), and
white blood cells (CD451) and the sorting of Tomato- or GFP-positive
mammary epithelial subsets (basal CD24LoSca12, luminal CD24HiSca12;
luminal CD24HiSca11).
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Extended Data Figure 4 | K8-CreERT2/Tomato and PIK3CAH1047R/
Tomato labelling in the mammary gland. a, Scheme depicting timeline
of tracing experiments. b, Representative images and FACS quantifications of
K8-CreERT2/Tomato and K8-CreERT2/PIK3CAH1047R/Tomato mammary
glands 4 days after tamoxifen (24 h after the last tamoxifen injection) (top:
immunofluorescence: n5 5 mice; FACS: n5 7 technical replicates (each 1–2
pooledmice); bottom: immunofluorescence n5 3mice; FACS: n5 3 technical
replicates (each 1 mouse)). Scale bars, 100mm, 20mm (magnifications).
c, Representative FACS plots of 4-week Tomato tracing. d, Percentage of total
Tomato-positive cells inmammary glands (K8-CreERT2/Tomato: 4 days n5 7,
4 and 8 weeks n5 4, 13 weeks n5 5 technical replicates (each 1–3 pooled
mice); K8-creERT2/PIK3CAH1047R/Tomato: 4 days n5 3, 4 and 8 weeks n5 4
and 13 weeks n5 3 technical replicates (each 1–2 pooled mice)). Bar graphs
show means6 s.e.m. *P, 0.05; two-sided unpaired Student’s t-test.
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Extended Data Figure 5 | Tracing of GFP-positive mammary subsets.
a, Percentage of GFP-labelled cells in K8-CreERT2/PIK3CAH1047R versus
K8-CreERT2/PIK3CAWT animals 4 days after tamoxifen (24 h after the last
tamoxifen injection) (n5 3 technical replicates, 2 mice per genotype).
b, d, Representative FACS plots and percentages of GFP-positive cells in
mammary gland subsets and total mammary epithelial cells 4 and 8–11 weeks
after tamoxifen. c, e, Bar graphs showing total numbers of GFP-positive cells
and numbers of GFP-positive cells in basal (CD24LoSca12) and luminal
(CD24HiSca12; CD24HiSca11) subsets of Lgr5-CreERT2/PIK3CAH1047R (c) and
K8-CreERT2/PIK3CAH1047R (e) mammary epithelial cells. b, c, 4 weeks:
non-induced control n5 3, control n5 9, PIK3CAWT n5 3, PIK3CAH1047R
n5 9 sortings with each 1–4 pooled mice; 8–11 weeks: non-induced control
n5 3, control n5 3, PIK3CAWT n5 3, PIK3CAH1047R n5 4 sortings with each
1–4 pooled mice. d, e, 4 weeks: PIK3CAWT and PIK3CAH1047R n5 3 sortings
with each 1–5 pooled mice; 8–11 weeks: PIK3CAWT n5 4, PIK3CAH1047R
n5 5–6 sortings with each 1–4 pooled mice. Bar graphs show means6 s.e.m.;
two-sided unpaired Student’s t-test; *P, 0.05; NS, not significant.
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Extended Data Figure 6 | Expression of PIK3CAH1047R induces Akt
phosphorylation. Immunoblot andquantification of lysates fromK8-CreERT2
control, PIK3CAWT and PIK3CAH1047R mammary glands 4 weeks after
tamoxifen for p110a, pAkt, Akt, pan-keratin and Erk2 (loading control).
n = 3 mice per genotype. Protein levels were normalized to pan-keratin for
normalization of epithelial content. Bar graphs depict fold change over control
lysate. Bar graph shows means6 s.d.; two-sided unpaired Student’s t-test;
*P, 0.006; NS, not significant.
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Extended Data Figure 7 | Expression of basal- and luminal-lineage genes
in PIK3CAH1047R subsets. a, Expression heat maps of selected luminal
and basal genes (left: Lgr5-CreERT2/PIK3CAH1047R versus control; right:
K8-CreERT2/PIK3CAH1047R versus control). LM, mature luminal cells; LP,
luminal progenitors; Myo, myoepithelial; SC, stem-cell enriched. b, c, Expres-
sion profiles of basal- and luminal-lineage genes in mammary subsets of
Lgr5-CreERT2/PIK3CAH1047R compared with Lgr5-CreERT2 control (b) and
K8-CreERT2/PIK3CAH1047R compared with K8-CreERT2 control animals
(c). The qRT–PCR results are representative of 2–3 experiments of 4 pooled
animals of each genotype. Bar graphs show means6 s.e.m.; two-sided
unpaired Student’s t-test; *P, 0.05; NS, not significant; N.d., not detected.
LETTER RESEARCH
G2015 Macmillan Publishers Limited. All rights reserved
Extended Data Figure 8 | Luminal PIK3CAH1047R cells repopulate a
mammary gland. a, b, Number of outgrowths in cleared-fat pad transplanta-
tion of GFP-negative Lgr5-CreERT2 control and GFP-positive Lgr5-CreERT2/
PIK3CAH1047R-expressing luminal subsets (CD24HiSca12) (a) and GFP-
negative K8-CreERT2 control and GFP-positive K8-CreERT2/PIK3CAH1047R-
expressing luminal subsets (left, CD24HiSca12; right, CD24HiSca11)
(b). Representative carmine-stainedwholemounts (bottom). Scale bars, 500mm.
c, Representative immunostained sections. Scale bars, 50 mm. a–c, Data from
three independent experiments. d, Percentage of K14-, K8/18- and double-
positive (K14/K8/18) colonies derived from Lgr5-CreERT2/PIK3CAH1047R,
Lgr5-CreERT2 control (left, pooled data from n5 4 independent experiments
(1–5 pooled mice)), K8-CreERT2/PIK3CAH1047R and K8-CreERT2 control
subsets (right, pooled data from n5 3 independent experiments (1–5 pooled
mice)). Total number of quantified colonies is shown. e, Representative
images of colonies. Arrowheads indicate K8/18- (white), K14- (yellow) and
double-positive (blue) colonies. Scale bars, 500 mm. f, Number of colonies
derived from basal and luminal cells from Lgr5- and K8-CreERT2/
PIK3CAH1047R and control mice. Left, pooled data from three independent
sortings (each 1–5 pooled animals), total n5 8 (control), n5 10 (mutant)
technical replicates for basal subset, n5 9 (control), n5 5 (mutant) technical
replicates for luminal CD24HiSca12 subset and n5 8 (control), n5 4
(mutant) technical replicates for luminal CD24HiSca11 subset. Right, pooled
data from two independent sortings (each 1–5 pooled animals), total n5 8
(control), n5 10 (mutant) technical replicates for basal subset, n5 5
(control), n5 10 (mutant) technical replicates for luminal CD24HiSca12
subset and n5 6 (control), n5 9 (mutant) technical replicates for luminal
CD24HiSca11 subset. Five-hundred cells were seeded for each replicate. A
colony was defined as a cell cluster of .5 cells. Bar graphs show
means6 s.e.m.; two-sided unpaired Student’s t-test; *P, 0.05. g, Bar graphs
showing number of spheres derived from FVB-control and PIK3CAH1047R-
expressing luminal (CD24HiSca12/1) mammary cells over three passages.
Representative data (three replicates, n5 4 mice per genotype) from two
independent experiments. Bar graphs showmeans6 s.d. *P, 0.02, two-sided
unpaired Student’s t-test. h, Representative images of spheres derived from
CD24HiSca12 cells in passage one (P1) and three (P3). Scale bars, 100 mm.
N.d., not determined; NS, not significant.
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ExtendedData Figure 9 | PIK3CAH1047R-evoked tumours express basal and
luminal markers. a, Representative FACS plots of Lgr5-CreERT2/
PIK3CAH1047R and K8-CreERT2/PIK3CAH1047R tumours (n5 3). b, Percent-
ages of total GFP-positive cells and GFP-positive basal (CD24LoSca12) and
luminal (CD24HiSca12/1) subsets of Lgr5-CreERT2 and K8-CreERT2/
PIK3CAH1047R tumours (n5 3). Bar graphs show means6 s.e.m. NS, not
significant; two-sided unpaired Student’s t-test c, Immunostaining for basal
and luminal markers on serial sections of a multi-nodular rosette-type
adenomyoepithelioma (Lgr5-CreERT2/PIK3CAH1047R) and adenomyoepithe-
lioma (K8-CreERT2/PIK3CAH1047R). Scale bars, 100mm, 50mm
(magnifications). d, Quantification of basal- and luminal-lineage markers of
Lgr5-CreERT2 and K8-CreERT2/PIK3CAH1047R tumours. Each dot represents
one tumour (top: K8/18, K14 and SMA n5 15, K5 n5 14, ER n5 10, PR
n5 9, p63 n5 8; bottom: K8/18, K14, SMA and K5 n5 15, ER, PR and p63
n5 10). All Lgr5-CreERT2/PIK3CAH1047R tumours and 8/10 and 6/10 of
K8-CreERT2/PIK3CAH1047R tumours show more than 1% of ER- and/or PR-
positive cells, respectively. Bar graphs show means6 s.d. e, Representative
haematoxylin and eosin stainings of tumour phenotypes. Scale bars, 100mm.
f, Percentage of benign and malignant mammary tumours.
LETTER RESEARCH
G2015 Macmillan Publishers Limited. All rights reserved
Extended Data Figure 10 | Expression profiling of K8- and Lgr5-CreERT2/
PIK3CAH1047R mammary tumours. a, Principle component analysis and
dendogram of a hierarchical clustering of gene expression profiles from 10
K8- and 10 Lgr5-CreERT2/PIK3CAH1047R tumours and 2–3 reference
mammary glands. Each dot indicates one sample. Circles represent
K8-CreERT2 and squares represent Lgr5-CreERT2 animals expressing
PIK3CAH1047R (filled symbols) or not (open symbols). b, Heat map of the top
1,000 genes that vary between K8-CreERT2/PIK3CAH1047R and Lgr5-CreERT2/
PIK3CAH1047R tumours and The Cancer Genome Atlas (TCGA) human
breast cancer gene signatures. Lum, luminal.
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